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ABSTRACT 
Human pregnancy is a challenge for the maternal immune system, which must maintain 
tolerance to a semi-foreign entity (the fetus) while keeping immunity against viral, bacterial 
and parasite infections. While the mechanisms involved in placental immune tolerance have 
been addressed for the last thirty years, very little attention has been given to the maternal 
immune system role in the elimination of infections. 
In preparation for implantation, the uterine endometrium undergoes modifications known as 
decidualization. The placental cells (trophoblast) invade the decidua to facilitate nutrient and 
gas exchanges. In particular, the extravillous trophoblast (EVT) of fetal origin detaches from 
placental villi, migrates into the decidual tissue and contacts directly with maternal immune 
cells such as decidual natural killer cells (dNK). 
dNK are the most abundant leukocyte type in decidua and have a different phenotype from 
peripheral NK cells (pNK). dNK have lower cytotoxicity in response to MHC-Class I – 
negative targets and secrete more cytokines and growth factors than pNK. dNK express high 
levels of killer cell immunoglobulin-like receptors (KIR) that recognize MHC Class I in 
maternal tissue and EVT. EVT express HLA-E and HLA-G, in addition to polymorphic HLA-
C. Recently, women who lack the gene for the activating receptor KIR2DS1 and carry a fetus 
expressing HLA-C2 (the ligand for KIR2DS1) were found to be at increased risk of recurrent 
miscarriage, fetal growth restriction and preeclampsia. The molecular and cellular 
mechanisms involved are unknown. The current hypothesis suggests that absence of 
activating KIR2DS1 and expression of KIR2DL1 (inhibitory receptor for HLA-C2) results in 
stronger inhibition of dNK upon interaction with fetal HLA-C2.  This inhibition dampens dNK 
secretion of growth factors involved in placentation and vessel remodeling, leading to 
pregnancy complications.  Particular combinations of KIR haplotypes and HLA allotypes are 
also associated with improved clearance of viral infection. Therefore we hypothesized that 
the protective effect of KIR2DS1 lies in a more efficient clearance of infections during early 
pregnancy. This may prevent virus-induced placental pathology and subsequent fetal and 
maternal complications. Both hypotheses are tested in the present work. In this thesis, 
human dNK phenotype and function in healthy pregnancy and viral/bacterial infections are 
characterized, focusing on the role of KIR2DS1. 
Chapter 1 of this thesis provides a general introduction to contextualize the data presented 
in the following chapters. Chapter 2 presents a characterization of KIR2DS1+ (S1+) dNK in 
healthy pregnancy. dNK are shown to express receptors for MHC Class I in higher 
frequencies than pNK, specifically KIR2DL1 and KIR2DS1, KIR2DL2/3 (inhibitory HLA-C1 
receptors) and NKG2A/NKG2C (respectively, inhibitory and activating HLA-E receptors). 
dNK express similar levels of the cytolytic molecules granzyme A and B as pNK, but lower 
VII 
 
levels of the pore forming protein perforin. Strikingly, dNK express much higher levels of the 
antimicrobial peptide granulysin than pNK. In addition, the expression of granzyme B, 
perforin and granulysin are increased in S1+ dNK. These observations point to a higher 
cytolytic potential of S1+ dNK. In fact, cytotoxicity of dNK from KIR2DS1+ women was not as 
efficiently inhibited by HLA-C2+ target cells as dNK from KIR2DS1- women and pNK from all 
donors. S1+ dNK also displayed the highest levels of degranulation of all 4 subsets (L1+, S1+, 
L1+S1+, L1-S1-) in response to HLA-C2+ target cells. Although dNK degranulated and 
secreted cytokines in response to MHC Class I-negative or HLA-C2+ cell lines, co-culture 
with EVT did not elicit secretion of IFN-γ, VEGF or GM-CSF. 
The failure of KIR2DS1+ dNK to secrete cytokines in response to HLA-C2+ EVT led to the 
hypothesis that the higher cytotoxic potential of KIR2DS1+ dNK contributes to an increased 
clearance of placental viral infections, a possibility explored in chapter 3. Human 
cytomegalovirus (HCMV) is the most common congenital viral infection and can lead to 
miscarriages, fetal growth restriction and permanent hearing damage. In chapter 3, dNK 
were shown to degranulate and secrete pro-inflammatory cytokines in response to HCMV-
infected decidual stromal cells (DSC). However, dNK did not respond to HCMV-infected 
choriocarcinoma cell line (JEG3) and sample-matched primary EVT. This demonstrates the 
high resistance to death by trophoblast and highlights the difficulties the maternal immune 
system faces to clear infections in the tolerogenic compartment of the placenta. 
Furthermore, KIR2DS1+ dNK were demonstrated to deliver an increased cytolytic response 
to HCMV-infected DSC expressing HLA-C2. This observation may explain the protective 
effect of KIR2DS1 in human pregnancy by limiting viral infection in the placenta. KIR2DS1+ 
dNK may control the spread of infection and reduce the risk for virus-induced pregnancy 
complications. 
Finally, in chapter 4, the role of dNK in the elimination of bacterial infections was 
investigated. The high expression of antimicrobial peptide granulysin by dNK was the basis 
for this study. dNK constitutively secreted high levels of granulysin. In addition, dNK cells 
and dNK supernatants were able to kill both extracellular and intracellular bacteria in JEG3 
without killing the host cell. This effect was independent of degranulation. This striking result 
reveals a novel function for dNK and strengthens their role as immune effector cells. 
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RESUMO 
A gravidez humana é um desafio para o sistema imunitário materno, o qual deve garantir 
tolerância a um feto semi-incompatível enquanto mantém imunidade contra infeções. Os 
mecanismos envolvidos na tolerância têm sido bastante explorados, mas o estudo da 
imunidade a infeções congénitas tem sido negligenciado. 
A implantação do embrião exige que o endométrio uterino sofra modificações profundas 
(decidualização). As células fetais da placenta (trofoblastos) invadem a decidua para 
permitir trocas eficientes de gases e nutrientes. Em especial, os trofoblastos extravilosos 
(EVT) migram para o tecido decidual, contatando directamente com linfócitos maternos 
como as células Natural Killer deciduais (dNK). As dNK são os leucócitos mais abundantes 
na decidua, mas são menos citotóxicas em resposta a células alvo que não expressam 
MHC Classe I que as NK do sangue (periféricas, pNK), e secretam mais citocinas e fatores 
de crescimento. As dNK expressam níveis elevados de recetores KIR (killer cell 
immunoglobulin-like receptors) que reconhecem proteínas MHC Classe I nos tecidos 
maternos e EVT. Os EVT expressam HLA-E e HLA-G e também HLA-C, que é polimórfico. 
Recentemente, foi encontrada uma associação prejudicial entre genes KIR maternos e 
alelos HLA-C do feto. As grávidas que não possuem o gene para o recetor ativador 
KIR2DS1 e cujo feto expressa HLA-C2 têm um risco elevado de aborto espontâneo, 
restrição de crescimento fetal e pré-eclâmpsia. Os mecanismos moleculares e celulares 
envolvidos não são conhecidos. A hipótese proposta atualmente sugere que a ausência de 
KIR2DS1 ativador e expressão de KIR2DL1 (recetor inibidor de HLA-C2) leva a uma 
inibição mais pronunciada das dNK aquando da interação com HLA-C2 fetal. Esta inibição 
reduz a secreção pelas dNK de fatores de crescimento envolvidos na placentação e 
remodelação de artérias uterinas, resultando em complicações na gravidez. São também 
conhecidas combinações de haplótipos de KIR com alelos de HLA que estão associadas a 
um melhor combate a infeções virais. Estes dados levaram à nossa hipótese de que o efeito 
protetor de KIR2DS1 está relacionado com uma resposta imunitária mais eficiente a 
infeções congénitas. Este fenómeno pode prevenir danos induzidos por vírus na placenta e 
consequentes complicações na gravidez. Ambas as hipóteses foram testadas no trabalho 
aqui apresentado. Nesta tese, é apresentada uma caraterização do fenótipo e função das 
dNK humanas em gravidezes saudáveis e afetadas por infeções virais ou bacterianas, com 
foco no papel de KIR2DS1.  
O capítulo 1 desta tese fornece uma introdução geral para contextualizar os dados 
apresentados nos capítulos seguintes. O capítulo 2 apresenta uma caraterização das dNK 
que expressam KIR2DS1 (S1+) em gravidezes saudáveis. A frequência de expressão de 
recetores para MHC Classe I nas dNK é mais elevada que nas pNK, em especial KIR2DL1 
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e KIR2DS1, KIR2DL2/3 (recetores inibidores de HLA-C1) e NKG2A/NKG2C (recetor inibidor 
e ativador, respetivamente, de HLA-E). As dNK contêm níveis semelhantes das proteínas 
citolíticas granzima A e B aos das pNK, mas níveis mais reduzidos de perforina, que forma 
poros nas membranas das células alvo. Em especial, as dNK contêm muito mais proteína 
anti-microbiana granulisina que as pNK. Ainda, a expressão de granzima B, perforina e 
granulisina é mais elevada em dNK S1+. Estas observações revelam um potencial citolítico 
elevado das dNK S1+. De facto, a citotoxicidade das dNK isoladas de grávidas que possuem 
o gene KIR2DS1 não foi inibida por células alvo HLA-C2+ com a mesma eficiência que dNK 
isoladas de grávidas sem KIR2DS1 ou pNK de todos os indivíduos da amostra. As dNK S1+ 
também demonstraram possuir a mais elevada citotoxicidade dos 4 subgrupos (L1+, S1+, 
L1+S1+ e L1-S1-) em resposta a células-alvo HLA-C2+. As dNK desgranularam (libertaram 
moléculas citolíticas) e secretaram citocinas em resposta a células alvo MHC- ou HLA-C2+, 
mas não secretaram IFN-γ, VEGF ou GM-CSF após cultura com EVT. 
 A falta de resposta das dNK à interação com EVT levou à hipótese de que o potencial 
citotóxico das dNK S1+ contribui para um combate mais eficiente às infeções virais na 
placenta. O vírus humano citomegalovírus (CMV) provoca a infeção congénita mais comum 
e pode levar a aborto espontâneo, restrição do crescimento fetal e danos auditivos 
permanentes. No capítulo 3, mostrou-se que as dNK desgranulam e secretam citocinas pró-
inflamatórias em resposta a células do estroma da decidua (DSC) infetadas com CMV. No 
entanto, as dNK não responderam a células de coriocarcinoma (JEG3) ou EVT primários 
infetados com CMV. Estas observações demonstram a resistência à morte dos trofoblastos 
e sublinham a dificuldade que o sistema imunitário materno enfrenta para eliminar infeções 
na placenta. Em especial, mostrou-se que as dNK S1+ são mais citolíticas em resposta a 
DSC HLA-C2+ infetadas com CMV. Esta observação pode explicar o efeito protetor de 
KIR2DS1 na gravidez humana ao limitar a infeção viral na placenta. As dNK S1+ podem 
controlar a disseminação da infeção e reduzir o risco de complicações da gravidez 
induzidas por vírus.  
Finalmente, no capítulo 4, investigou-se o papel das dNK na eliminação de infeções 
bacterianas. A expressão elevada do péptido anti-microbiano granulisina em dNK constituiu 
a base para este estudo. As dNK secretam granulisina constitutivamente, e as células dNK 
e sobrenadantes das suas culturas conseguiram eliminar bactérias extracelulares e 
intracelulares em JEG3 sem matar as células hospedeiras. Este efeito foi independente de 
desgranulação. Este importante resultado revela uma nova função das dNK e reforça o seu 
papel como células imunitárias efetoras.  
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The human immune system is a complex set of cells and proteins that resulted from millions 
of years of co-evolution of humans and their pathogens. To allow survival of the individual 
and, more broadly, of human populations, each human being has a system ready to defend 
it from bacteria, viruses, fungi and parasites (1).  
The functioning of the immune system is complex and two main arms can be identified: 
innate and adaptive immune system. The innate immune system constitutes the first line of 
defense and delivers a quick response to any invading pathogen by recognizing common 
patterns absent in the human body. The adaptive immune system, although slower, is more 
efficient, because it can recognize specific markers in each pathogen and save that 
information. This way the adaptive immune system can instantly eliminate subsequent 
infections of the same pathogen and clear the infection before any significant damage 
occurs. This property of the immune system to “remember” is named “immune memory” and 
is the basis for the many vaccines available today (1).   
How the immune system attacks only foreign (“non-self”) and dangerous pathogens, while 
remaining controlled and not damaging (“tolerating”) our own (self) tissues will be discussed 
in detail below. This introduction will cover three main areas: self vs non-self recognition in 
the systemic immune system, the characteristics and role of Natural Killer cells and the 
complexity of the local immune system regulation during pregnancy. In the first part, the 
mechanisms of self and foreign tissue and pathogen recognition by immune leukocytes will 
be discussed. In the second part, the function of Natural Killer cells, their subsets, receptors 
and ligands will receive special attention. In the third part, the regulation and function of the 
immune system during pregnancy will be described. This last part will emphasize the double-
edged challenge faced by the local immune system in the maternal-fetal interface: 
maintaining immune tolerance to semi-foreign fetal tissues while remaining active against 
potential viral, bacterial and parasite infections. The protective role of the NK cell receptor 
KIR2DS1 (Killer cell Immunoglobulin-like Receptor, 2 extracellular Domains, Short 
cytoplasmic tail 1) in healthy and complicated pregnancy will be addressed in detail. 
1. Self vs. Non-Self recognition 
The innate immune system recognizes common proteins and chemicals released by injured 
cells. These molecules include chemicals that induce the secretion of cytokines, activate 
innate immune leukocytes to secrete other chemicals or attack the pathogens, or 
chemokines that recruit additional leukocytes to the site of infection. These leukocytes are, 
for example, phagocytes (e.g. macrophages or dendritic cells) that express proteins at the 
surface known as “pattern recognition receptors” (PRRs). PRRs recognize common proteins 
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from pathogens, leading the phagocytes to engulf the pathogens and lyse them 
(phagocytosis) (2).  
The adaptive immune system relies on Major Histocompatibility Complex (MHC) molecules  
that present self and non-self peptides to T and B cells (3). The MHC locus contains the 
most variable (polymorphic) functional genes described in vertebrates. In humans, these 
proteins are known as human leukocyte antigens (HLA) and two classes can be recognized: 
Class I and Class II. While Class I HLA are expressed by all nucleated cells, Class II are 
constitutively expressed only by bone marrow-derived antigen1 presenting cells (APC), such 
as macrophages, dendritic cells, B cells and thymic epithelial cells (1). 
MHC Class I molecules are surface proteins which extracellular part is composed of 3 alpha 
domains and a β2-microglobulin chain. The 1 and 2 domains form a groove where a 
peptide can bind. The 3 domain contains a binding site for the co-receptor CD8 expressed 
in CD8+ T cells, discussed below. During and following regular protein synthesis, a 
proportion of the resulting proteins are rapidly degraded into peptides by the proteasome. 
The resulting peptides are translocated into the lumen of the endoplasmic reticulum (ER) via 
the transporter associated with antigen processing (TAP). Within the ER, the peptides are 
loaded onto newly synthesized MHC I heavy chain/β2-microglobulin heterodimers (3). MHC 
Class I constantly display short intracellular endogenous peptides (8-9 aminoacids long) as a 
sign of the status of the cell to be surveyed by T cells. When a cell is infected by an 
intracellular pathogen (e.g. virus), or 
starts producing new and damaged 
proteins due to tumor formation, the 
complex formed by pathogen-derived 
peptides and MHC Class I are recognized 
by CD8+ T cells (cytolytic T lymphocytes) 
and elicit an immune response (4). 
In humans, six MHC Class I genes can 
be identified: 3 classical highly 
polymorphic genes (HLA-A, B and C) and 
3 non-classical (HLA-E, G and F). All 
nucleated cells express HLA-A, B and C, 
which main function is antigen 
presentation, and also HLA-E, which 
although non-polymorphic, has a role in 
Natural Killer cell inhibition. HLA-G is 
                                                          
1 Antigen – any molecule that elicits an immune response (1). 
Table I – MHC Class I genes, proteins and number of 
alleles. Source: HLA Nomenclature (http://hla.alleles.org/) 
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tissue restricted and is believed to be involved in immune modulation (e.g. induction of 
regulatory T cells). HLA-F function is still unknown (5–7) (Table I). 
MHC Class II molecules, unlike MHC Class I, are tissue restricted. Class II are only 
expressed by professional antigen presenting cells (APC) like dendritic cells, macrophages 
and B cells (antibody producing cells). MHC Class II proteins have 2 heavy chains, one with 
two  domains and one with two β domains. The groove formed by the 1 and β1 domains 
can present a longer peptide than MHC Class I, which is usually derived from extracellular 
pathogens (e.g. phagocytosed bacteria) which proteins were subsequently degraded. MHC 
Class II contains a binding side for the co-receptor CD4 in CD4+ T cells (T helper cells). The 
recognition of the MHC-peptide complex by CD4+ T cells will activate them and lead to the 
immune response. In humans, 3 main MHC Class II proteins can be identified: HLA-DR, 
HLA-DQ and HLA-DP, which are also highly polymorphic (8) (Table I). 
T cells are the main immune lymphocytes involved in the recognition of MHC-peptide 
complexes. T cells originate from hematopoietic precursors in the bone marrow and later 
migrate to the thymus to finish their maturation. T lymphocytes come in two flavors, CD4+ 
and CD8+, and can be further divided into several subsets with different functions. All T cells 
express a T cell receptor in the surface, the TCR, which is exclusive and different for each T 
cell and recognizes a different MHC-peptide complex. The different TCRs are formed by 
somatic rearrangement of the TCR genes, which leads to a different sequence and, 
consequently, a different specificity of each T cell. The diversity of TCR in a given individual 
is enormous, and since their formation is random, some TCRs recognize self-peptides that 
can lead to auto-immune attack (9). To avoid this, T cells need to go through a mechanism 
of positive and negative selection in the thymus during development. T cells that have too 
low affinity to self MHC-peptide complex (negligent) or too high affinity to self MHC-peptide 
complex (auto-reactive) are eliminated in the thymus (positive and negative selection, 
respectively). This way, only T cells specific for self-MHC presenting foreign peptides and 
can be activated by them are allowed to leave the thymus (10).  
CD4+ T cells are usually identified as T helper cells (Th). When in the periphery, Th cells 
interact with APCs expressing their specific MHC-Class II – peptide complex, leading to their 
activation, proliferation and differentiation into different types of T helper cells (depending on 
the cytokine environment) (11). CD4+ T cells can differentiate into Th1 cells, which produce 
more inflammatory cytokines like interferon-γ (IFN- γ) and tumor necrosis factor  (TNF-), 
helping CD8+ T cell, NK cell and macrophage responses. CD4+ T cells can also differentiate 
into Th2, which produce interleukins 4 and 5 (IL-4 and IL-5) that provide help to antibody-
producing B cells. Upon clearing of the infection, a subset of CD4+ T cells differentiates into 
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memory cells that will be able to respond faster to a second infection by the same pathogen 
(12).  
T regulatory cells are also CD4+, but have a very distinct phenotype (expressing high levels 
of CD25 and the transcription factor FoxP3). These cells are involved in immune tolerance 
and dampen the immune response, avoiding auto-immune reactions (13). 
CD8+ T cells are the major immune cells involved in tumor and viral clearance. CD8+ T 
lymphocytes directly recognize MHC-Class I-peptide complexes, which leads to their 
activation, proliferation and differentiation into cytotoxic T lymphocytes (CTL) (11). CTLs 
directly kill infected or tumor cells by several ways, the most important being the release of 
cytotoxic molecules to the point of contact between the T cell and the target cell (immune 
synapse - IS). Among the cytotoxic molecules are perforin, a pore forming protein that 
creates an opening in the target cell membrane, allowing the entrance of granzymes, which 
lead to apoptosis of the target cell by several pathways (caspase-dependent or independent) 
(14, 15). Upon activation and clearance of infection, a subset of CD8 T cells differentiates 
into memory T cells that can elicit a rapid response upon a subsequent infection with the 
same pathogen (16). 
The other adaptive immune lymphocyte which can play a role in the immune response are B 
cells. B cells have a B cell receptor (BCR), also highly specific to foreign epitopes2 (since 
each B cell undergoes somatic rearrangements in their BCR locus) (17). However, these 
cells do not need to bind a MHC-peptide complex for activation. Instead, their BCR 
recognizes free antigen, but the B cells need interaction with primed T cells of similar antigen 
specificity to start their differentiation and proliferation (18, 19). Upon activation, B cells 
produce antibodies (immunoglobulins, Ig), highly specific molecules. The antibodies 
produced by a given B cell have the same specificity of the BCR, and their diversity is as 
high as the TCR diversity (the result of somatic rearrangements in the immunoglobulin 
genes) (17). Antibodies can be secreted and help in the elimination of pathogens by several 
ways – opsonization (coating of a pathogen, flagging it for phagocytosis), aggregation of 
pathogens or antibody-mediated cell death (by binding receptors in Natural Killer cells – 
discussed in the section below - or macrophages) (20). 
Natural Killer cells, which will be discussed in more detail on section 2, are lymphocytes 
commonly categorized as innate immune cells, but recent studies have identified NK cell 
functions that place NK in the border between immune and adaptive immunity. NK cells 
share some characteristics with cytotoxic T lymphocytes, in particular the ability to form 
immune synapses and deliver cytolytic granules for target cell killing (21).  Unlike T cells, NK 
do not recognize specific epitopes in target cells; instead, NK cells express activating 
                                                          
2 Epitope – specific region of an antigen recognized by TCR or antibodies (1). 
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receptors that identify stress-induced proteins upregulated by infected or cancerous cells, 
and quickly eliminate them without prior stimulation (22). However, NK cells have recently 
been shown to possess the ability to recognize specific viral proteins expressed in infected 
cells, leading to their proliferation and stronger response upon second encounter with the 
same antigen (23). These studies have been the subject of controversy and require further 
development.  In addition, NK cells express a wide range of inhibitory receptors that bind 
groups of alleles of MHC Class I, as a way of protecting healthy self tissues from NK attack 
(24). 
1.1 HLA recognition and the allogeneic response 
The MHC locus is the most variable (polymorphic) region in the human genome. These MHC 
polymorphisms allow for a great variety of pathogenic peptides to be presented, resulting in 
an increased ability to clear a large diversity of pathogens. However, these polymorphisms 
also underlie the extreme difficulty in finding perfectly matched organs or unrelated bone 
marrow donors that will not induce a strong anti-graft response (25). In the next paragraphs 
the mechanisms of transplant allorecognition will be discussed to illustrate how the maternal 
immune system could potentially respond to the allogeneic fetal tissues during pregnancy. 
1.1.1 Transplant allorecognition 
Transplantation is the artificial transfer of cells, tissues or organs from one individual to 
another. When the graft is syngeneic (genetically identical to the host) or autologous (a 
transplant from one individual into itself) there is perfect histocompatibility and no significant 
immune response is elicited. When there is incompatibility, in general an immune response 
is directed against the foreign antigens. Allorecognition is the term used to describe the 
recognition of transplanted allogeneic tissues by the host, while alloresponse denotes the 
effector mechanisms recruited in the reaction to the foreign tissue and the outcome of those 
effects (25). Allorecognition can proceed via two mechanisms: direct allorecognition, where 
T cells recognize epitopes on the intact donor MHC molecules displayed in the surface of 
transplanted cells; or indirect allorecognition, in which donor MHC molecules are processed 
and presented as peptides by self-MHC molecules (in a similar fashion to antigen 
processing) (26). 
 1.1.1.1 T cell responses to transplants 
 Alloreactive T cells can identify foreign tissue by both direct allorecognition and 
indirect allorecognition. While direct allorecognition can be carried out by both CD8+ and 
CD4+ T cells (by recognizing donor MHC Class I and MHC Class II molecules, respectively), 
indirect allorecognition is exclusive of CD4+ T cells, which identify the recipient APC 
displaying MHC Class II - donor peptide complexes. 
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The vigorous nature of the direct alloresponse and its immediacy (acute rejection) in 
comparison with the indirect pathway is the result of direct recognition of intact MHC by T 
cells without the need for processing and presentation of self-MHC (25) (Figure 1A).  
The indirect pathway differs from the direct pathway by the requirement for antigen 
processing. Alloantigens shed from a graft are processed as exogenous antigens and 
presented by APCs in association with self-MHC Class II. These responses are considerable 
slower compared to the direct pathway (Figure 1B).  The indirect response is likely to be 
responsible for long term responses to engrafted tissues once donor APCs are exhausted. 
The presence of donor APCs in transplanted tissues at the time of transplantation can lead 
to a vigorous anti-donor alloresponse in the early period post-engraftment. The death and 
removal of these APCs over time reduces this response. The indirect alloresponse, on the 
contrary, requiring antigen capture and processing, is less rapid than the direct pathway but 
continues for the life of the graft, as graft derived antigens are continuously acquired and 
processed (chronic rejection). Acute rejection of transplanted tissues is more commonly 
observed in the early post engraftment period, while tolerance to grafts develops at a later 
time point. This correlates with demonstrations that regulatory T cells able to mediate 
transplant tolerance have indirect rather than direct pathway alloreactivity (26). 
Figure 1. Transplant allorecognition mechanisms by T and NK cells. A) Direct allorecognition of MHC Class 
II in APC by CD4+ T cells (left) and of donor MHC Class I by CD8+ T cells (right). B) Indirect allorecognition of 
recipient MHC/donor peptide complex in receptor APC by CD4+ T cells. Donor MHC fragments (antigens) are 
taken up by APCs (black arrow) and presented via MHC Class II (arrowhead) to CD4+ T cells.  C) NK recognition 
of donor tissue. On the left, the donor shares MHC alleles with the recipient, inhibiting NK responses. On the 
right, recipient NK does not recognize donor MHC (missing self), leading to activation. 
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 1.1.1.2 B cell responses to transplants 
 B cells can contribute to transplant rejection via two major mechanisms – as antigen-
presenting cells (APC), contributing to indirect allorecognition, and as antibody producers. B 
cells can be activated and secrete antibodies specific to donor MHC molecules. The 
presence of donor-specific HLA antibodies in the circulation of transplant recipients has a 
negative impact on transplantation outcome (18). These alloantibodies mainly induce 
rejection by complement-dependent mechanisms. The complement system is a complex set 
of proteins that, when triggered by antibody-antigen, lead to a cascade of reactions resulting 
in cell lysis by membrane disruption, or chemo-attraction of macrophages and other 
phagocytes able to clear the foreign cells (27). 
1.1.1.3 Natural Killer cell responses to transplants 
NK cells express inhibitory receptors that bind groups of alleles of self-MHC Class I 
and are responsible for protection of self tissue from NK attack. In a MHC-mismatched 
transplant, MHC class I alleles expressed in the donor tissue are different from the 
recipient’s and unable to inhibit NK (missing-self). NK cell-mediated rejection of transplants 
is included in the direct alloresponse, leading to acute rejection (Figure 1C) (28). 
2. Natural Killer (NK) cells – between innate and adaptive immunity 
Human Natural Killer cells (NK) are a subpopulation of lymphocytes, like B and T cells, that 
originate from hematopoietic progenitors in the bone marrow. Unlike T cells, all their 
development takes place in the bone marrow, from where they migrate into various tissues, 
including secondary lymphoid organs and the blood (circulating or peripheral NK cells – 
pNK) (22).  
NK were initially defined by their ability to kill target cells without prior immunization. While T 
cells require a first encounter with a pathogen to prime their activity, differentiation and 
proliferation, leading to formation of memory, NK can deliver a rapid response upon first 
encounter (21). One of the hallmarks of NK is their lack of need to recognize specific 
epitopes or antigens to be activated. NK express non-rearranged somatic activating 
receptors that identify common ligands on target cells – stress ligands. However, NK need 
another layer of regulation to keep them from attacking healthy tissue. In fact, NK express 
inhibitory receptors that recognize self MHC Class I molecules – different receptors 
recognize different groups of alleles (28). Healthy cells always express MHC Class I 
molecules, flagging them to be spared by NK. Infected or tumor cells upregulate stress-
induced surface proteins and, as a mechanism of immune evasion, also downregulate MHC 
molecules to escape attack by T cells. The combination of stress signals and low MHC 
expression works as a danger signal for NK, which take over the immune response (29). 
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2.1 NK cell phenotype 
Two main populations of NK can be found in peripheral blood, defined by the expression of 
two surface markers: CD56 and CD16. About 90% of NK in the blood are CD56lowCD16+, the 
main cytotoxic subpopulation, containing cytolytic granules as CD8+ T cells. The remaining 
10% are CD56highCD16- and are not cytotoxic. CD16- NK do not contain cytolytic molecules 
and are defined by the secretion of cytokines (e.g. IFN-γ). CD16- NK are also the main 
population of NK found in secondary lymphoid organs. CD56highCD16- and CD56lowCD16+ 
subsets are also sequential stages of maturation and CD56high can progress to CD56low cells 
upon activation, as occurs in reactive lymph nodes or inflamed tissues (30). 
NK can be further subdivided in an impressive array of subsets, based on their expression of 
activating and inhibitory receptors (31). The receptors belong to different families of proteins 
and recognize different ligands and will be addressed in more detail below. The most 
interesting characteristic of NK cell receptors is their random expression in the population of 
NK of a given individual. Each NK can express any number of receptors from zero to 30+ in 
different combinations. The pattern of receptors of each NK is defined during maturation and 
is maintained throughout the life of the cell and during division, generating clones. The 
balance between activating and inhibitory receptors, combined with the expression of ligands 
in the target cell, is crucial for the outcome of the NK cell response (32). 
2.2 NK cell immune synapse and degranulation 
Activation of NK triggers a complex and highly regulated response leading to cytolytic 
granule release, resulting in the death of the target cell. Conversely, interaction of inhibitory 
receptors with their ligands negatively regulates NK activity. Activation and inhibition take 
place at the specialized contact sites between NK and target cells, known as the 
immunological synapse (IS) (33). Upon encountering a target cell (i.e. a cell with 
downregulated MHC Class I molecules and expressing stress signals at the surface), NK 
form an activating synapse. This requires several steps: I. Contact and adhesion, led by 
integrins such as LFA-1. II. Receptor ligation and segregation linked to initial signaling. III. 
Actin cytoskeleton rearrangements (tight conjugation). IV. Further receptor clustering and 
sustained signaling (signal amplification). V. Microtubule cytoskeleton rearrangements 
(MTOC polarization). VI. Granule polarization and degranulation. VII. IS disassembly (34). 
Similarly to T cells, NK contain cytolytic granules with molecules such as the serine 
proteases granzymes and the pore-forming protein perforin. Upon synapse formation, these 
granules exocytose their contents, releasing perforin which will polymerize in the target cell 
surface, opening a pore which allows granzymes to enter. Granzymes are then responsible 
for apoptosis by triggering caspase-dependent and independent pathways (Figure 2A) (14, 
15). 
10 
 
2.3 Other mechanisms of NK cell target killing 
Synapse formation is the main killing mechanism employed by NK, but other pathways can 
be followed. For example, NK express death receptor ligands such as TRAIL or Fas-L, which 
engage death receptors on the surface of target cells and initiate target cells apoptosis(35). 
Furthermore, NK cells can also secrete cytokines such as IFN-γ and TNF- which can 
increase inflammation and activate T cells and dendritic cells to ensure clearance of target 
cells (Figure 2B and C) (36). 
2.4 Activating and Inhibitory receptors in NK cells – a balance 
NK express several receptors responsible for modulating NK function when facing a target 
cell. The most important receptors can be subdivided in 5 families: Natural Cytotoxicity 
Receptors (NCR), Fc receptors (FcR), C-type lectins, Leukocyte Immunoglobulin-like 
receptors (LILR) and Killer cell Immunoglobulin-like receptors (KIR). While some families 
include only activating (NCR and FcR) or inhibitory receptors (LILR), others include both 
Figure 2. NK cell target killing mechanisms. A) Granule exocytosis. The recognition of activating ligands (and 
lack of MHC Class I molecules) or antibodies bound to target cell antigens (antibody dependent cell cytotoxicity) 
leads to immune synapse formation and degranulation of NK. The same stimuli lead to cytokine secretion (e.g. 
interferon-gamma, IFN-γ) that increase inflammation and activate T cells, dendritic cells (DC) and macrophages 
(Mϕ) (B). (C) Apoptosis induction. The engagement of death-inducing receptors (FasR, TRAIL receptor) by NK 
ligands (FasL, TRAIL) and tumor necrosis factor (TNF)-α production by NK lead to apoptosis of target cells. 
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types (KIR and C-type lectins) (Figure 3 and Table II). NK cells express several other 
receptors (e. g. adhesion molecules, integrins, etc.), that contribute to NK activation but, for 
clarity, such proteins will not be addressed here. 
2.4.1 Natural Cytotoxicity Receptors (NCR) 
The major NK receptors able to induce NK-mediated killing are the natural cytotoxicity 
receptors (NCRs) belonging to the Immunoglobulin-like superfamily — NKp46 (NCR1), 
NKp44 (NCR2) and NKp30 (NCR3). The activating receptors are organized into multi-chain 
complexes where the ligand-binding and signal-transducing sub-units are separate. The 
ligands for these receptors are mostly unknown but believed to be viral proteins or stress 
ligands expressed at the surface of infected cells. The signal transducing units are diverse, 
and include CD3ζ, FcεRγ and DAP12 (DNAX activation protein of 12kDa). DAP12 contains 
an intracellular immunoreceptor tyrosine-based activation motif (ITAM) that recruits protein 
kinases involved in activating signaling such as Spleen tyrosine kinase (SYK) and Zeta-
chain-associated protein kinase 70 (ZAP70). These receptors also use different downstream 
pathways leading to the NK activation (28). 
2.4.2 C-type lectins  
C-type lectins are a family of transmembrane proteins characterized by a type II membrane 
orientation (extracellular C terminus) and the presence of a C-type lectin domain. This family 
includes both activating and inhibitory receptors of NK. 
The best-characterized activating C-type lectin is NKG2D. NKG2D recognizes “induced-self” 
ligands – molecules not expressed or expressed at low levels on normal cells, but 
upregulated on unhealthy cells due to the activation of pathways associated with cancer, 
infection or stress. NKG2D ligands include MHC class I polypeptide-related sequence A and 
B (MICA/MICB) and UL16-binding proteins (ULBP) 1-6 in humans. NKG2D associates with 
the signal transducing proteins DAP10 or DAP12 (Figure 3). NKG2D recognition of target 
cells is one of the most important pathways of killing of tumor cells (37).  
In addition, two other C-type lectins have been well studied: NKG2A and NKG2C. Both of 
these proteins form a heterodimeric receptor in association with another type II 
transmembrane molecule: CD94 (Table II). Both CD94/NKG2C and CD94/NKG2A are 
specific for the non-classical MHC class I (class Ib) molecules HLA-E (38). While NKG2C is  
an activating receptor associated with DAP12 (Figure 3), NKG2A is an inhibitory receptor 
that transduces negative signaling through immunoreceptor tyrosine-based inhibitory motif 
(ITIM) sequences present in its cytoplasmic tails (Figure 3). Upon tyrosine phosphorylation, 
ITIM interacts with Src homology region 2 domain-containing phosphatase (SHP)-1/2 that 
disrupt the activating signaling pathways (39).  
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2.4.3. Fc Receptors 
Fc receptors are commonly expressed in macrophages and bind the Fc common part of 
antibodies bound to antigens on the surfaces of other cells. NK express the Fc receptor 
FcγRIII (CD16), which triggers antibody-dependent cell cytotoxicity (ADCC). FcγRIII signals 
through FcεRγ and CD3ζ transducers (Figure 3), leading to degranulation and cytokine 
production (32).  
2.4.4 Leukocyte Immunoglobulin-like Receptors (LILR) 
The Leukocyte immunoglobulin-like receptor genes (LILRB1 and LILRB2) are mapped in 
the chromosome 19 Leukocyte Receptor Complex (LRC) region. LILRB1/LIR1 and 
LILRB2/LIR2 are inhibitory receptors that display four extracellular Ig-like domains and a 
cytoplasmic portion characterized by ITIM motifs that mediate association with the SHP-1 
phosphatase (Figure 3) (40). These receptors are expressed on monocytes and dendritic 
Table II – NK cell receptors and ligands. 
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cells and LILRB1 is also expressed on B-cells, some T-cells and subsets of NK. They bind to 
the non-classical class I molecules HLA-G, HLA-F and a similar broad spectrum of HLA-A, -
B and -C alleles (41).  
2.4.5 Killer cell Immunoglobulin-like Receptors (KIR) 
Killer cell Ig-like Receptors (KIRs) are the major MHC Class I NK receptors and have 
specificity for discrete groups of HLA Class I alleles. Their genes map in the leukocyte 
receptor complex (LRC) located on human chromosome 19q13.4 (42). Although most of the 
functional KIRs are inhibitory, a few have activating function. The ~150 kb KIRs cluster 
consists of 14 genes and 2 pseudogenes. However, due to rearrangements that lead to 
deletions and duplications during evolution, each individual possesses a different number of 
genes in this locus. Based on their gene content, two haplotypes have been defined: 
haplotype A characterized by identical genes number and content (with mostly inhibitory 
receptors and only one activating receptor gene), and haplotype B, highly variable in terms 
of gene number (Figure 4). The KIRs cluster may have evolved almost 50 million years ago 
from an ancestral gene (KIR3DL0 also known as KIR3DX1) (43). 
The inhibitory KIR receptors have an extracellular portion with two (KIR2D) or three (KIR3D) 
Ig-like C2-type domains, a transmembrane region characterized by non-polar amino acid 
residues, and a long (L) cytoplasmic tail containing two ITIM sequences (Figure 3). Upon 
recognition of sufficient levels of MHC class I molecules, KIRs generate src kinase-
dependent tyrosine phosphorylation of ITIMs. Phosphorylated ITIMs serve as docking motifs 
for SHP1 or SHP2 through the formation of a ternary complex with -arrestin-2. This 
complex finally blocks the signaling cascades induced by activating receptors (44). The 
inhibition of NK-mediated cytotoxicity requires co-aggregation with triggering receptors and it 
is focused in the immune-synapse area and not over the whole cell membrane. This way, an 
NK cell, although inhibited in the limited area of contact with a particular target cell, may still 
survey for transformed/infected tissues and maintain their killing potential (45).  
Among the 14 KIR genes described so far in humans, five encode receptors associated with 
activating rather than inhibitory potential (Table II) (43). These molecules have a shorter (S) 
cytoplasmic tail not containing ITIM sequences, and a transmembrane portion displaying a 
polar lysine residue. This residue forms a salt bridge with the opposite charged amino acid 
present in the transmembrane region of the ITAM–containing adaptor DAP12 (Figure 3) (46). 
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Activating KIRs are unevenly distributed between KIR haplotypes. KIR-B haplotypes are the 
ones with higher, although variable, numbers of genes encoding activating KIR, while 
haplotype KIR-A is characterized by a single gene coding for triggering Ig-like receptor 
(KIR2DS4) (47). 
Different from the other long-tailed KIR receptors, KIR2DL4 triggers NK activation rather 
than inhibition. This is possible because, although it displays a single non-functional ITIM-
like sequence, it may associate with FcγRI chain through the formation of a transmembrane-
embedded salt bridge (Figure 3). KIR2DL4 is able to bind soluble HLA-G molecules inducing 
the release of proinflammatory/proangiogenic mediators, thus promoting vascularization in 
maternal decidua, site of HLA-G expression, and facilitating implantation during pregnancy 
(48, 49). 
2.4.5.1 KIR specificity 
Different KIR family members, particularly the ones with inhibitory function, have 
been characterized for their HLA class I allele specificity. The distal domains of KIR 
receptors have been found to be responsible for defining the HLA class I allele specificity. 
Most KIR2D molecules are specific for the recently evolved HLA-C alleles (Table II). 
KIR/HLA-C alleles recognition is based on dimorphic residues present in the HLA-C 1-helix 
at position 80 (Table II and Figure 3). Thus, KIR2DL1 and KIR2DS1 bind HLA-C2 alleles 
(Cw2, Cw4, Cw5, Cw6, Cw15 and Cw16) characterized by the presence of a Lys80, while 
both KIR2DL2 and KIR2DL3 recognize HLA-C1 alleles represented by Cw1, Cw3, Cw7, 
Cw8, Cw12, Cw13 and Cw14 characterized by an Asn80 (Table II) (32).  The three-domain 
receptor KIR3DL1 specifically binds HLA-B alleles sharing the Bw4 epitope (50). Other HLA-
Figure 4. Human KIR haplotypes. The human KIR locus consists of centromeric and telomeric regions that 
recombine to produce KIR-A and KIR-B haplotypes with a distinctive gene content. Structures of common 
haplotypes are shown. Gray boxes indicate conserved framework genes; orange boxes indicate genes 
characteristic of KIR-A haplotypes; purple boxes indicate KIR-B haplotype–specific genes. The centromeric (Cen) 
and telomeric (Tel) gene-content motifs are listed at left. Adapted from reference (212). 
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A alleles (HLA-A3 and -A11) bind KIR3DL2 and apparently display some peptide specificity 
(Table II) (51). 
2.5 NK cell education 
Until recently, it was thought all NK expressed at least one inhibitory receptor for self-MHC 
class I molecules; this model provided a satisfactory explanation for self-tolerance and for 
the involvement of NK in missing-self recognition (52). However, studies of humans and 
mice that lacked MHC class I molecules had shown they were hyporesponsive, even though 
these individuals had normal numbers of NK. These NK were not able to release their 
cytotoxic granules to kill MHC Class I – negative target cells (53). Hyporesponsive NK were 
thought to be unique to MHC class I-deficient individuals, but work from several laboratories 
has now shown they also exist in normal humans and mice, and are characterized by a lack 
of inhibitory receptors (53). The active engagement of inhibitory receptors on NK by self-
MHC class I molecules during maturation is the key event that determines whether an NK 
will be functionally capable of mediating missing-self recognition (education), or whether it 
will be of low cytotoxicity following stimulation (54). There are several models to explain how 
this education/licensing occur. However, the rheostat model is the most widely accepted.  
The rheostat model proposes NK have increased or decreased responsiveness depending 
on the strength of the inhibitory signal received during maturation. For example, NK with no 
or low expression of inhibitory KIR for self HLA molecules will establish weak interactions 
with their ligands during maturation, leading to lower cytotoxicity upon later encounter of 
target cells in the periphery. This suggests NK education operates in a quantitative manner 
(cytotoxicity is increased or decreased) and states that NK cytotoxicity can either be ‘tuned 
up’ (arming) or ‘tuned down’ (disarming) rather than in a binary manner (e.g. cytotoxicity is 
completely shut down or turned on). The tuning of NK thus depends on the inhibitory signal 
received by individual NK cells (55).  
The licensing or education of NK by their receptors adds a level of sensitivity to self MHC 
ligand expression. Productive licensing through inhibitory signaling provides a two-fold 
benefit to NK function. It serves to simultaneously enhance effector responses (e.g. IFN-γ 
secretion and cytotoxicity) and broaden the NK cell’s target specificity to include aberrant 
cells that would not be detected by stimulatory receptors alone (56). 
2.6 NK cell response to viruses, tumors and transplants 
NK play a key role in the immune fight against viral infections and tumor cells and can both 
have a beneficial or harmful role during transplantation. Due to the high polymorphism of 
MHC molecules and the diversity of KIR haplotypes in the population, certain combinations 
of MHC-KIR can lead to different outcomes (Figure 5). 
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2.6.1 Viral responses 
Viruses are intracellular pathogens that take advantage of the host cell machinery to 
replicate. Cells infected with viruses will enter a state of stress leading to the expression of 
ligands for activating NK receptors (e. g. MICA/B, recognized by NKG2D). Certain viruses, 
such as influenza and human cytomegalovirus (HCMV) express proteins that are displayed 
at the surface of infected cells and act as ligands for NK receptors [e.g. influenza 
hemagglutinin (HA) – NKp46 and HCMV pp65-NKp30]. To escape T cell immune responses, 
most viruses interfere with the MHC Class I processing and surfacing, leading to a lower 
expression of MHC by infected cells. This phenomena leads to “missing-self” recognition by 
NK, tipping the balance towards activation instead of inhibition (Figure 5A) (57).  
Interestingly, human studies provide evidence that individuals of matched KIR/HLA class I 
may exhibit enhanced viral control. These correlations have been observed in immune 
responses to HIV-1 (3DL1:HLA-Bw4), hepatitis C virus (HCV) (2DL3:HLA-C1), influenza 
(3DL1:HLA-Bw4;2DL2/DL3:HLA-C1), and HCMV (58). The combined presence of KIR3DS1 
and HLA-Bw4 alleles was associated with significantly slower progression to AIDS, lower 
viral load and slower decline of CD4+ T cells (59–61). In addition, KIR3DS1 and KIR2DS1 
Figure 5. NK cell response to viruses, tumors and transplants. A) Viral infected cells express viral and stress 
proteins that serve as activating ligands for natural cytotoxicity receptors (NCR) in NK and downregulate MHC 
Class I, leading to NK activation and degranulation. B) Tumor cells upregulate stress ligands (e.g. MICA/B), 
death receptors (e.g. FasR) and misfolded proteins that can be recognized by antibodies. In addition, tumor cells 
downregulate MHC Class I. NK cells are activated through NKG2D (MICA/B receptor) and FcR (antibody 
receptor, triggering ADCC), leading to degranulation, and can engage death receptors in tumor cells through 
TRAIL and FasL expression. C) MHC-matched transplant donor cells are protected from NK attack due to 
inhibitory KIR engagement. Mismatched receptors (missing self) do not inhibit NK and are rejected. D) Missing 
self recognition by donor NK, in addition to engagement of activating ligands expressed by recipient leukaemia 
cells, lead to donor NK activation and elimination of leukaemia cells. 
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were shown to be protective against respiratory papillomatosis caused by human 
papillomavirus (62). Finally, activating KIRs characteristic of B haplotypes have been shown 
to play a role in NK mediated clearance of HCMV infection following hematopoietic stem cell 
(HSC) or solid organ transplantation (63–66) (Table III).  
2.6.2 Tumor responses 
Tumor (or cancer) cells are modified cells that proliferate uncontrollably and accumulate 
uncorrected mutations. This phenomenon can lead to the production of new and misfolded 
proteins and generates new epitopes which can be presented via MHC to T cells, or 
recognized by antibodies produced by B cells. NK can then eliminate the tumor cells by 
antibody-dependent cell cytotoxicity (ADCC). In addition and similarly to virus-infected cells, 
the high stress level of tumor cells leads to the upregulation of proteins that serve as 
activating ligands to NK receptors (80). Tumor cells also downregulate of MHC Class I 
molecules, disrupting T cell responses and leading to NK activation through missing self 
recognition. Tumor cells may also upregulate FasR and other death inducing receptors for 
which NK express ligands like FasL, leading to caspase-dependent apoptosis of the tumor 
cell (Figure 5B) (81).  
Table III 1 
Table III 2 
Receptor Haplotype Ligand Function Clinical Effects 
KIR2DL1 A+B HLA-C2 Inhibitory 
Recurrent HCMV infection, severe influenza (67, 
68) 
KIR2DL2/3 A+B HLA-C1 Inhibitory 
Severe influenza  (69) 
Resolution of HCV infection  (70) 
KIR2DS1 B HLA-C2 Activating 
Protection from pregnancy complications (71) 
Decreased incidence of HCMV infection after 
hematopoietic stem cell and solid organ 
transplantation (63) 
Susceptibility to psoriasis  (72, 73) 
KIR2DS2 B Unknown Activating Scleroderma and rheumatoid vasculitis (74, 75) 
KIR2DS3 B Unknown Activating 
Decreased incidence of HCMV infection after 
hematopoietic stem cell and solid organ 
transplantation (63) 
KIR2DS5 B Unknown Activating 
Protection from pregnancy complications in African 
population (76, 77) 
KIR3DS1 B HLA-Bw4? Activating Slower progression to AIDS (59, 78) 
NKG2C A+B HLA-E Activating 
Increased clearance of HCMV-infected cells 
through ADCC  (79) 
Table III – NK cell receptors, ligands and clinical effects. 
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2.6.3 NK cells in haploidentical haemopoietic stem cell transplantation (HSCT) 
In some cases of hematopoietic stem cell transplantation (HSCT), there are mismatches 
between the KIR-HLA combinations of donor and recipient. This situation is a classical 
“missing-self” setting, which leads the recipient NK to attack the donor cells due to lack of 
inhibition (Figure 5C). However, HSCT is a special transplant because it contains immune 
cells from the donor, including NK cells. A fraction of NK from the donor may be able to kill 
target cells from the recipient and lead to Graft-vs-Host Disease (GvHD) (82). Remarkably, 
the contrary has been observed: the presence of alloreactive donor-derived NK have been 
correlated with highly improved survival after HSCT for acute myelogenous leukaemia (AML) 
and alloreactive NK promote engraftment and decrease leukaemic relapses (83). Leukaemic 
cells express high levels of ligands for NCR that promote lysis by NK, and combined with 
missing self, leads to their elimination by donor NK cells (Figure 5D). In particular, Moretta 
and others showed a mismatch between homozygous HLA-C1+ and HLA-C2+ donor/receptor 
pairs lead to the elimination of leukemia blasts (e.g. donor KIR2DL1+ NK kill leukemia blasts 
from a HLA-C2- receptor) (84). (Figure 5D). 
Recent experimental evidence has revealed some activating KIR are also involved in the 
graft-vs-leukemia effect. In a recent study, Moretta and others provided direct evidence that 
donor KIR2DS1+ NK play a crucial role in the lysis of receptor C2/C2 leukaemia blasts (85). 
Cytolysis was inhibited by monoclonal antibody (mAb)-mediated blocking of KIR2DS1. 
These data strongly support the clinical relevance of activating KIRs in the elimination of 
leukaemic cells and the benefit of HLA-C mismatched HSCT. 
 
3. Pregnancy - an immunological paradox 
Human reproduction occurs by viviparity. This carries obvious advantages for the fetus, 
which enjoys protection and efficient exchange of gas and nutrients with the maternal blood 
(86). Human placentation is classified as haemochorial, the most invasive type of 
placentation. In preparation for implantation, the human uterine mucosa is transformed into 
decidua, a highly specialized tissue able to support placental invasion. Following 
implantation, the blastocyst develops into an inner cell mass (the fetus precursor) and an 
external layer of cells (trophoblast) which gives rise to the placenta and fetal membranes 
(Figure 6). Over gestation, the trophoblast evolves into a fully formed placenta, constituted 
by several layers of cells. Villous trophoblasts (VT) form tree-like structures that extend the 
surface of the placenta in contact with maternal blood. VT include cytotrophoblast 
(proliferating cells composing the inner cell layer of the villi) and syncytiotrophoblast 
(composed by cells that fuse together to form a single layer over the villi). In addition, the 
placenta contains extravillous trophoblast (EVT). EVT is the most invasive type, detaching 
from villi and infiltrating the uterine tissue and the maternal vessels. EVT replaces the 
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endothelium of uterine spiral arteries, while the smooth muscle cell layer is degraded. These 
processes open the maternal vessels and reduce resistance to allow for a low pressure 
blood flow into the placenta and intervillous space. The maternal blood surrounds the 
syncytiotrophoblast and facilitates the exchange of nutrients and gases with the fetus (86) 
(Figure 7). Shallow placentation or inadequate maternal vessel transformation can lead to 
serious conditions later in pregnancy that include intrauterine growth restriction, stillbirth and 
preeclampsia, a hypertensive disorder of pregnancy (87–89). 
The evolution of hemochorial placentation allowed for a better support of fetal development. 
However, such an intimate contact between mother and fetus exposes the fetal trophoblast 
(a semi-allogeneic entity) to the maternal immune system. In previous sections, the immune 
responses that can be raised against mismatched transplants were discussed; however, in 
human pregnancy, the mother tolerates a semi-allogeneic organ for 9 months. This 
phenomenon raises a question that has fascinated immunologists for 60 years, starting with 
Sir Peter Medawar. In his monolog “Some immunological and endocrinological problems 
raised by the evolution of viviparity in vertebrates,”(90) he proposed three explanations for 
maternal immunological tolerance: physical separation of maternal and fetal tissues, the 
antigenic immaturity of the fetal tissues, and immunological inertness of the mother. 
Although none of those explanations have held up, they had a profound influence on 
research concerned with maternal-fetal tolerance and mechanisms of fetal immune evasion 
(91).  
Figure 6. Diagram of the gravid uterus showing the placenta, extraembryonic membranes and decidualized 
uterus wall. Image courtesy of Ana Haydeé Linares, adapted from reference (94). 
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3.1 MHC class I and II expression in human placenta 
The fetal-placental cells (trophoblasts) come in close contact with the maternal immune 
system in two interfaces. The syncytiotrophoblast is surrounded by maternal blood, while the 
extravillous trophoblast invades the uterine decidua and encounters the tissue resident 
immune cells (Figure 7). To understand the mechanisms involved, both the MHC status of 
trophoblast cells and the maternal leukocytes present in the lining of the uterus are important 
considerations. 
The syncytiotrophoblast layer, which is in direct contact with the maternal immune cells, 
does not express any MHC molecules or NK stress ligands. This way, the 
syncytiotrophoblast can be considered immunologically inert, not being able to elicit CD8+ T 
cell or NK cell-mediated immune responses (92). 
Extravillous trophoblasts (EVT), which are in contact with the immune cells in the decidua, 
express an unusual combination of HLA-C, HLA-E and HLA-G molecules. While all cells in 
the body express HLA-C and HLA-E, HLA-G is restricted to trophoblast and believed to 
modulate NK and T cell functions towards tissue tolerance(93). The HLA-A and HLA-B 
Figure 7. Anatomy of the interface between placental trophoblast and maternal decidua. The different types of 
trophoblast cells and maternal immune cells (yellow) present in the first trimester are shown. The regions of uterine 
spiral arteries where epithelium was substituted by EVT are shaded in red. Image courtesy of Ana Haydeé Linares, 
adapted from reference (94). 
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molecules, which initiate allograft rejection, are not expressed, which leaves HLA-C as the 
only polymorphic molecule in the trophoblast surface that could represent a mismatch 
between mother and fetus. All 3 MHC Class I molecules interact with receptors — such as 
KIRs, CD94/NKG2 and LILR — expressed by NK and subsets of T cells (94).  Interestingly, 
microarray and functional gene set enrichment analysis revealed a striking immune-
activating potential for EVT that is absent in villous trophoblast (95). 
3.2 Decidual leukocytes and potential immune responses 
During pregnancy, the decidua accumulates several types of immune cells. The relative 
amounts and the phenotype of these cells are very different from the ones found in blood. 
Decidual leukocytes are composed of 60-80% NK cells, followed by 15-20% macrophages 
and 5-10% T cells in first trimester of pregnancy (Figure 7). Low percentages of dendritic 
cells, γ T cells and NKT cells can also be found, but B cells are virtually absent. Below is a 
short description of the most important immune cells found at the fetal-maternal interface 
(Figure 7). 
3.2.1 T helper cells, cytotoxic T cells and regulatory T cells 
T cells are the main immune cell population found in blood (70%), which is in stark contrast 
to decidua, where they represent only 5-10% in first trimester, but this percentage increases 
to 60-80% at term. Their low frequency is considered a mechanism of immune evasion, 
since T cells could recognize mismatched HLA-C alleles in EVT and elicit rejection. Both 
CD4+ and CD8+ T cells in decidua display an activated phenotype; however, the percentage 
of regulatory T cells found in decidua is much higher than in blood (96). Studies in abortion-
prone mice where Tregs were adoptively transferred to the site of pregnancy, avoiding fetal 
resorption, showed the vital importance of these cells in pregnancy outcome (97). In 
addition, Tilburgs et al demonstrated an HLA-C mismatch between mother and fetus leads to 
an increase in the number and activity of activated T cells in the maternal-fetal interface. As 
a compensatory mechanism, the function of Tregs in the mismatched pregnancies is also 
enhanced. (98). Moreover, EVT have the ability to induce Treg differentiation in decidua 
(95). 
Some of the mechanisms employed by EVT to avoid T cell attack involved expression of Fas 
ligand (which can induce apoptosis in Fas receptor-expressing cells like activated CD4+ and 
CD8+ T cells) and expression of B7 family members (co-stimulatory molecules) that have an 
inhibitory effect on T cell activation (B7-H1, B7-H2, B7-H3, B7-DC) (91). In addition, 
trophoblast cells and APC produce the tryptophan catabolizing enzyme IDO, which inhibits T 
cell proliferation by tryptophan depletion or production of toxic metabolites (99). 
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3.2.2 Macrophages and dendritic cells 
Macrophages (Mϕ) comprise the second most abundant leukocyte in human decidua (10-
15%). The large abundance of CD14+ decidual macrophages (dMϕs) and the near absence 
of CD14- dendritic cells (DC) suggest they are the most important professional APCs in the 
decidua (100). Therefore, dMϕs, which express MHC class II, are likely to play a crucial role 
in antigen presentation to decidual T cells and may contribute in the establishment of fetal–
maternal immune tolerance. In addition to their  antigen presenting function, dMϕs have 
been shown to express receptors important for phagocytosis of degraded extracellular matrix 
products (101) as well as in apoptotic cell clearance and tissue remodeling (100, 102). 
Furthermore, CD14+ dMϕs produce immunomodulatory proteins such as TGF-β, but also 
proinflammatory IL-6 and IL-8 when stimulated by cell lines expressing the fetal-trophoblast 
HLA-G homodimer (48). Recently, our lab identified two distinct populations of dMϕs in 
decidua: CD11chigh and CD11clow. CD11chigh dMϕs express genes associated with lipid 
metabolism and inflammation, whereas CD11clow dMϕs express genes associated with 
extracellular matrix formation, muscle regulation, and tissue growth. The CD11chigh dMϕs 
also differ from CD11clow dMϕs in their ability to process protein Ag and are likely to be the 
major APCs in the decidua(103). 
3.2.3 Natural killer cells 
The infiltration of decidual NK (dNK) cells is part of the cyclical changes of the endometrium 
and is clearly influenced by sex hormones, particularly progesterone. While in blood NK cells 
represent about 10% of lymphocytes, in decidua they are particularly abundant, constituting 
up to 70% of leukocytes. dNK start accumulating even before implantation, which may 
implicate a role in placentation. During early pregnancy, dNK accumulate as a dense 
infiltrate around the trophoblast and they progressively disappear from mid-gestation 
onwards and at term represent only 10-20%. Therefore, their presence is coincident with the 
period of trophoblast invasion (placentation is complete by about 20 weeks gestation) (94). 
Our lab and others have shown dNK form a distinct NK cell population that has many 
differences in gene expression profile, cytokine secretion profile and cytolytic capacity in 
comparison with peripheral blood NK cells (pNK) (Table IV). While 90% of pNK are 
CD56lowCD16+, all dNK are CD56highCD16-. dNK express KIRs and NKG2 receptors, and 
contain high levels of the cytolytic molecules perforin, granzyme B, and granulysin (104, 
105). These characteristics, however, do not lead to high cytotoxicity, as they are not able to 
kill MHC Class I negative targets as efficiently as pNK (e.g. cell lines K652 or 721.221).  The 
low cytotoxicity of dNK is due to an intrinsic deficiency in polarizing cytolytic granules to the 
immune synapse (106).  
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dNK have been shown to secrete high levels of Interleukin-6 (IL-6), IL-8 and vascular 
endothelial growth factor (VEGF) in response to HLA-G transfected 721.221 cells (221.HLA-
G) and antibody stimulation (48, 107). The potential to secrete cytokines led to the 
hypothesis that dNK facilitate implantation and placental growth by producing chemokines 
for EVT invasion and growth factors involved in vascular remodeling of the spiral arteries. 
However, our lab recently showed that contact with EVT alone does not induce secretion of 
VEGF, IFN-γ or the granulocyte-monocyte colony-stimulating factor GM-CSF by dNK, which 
indicates other stimuli are involved in the activation of dNK cytokine secretion (95). In mice, 
uterine NK cells have in fact been shown to be crucial for proper vascularization of the 
maternal-fetal interface(108). 
dNK express many of the receptors that can interact with the MHC Class I expressed in the 
EVT. HLA-G was thought to modulate NK responses, but more recent findings have added 
controversy to that claim (109, 110). While HLA-E could potentially inhibit NK responses 
against the trophoblast (111), mismatched paternal HLA-C alleles could lead to missing self 
recognition by dNK (112).  
 
Table IV – Differences between pNK and dNK. 
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3.3 HLA-KIR interactions in maternal and fetal health 
Similarly to pNK, dNK express both activating and inhibitory receptors, especially MHC-
Class I receptors. Interestingly, they are found at higher frequencies and higher expression 
levels in decidua (113). While KIR and MHC can influence viral clearance or HSCT outcome, 
pregnancy outcome and complications can also be traced down to KIR-HLA interactions 
between maternal dNK and trophoblast. 
In 2004, Hiby et al reported that mothers homozygous for KIR-A haplotypes (genotype AA) 
were at greater risk for preeclampsia than mothers having one (AB) or two (BB) KIR-B 
haplotypes (114). The risk was further increased for the subset of KIR-AA mothers carrying 
babies bearing the HLA-C2 epitope. KIR-A haplotypes are characterized for the presence of 
the inhibitory receptor (KIR2DL1) and the absence of the activating receptor (KIR2DS1) for 
HLA-C2 (Figure 4). More recently, by comparing the pregnancies of mothers whose KIR-B 
haplotype genes are only centromerically or telomerically located (Figure 4), Hiby et al 
focused the protection effect within the telomeric KIR-B haplotype genes: KIR3DS1, 
KIR2DL5, KIR2DS3/5, and KIR2DS1 (71). Although genetic analysis cannot distinguish 
between them, because of strong linkage disequilibrium, functional studies point to KIR2DS1 
as the protective gene. KIR2DS1 is a well-defined HLA-C2 receptor and protection increased 
when the fetus expressed HLA-C2. In addition, the protective effect was extended from only 
pre-eclampsia to recurrent miscarriage and fetal growth restriction (Table III)  (71). 
Interestingly, the detrimental association of KIR-AA with HLA-C2 may have been a strong 
evolutionary force for the distribution of KIR and MHC haplotypes in human populations. 
Frequency of AA haplotype and HLA-C2 epitope is inversely correlated. For example, the 
Japanese have high KIR AA and low C2 frequencies (115). In the US Caucasian population, 
KIR AA has a frequency of 30%, while HLA-C2 epitope frequency is about 50%. The 
KIR2DS1 gene frequency in the Eastern US population is of 33%(116). 
The cellular mechanisms involved in this genetic association are mostly unknown, but the 
current hypothesis is that dominance of the inhibitory HLA-C2 receptor (KIR2DL1) in women 
with KIR-AA genotype reduces dNK stimulation of EVT and the depth of EVT invasion. This 
hypothesis relies on the paternal HLA-C2 as responsible for the inhibition of dNK and was 
tested in a mouse model of these associations. However, the mouse studies demonstrated 
the parental origin of the inhibitory MHC is irrelevant (117). On the other hand, women with 
telomeric KIR-B haplotypes are protected, because dNK are activated through 
KIR2DS1/HLA-C2 interaction, counterbalancing inhibition and leading to the secretion of 
cytokines facilitating trophoblast invasion and placental growth (118).  
A recent study addressed the cytokine secretion capacity of KIR2DS1+ dNK and identified 
GM-CSF as a growth factor secreted by KIR2DS1+, but not KIR2DS1- dNK. GM-CSF was 
shown to promote the migration of trophoblast cell lines (117, 118). This increase in cytokine 
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production was observed when dNK were stimulated with KIR2DS1 antibodies and classical 
MHC negative target cells, but our recent study demonstrated EVT do not elicit cytokine 
responses by dNK even when KIR2DS1 and HLA-C2 are present (95). Therefore, these 
genetic associations demand further investigation into the molecular mechanisms underlying 
the protective effect of activating KIRs, and in particular KIR2DS1, from pregnancy 
complications (described in chapters 2 and 3). 
3.4 Viral, bacterial and parasite infections in pregnancy 
The tolerant environment of the placenta allows the development of the fetus, but also 
makes it an ideal place for pathogens to evade an immune attack. Viral [e. g. HCMV, HIV, 
herpes simplex virus (HSV) and influenza virus], bacterial [e. g. Listeria monocytogenes, 
Group B Streptococcus, Treponema (syphilis)] and parasitic infections (Toxoplasma, 
malaria) can cause severe maternal and fetal disease and morbidity when they occur during 
pregnancy (119–121). Infections have been reported to cause recurrent spontaneous 
abortions at a rate of about 4%. However, difficulties in demonstrating the pathogenic role of 
a wide variety of viral pathogens may result in under-diagnosis (122). 
3.4.1 Viral infections 
HCMV is the most common congenital viral infection and occurs in 0.5–2% of all live births. 
HCMV causes placental thickening and insufficiency, leading to fetal growth restriction (123–
126). HCMV-infected individuals often have detectable virus specific T cell immunity, but a 
process of immune tolerance combined with viral escape mechanisms overpower the 
efficient eradication of the virus (127). Therefore, primary infection with HCMV leads to life-
long persistence of the virus in the infected host and 50 to 80% of all people in the United 
States are infected with HCMV. HCMV infection is latent in the majority of the hosts, but 
episode of reactivation are known to occur, particularly in immunocompromised patients 
such as recipients of hematopoietic stem cell transplantation (82). HCMV significantly 
inhibits the expression of HLA-A and HLA-B molecules on the cell surface of infected cells 
(128), diminishing viral peptide presentation and subsequent immune recognition by CD8+ 
effector T cells. The low numbers of CD8+ T cells in decidual tissue and the HCMV-induced 
down regulation of HLA-A and HLA-B molecules limit the effectiveness of CD8+ T cells to 
respond to HCMV at the maternal-fetal interface. This leaves dNK cells as the predominant 
immune cell able to control viral infections in decidua and placental tissue.  
Interestingly, similar to HIV infection, HCMV specifically retains HLA-C molecules on the cell 
surface (129). This allows for interaction with NK cells through KIR that bind to HLA-C2 
(KIR2DL1, KIR2DS1) or HLA-C1 (KIR2DL2, KIR2DL3) group molecules. Infection of HLA-
C2+ placental cells may be more efficiently cleared by dNK expressing activating KIR2DS1 
(present in women with KIR-B haplotypes) preventing pregnancy complications caused by 
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viral infection in later gestation. dNK from women with KIR-AA haplotypes (lacking the 
KIR2DS1 gene) would be primarily inhibited by HLA-C2, preventing viral clearance. This 
hypothesis lays the basis for the work presented in Chapter 3.  
3.4.2 Bacterial infections 
Bacterial infections are also common in pregnancy, and can lead to fetal loss, premature 
labor, congenital anomalies and fetal distress. GBS colonize the vagina and can cause an 
ascending infection in pregnant women, spontaneous abortion and neonatal meningitis and 
sepsis (130). Listeria monocytogenes infection among pregnant women is 17-fold higher 
than among the general population (12 per 100,000 vs. 0.7/ 100,000 respectively) (131). L. 
monocytogenes is a Gram-positive rod that causes severe fetal sequelae with spontaneous 
abortion in 10–20%, intrauterine fetal death in 11%, and preterm birth in 50% (132). The 
mechanism of fetal death may result from impaired suppression of maternal T cells to fetal 
antigens by maternal Foxp3+ T regulatory cells (133). Infection by L. monocytogenes during 
pregnancy can result in miscarriage, stillbirth, preterm delivery, and maternal and neonatal 
sepsis (134). Intracellular bacterial infections are primarily eliminated by killer cells (CTL and 
NK), in a mechanism involving synapse formation with the infected target cells and the 
release of perforin and granzymes, which lead to infected cell death (135). In addition, CTL 
and NK cells release granulysin, a microbicidal protein that leads to bacterial cell death in 
combination with granzymes (136, 137). Interestingly, dNK contain high levels of granulysin 
(138), which indicates a possible role in placental bacterial infection and will be the focus of 
Chapter 4 of this thesis. 
3.4.4 Parasite infections 
Parasites such as Toxoplasma gondii and the malaria-causing Plasmodium falciparium can 
also affect pregnancy and cause fetal disorders.  Toxoplasma gondii is a highly prevalent 
infection throughout the world with human transmission generally occurring after ingestion of 
raw meat or exposure to cat feces; fetal damage is characterized by brain and eye injury. T. 
cruzi, also known as Chagas disease, is endemic in Mexico and Central and South America. 
Congenital T. cruzi infection is associated with low birth weight, hepatosplenomegaly, 
anasarca, and stillbirth (132). Plasmodium falciparum infection is especially prevalent in 
regions of Africa, and leads to chronic anaemia and placental malaria infection, reducing the 
birth weight and increasing the risk of neonatal death(139, 140).  
The severity of these infections, both for mother and fetus, requires immediate action to 
improve maternal and fetal health. To understand how and where to act, the achievement of 
a better understanding of the balance between fetal tolerance and immune response to 
infections is crucial. 
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AIMS 
The aim of this thesis is to provide a detailed characterization of the decidual NK cell 
responses to healthy and viral and bacterial-infected placental cells. A particular focus is 
placed on the interaction between placental (fetal) HLA-C and maternal KIR receptors 
expressed by dNK. Chapter 2 presents a study on the phenotype and function of dNK that 
express the activating receptor KIR2DS1. Specifically, the influence of KIR2DS1 expression 
in the cytolytic granule content, degranulation in response to HLA-C2+ targets and cytokine 
secretion in response to primary trophoblast were investigated. In Chapter 3, the 
KIR2DS1/HLA-C2 interactions were further studied in a model for placental viral-infection.  
dNK and pNK response to HCMV-infected decidual stromal cells and fetal trophoblast, in 
particular KIR2DS1+ dNK, were studied. Finally, Chapter 4 introduces a preliminary study on 
dNK responses to bacterial-infected placental cells and the role of dNK-derived granulysin in 
bacterial clearance. The data presented in this thesis contributes for a better understanding 
of the dNK role in human pregnancy and aim to help establish dNK as true immune effector 
cells, in addition to their function in the production of growth factors for facilitation of 
trophoblast invasion. 
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CHAPTER 2 
 
CHARACTERIZATION OF THE PHENOTYPE, CYTOTOXICITY 
AND CYTOKINE SECRETION CAPACITY OF KIR2DS1+ 
DECIDUAL NK CELLS 
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INTRODUCTION 
One of the most interesting observations in the last decade in reproductive immunology 
research is the association between the presence of the killer cell immunoglobulin-like 
receptor 2DS1 (KIR2DS1) in the mother’s genome and a lower risk of developing pregnancy 
complications. In contrast, women who lack KIR2DS1 are at increased risk (71, 114). The 
protective effect of maternal KIR2DS1 expression is most obvious when the fetus expresses 
the ligand for KIR2DS1, the HLA-C2 group allotype of HLA-C (71). This association was also 
found to increase birthweight (76).  Recently, presence of KIR2DS5 was also identified as a 
protection factor in pregnancies of African women, while the effect of KIR2DS1 seems to be 
characteristic of European populations (77). The presence or absence of the KIR2DS1 gene 
is due to the various rearrangements suffered by the KIR locus during human evolution 
(141). These rearrangements resulted in two main KIR haplotypes, KIR-A and KIR-B. The 
KIR-A haplotype lacks most activating KIR, including KIR2DS1, and is associated with 
increased risk for pregnancy complications. In contrast, the KIR-B haplotypes include one or 
more activating KIR genes and reduce the risk of developing complications. Protection from 
pregnancy complications include severe maternal and fetal syndromes that occur in high 
frequencies in the population such as pre-term birth (5-9%), fetal growth restriction (3-10%) 
and preeclampsia (3-5%). 
KIR2DS1 is an activating NK receptor expressed with increased frequency on decidual NK 
cells (dNK) at the maternal-fetal interface compared to peripheral blood NK cells (pNK) 
(113). The current hypothesis states that the protective effect of KIR2DS1 lies in the 
activation of dNK through binding to its ligand, HLA-C2 group molecules, expressed by fetal 
extravillous trophoblasts (EVT).  The activation through HLA-C2/KIR2DS1 provides dNK with 
the ability to secrete beneficial cytokines and growth factors, especially granulocyte-
monocyte colony stimulation factor (GM-CSF), to facilitate trophoblast invasion and placental 
growth (71, 118). This increase in cytokine production was observed when dNK were 
stimulated with KIR2DS1 antibodies and classical MHC negative target cells, but one recent 
study demonstrated EVT do not elicit GM-CSF or even IFN-γ or VEGF secretion by dNK  
(95).  
dNK are by far the most abundant decidual leukocyte subset present at the maternal-fetal 
interface in early pregnancy (60-80%). Our lab and others have shown dNK form a distinct 
NK population which has many differences in gene expression profile, cytokine secretion 
profile and cytolytic capacity in comparison with pNK (48, 105–107, 118). We recently 
demonstrated that many dNK form immune synapses with one EVT in which perforin is not 
localized to the synaptic region, typical for a non-lytic synapse. During the immune synapse 
of dNK and EVT, dNK acquired HLA-G from the EVT through trogocytosis (Tilburgs et al, 
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provisionally accepted). Interestingly, KIR2DS1+ dNK incorporated significantly increased 
levels of HLA-G into their membrane, suggesting a strong interaction between KIR2DS1+ 
dNK and EVT. Prolonged intracellular signaling and possibly distinct functional properties 
may result. 
The protective association between maternal KIR2DS1 and fetal HLA-C2 suggests the 
activation of dNK through KIR2DS1 elicits dNK functions involved in the establishment and 
maintenance of a successful pregnancy. However, activation may lead to higher cytotoxicity 
which may be detrimental for placental cells if not controlled. To analyze the function of 
KIR2DS1+ dNK in healthy pregnancy, the cytolytic capacity and cytokine secretion of dNK 
from KIR2DS1+ versus KIR2DS1- women was studied. In particular, the expression of NK 
receptors, cytolytic granule content, signaling molecules, degranulation in response to HLA-
C2+ cell lines, as well as cytokine production in response to primary EVT, were analyzed. 
Our results reveal a higher cytolytic potential of KIR2DS1+ dNK which does not translate into 
EVT-induced cytokine secretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
32 
 
MATERIALS AND METHODS 
Isolation of NK and trophoblast  
Discarded human placental and decidual material (gestational age 6-12 weeks) were 
obtained from women undergoing elective pregnancy termination at a local reproductive 
health clinic. Peripheral blood leukocytes were isolated from discarded Leukopacks® from 
healthy volunteer blood donors at the Massachusetts General Hospital in Boston, MA. All of 
the human tissue used for this research was de-identified, discarded clinical material.  The 
Committee on the Use of Human Subjects (the Harvard IRB) determined this use of 
placental and decidual material is Not Human Subjects Research. The procedure to isolate 
EVT, dNK and pNK has recently been described (95). Briefly: Decidual and villous tissues 
were macroscopically identified and separated. Decidual tissue was washed with PBS, 
minced and thereafter digested with 0.1% collagenase type IV and 0.01% DNase I (Sigma-
Aldrich) gently shaking in a water bath for 60-75 min at 37°C. Released lymphocytes were 
washed with RPMI 10% FBS (8 min, 1800 rpm) and filtered through 100μm, 70μm and 40μm 
sieves (BD, Labware; NJ). Lymphocytes were dissolved in 20 ml 0.830 g/ml Percoll (GE 
Healthcare) and layered on a Percoll gradient (10 ml 1.085g/ml; 15 ml 1.054g/ml) for density 
gradient centrifugation (30min/2000rpm). Lymphocytes were isolated from the 1.085 – 
1.054g/ml interface, washed twice and directly stained for flow cytometric analysis or FACS 
sort. Peripheral blood NK were isolated using a RosetteSep™ human NK enrichment 
cocktail (StemCell Technologies) followed by Ficoll (GE Healthcare) density gradient 
centrifugation (20 min, 2000 rpm).  
Villous (VT) and extravillous (EVT) trophoblast were obtained as described previously (142). 
Briefly, villous tissue was macroscopically identified and gently scraped from the basal 
membrane. Thereafter the tissue was digested for 8 min at 37°C with a trypsin (0.2%) EDTA 
(0.02%) solution. Trypsin was quenched with F12 medium containing 10% Newborn Calf 
Serum (NCS) and 1% Pen/Strep (all from Gibco) and filtered over a gauze mesh. Filtrate 
was washed once (7 min, 1800 rpm) and layered on Ficoll (GE Healthcare) for density 
gradient centrifugation (20 min at 2000 rpm). Cells were collected, washed once (7 min, 
1800 rpm) and incubated 20 min at 37°C in a 30 mm tissue culture dish for removal of 
macrophages. Cells were collected and thereafter directly stained for flow cytometric 
analysis or FACS sort. Decidual stromal cell lines were obtained as described previously 
(143). HLA typing was performed by the American Red Cross tissue typing facility, Dedham, 
Massachusetts. 
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Cell culture 
pNK and dNK were cultured in X-VIVO 10TM media (Lonza) supplemented with gentamycin, 
5% human AB serum (Corning) and 20 ng/ml recombinant IL-15 (Biolegend). 50.000 CD45- 
sorted VT and EVT were plated in 48-well cell culture plates (Costar) pre-coated with 
fibronectin (100μl of 20ng/ml for 45 min, BD), in DMEM/F12 medium (Gibco) supplemented 
with 10% NCS, 1x Pen/Strep and 1x Glutamine, insulin, transferrin, selenium (Gibco), 5 
ng/ml EGF (Peprotech) and 400 units human gonadotropic hormone (Sigma) as described 
previously (95) . 721.221 (221) and K562 immortalized cell lines were cultured in RPMI 10% 
FCS, while 721.221-HLA-Cw3 (221.Cw3), 721.221-HLA-Cw7 (221.Cw7),  721.221-HLA-Cw4 
(221.Cw4), 721.221-HLA-Cw6 (221.Cw6) (144), K562-Cw1 and K562-Cw6 were cultured in 
RPMI 10% FCS supplemented with 1.6 g/L G418.  
 
Flow Cytometry 
Antibodies used for flow cytometric analysis and FACS sort are listed in Supplemental Table 
S1. For surface staining, cells were stained for 30 minutes on ice in the dark in PBS 1%FCS. 
For KIR2DS1 staining,  NK were stained with KIR2DL1 first (Clone 143211, 1.5μg/ml, 20 
min)  and thereafter with KIR2DL1/S1 (Clone EB6, 0.5μl, 15 min) as described previously  
(145). Cells were analyzed immediately or fixed in 1% paraformaldehyde (PFA) for 10 
minutes for next day analysis. For intracellular staining, cells were fixed and permeabilized 
using the BD CytoFix/CytoPerm kit (BD). Analysis was performed on a FACSCalibur (BD) or 
LSR II (BD) and FACS sort was done using a BD Aria III, MoFlo XDP or MoFlo Astrios 
(Beckman Coulter). 
 
Phosphorylation assessment 
Freshly isolated pNK and dNK cells were incubated at 1 million/ml in X-VIVO 10 media 
(Lonza) for 30 min at 37ºC with or without 100 μM pervanadate solution. Cells were 
subsequently fixed for 10 minutes in equal volume of BD Cytofix buffer (BD) at 37ºC, 
washed, and stained for surface markers for 30 min. The cells were then washed and 
permeabilized with prechilled (-20ºC) BD Phosflow Perm Buffer III for 30 min on ice, followed 
by intracellular staining with BD Phosflow antibodies for 20 minutes.  
 
Degranulation assays 
For degranulation assays, dNK and pNK were cultured overnight in X-VIVO 10TM 
supplemented with 20ng/ml IL-15 (Biolegend). The dNK and pNK (effectors) were harvested, 
counted and co-cultured with 721.221 (221), 221-HLA-C1 (221.C1) and 221.HLA-C2 
(221.C2) in X-VIVO 10 TM in 96 well plates in a 1:3 (effector:target) ratio for 2 hours. For 
NKG2A blocking experiments, dNK were incubated with anti-NKG2A antibody or isotype 
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control for 30 min at 37ºC prior to co-culture with targets. 250ng/ml CD107a PerCP-Cy5.5 
antibody was added to all co-cultures. NK were collected and fixed for 10min in 1% PFA and 
subsequently stained for all relevant surface markers for FACS analysis.  
 
Cytokine secretion analysis 
dNK were co-cultured for with 221, 221.C2 and EVT in a 1:1 mix of trophoblast media and X-
vivo media (supplemented with 20 ng/ml IL-15) for 18h. Supernatants were snap frozen at -
80 °C and all cytokines were analyzed using a multiplex cytokine assay (Magpix, Bio-Rad) 
according to manufacturer’s protocols.  
 
Statistical analyses 
All data was analyzed using GraphPad Prism (version) software. To determine differences 
between 2 unpaired groups, a non-parametric Mann-Whitney test was performed, whereas 
between 2 paired groups a non-parametric Wilcoxon Signed Rank test was performed. To 
determine differences among more than 2 unpaired groups, a non-parametric Kruskal-Wallis 
test with Dunn’s multiple comparison post-test was performed. To determine differences 
among more than 2 paired groups, a non-parametric Friedman’s test with Dunn’s multiple 
comparison post-test was performed. For correlation analyses, Spearman correlation 
analysis was used. All data are depicted with median and interquartile range. P-values <0.05 
were considered to reflect significant differences.*-p<0.05;**-p<0.01; *** p<0.005 
 
 
 
 
 
 
 
 
  
35 
 
TABLE I 
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RESULTS 
Frequency of KIR2DS1+ NK cells is significantly increased in decidua  
The extracellular domains of KIR2DL1 and KIR2DS1 are almost identical, making the 
development of specific antibodies a challenging task. No specific antibodies for KIR2DS1 
are available, but the combination an antibody clone specific for KIR2DL1 (143211) with a 
clone that binds both KIR2DL1 and KIR2DS1 (EB6) allows the identification of KIR2DL1 and 
KIR2DS1 gene carriers (145). This strategy also discriminates four NK populations in 
KIR2DL1+ and KIR2DS1+ gene carriers: KIR2DL1 single positive (L1+ S1-), KIR2DS1 single 
positive (L1-S1+), KIR2DL1+ and KIR2DS1+ double positive (L1+S1+) and double negative 
(L1-S1-). In KIR2DL1+ but KIR2DS1- gene carriers, two NK populations can be identified: 
KIR2DL1 single positive (L1+) and KIR2DL1 negative (L1-) (Figure 1A). Among the KIR2DS1 
Figure 1. Frequency of MHC Class I receptor-positive NK cells is significantly increased in decidua  
A) Representative FACS plots of KIR2DL1 and KIR2DS1 expression in dNK from KIR2DS1- (top left) and 
KIR2DS1+ (top right) women, and in pNK from KIR2DS1- (bottom left) and KIR2DS1+ (bottom right) donors. Cells 
were gated in Live cells CD45+CD56+. B) Graphs depict the percentages of dNK and pNK subsets defined by 
KIR2DL1 (L1) and KIR2DS1 (S1) expression. Representative FACS plots of KIR2DL2/L3 (C), NKG2A (D) and 
NKG2C (E) expression in pNK and dNK. Graphs depict the percentages of dNK and pNK expressing 
KIR2DL2/L3 (L2/L3) (F), NKG2A (G) and NKG2C (H). 
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gene carriers, the frequency of both L1-S1+ and L1+S1+ NK was significantly higher in 
decidua than blood (Figure 1B). In KIR2DS1- individuals, L1+ NK were more frequent in 
decidua than in blood (Figure 1B). In addition, KIR2DL2/L3+, NKG2A+ and NKG2C+ NK 
frequencies were also increased in decidua (Figure 1 C-H). These results confirm previous 
reports demonstrating a skewing of dNK receptor expression towards recognition of MHC 
Class I, especially HLA-C, and particularly, the potential of dNK to develop an activating 
response to HLA-C2 through KIR2DS1 (118, 146).  
  
KIR expression influences granule content in dNK 
To determine whether the presence of KIR2DS1 influenced the cytolytic potential of NK 
cells, freshly isolated dNK and pNK were stained for KIR2DS1 and KIR2DL1 and examined 
for the intracellular expression of the cytolytic molecules granzyme A, granzyme B, perforin 
and the 9 kDa active form of granulysin (147). pNK express significantly higher levels (as 
demonstrated by mean fluorescence intensity, MFI) of perforin compared to dNK, whereas a 
significantly higher percentage of dNK expressed granulysin compared to pNK. Granulysin 
was also expressed at a significantly higher level in dNK. No difference was found between 
expression of granzyme A and B by dNK and pNK (Figure 2 A-C). 
pNK and dNK of KIR2DL1+/S1+ individuals were divided in the four NK subtypes and a 
significantly higher percentage of S1+ dNK (L1-S1+ and L1+S1+) expressed granzyme B, 
perforin and granulysin compared to the L1-S1- dNK subset (Figure 2 D and F). In addition, 
L1-S1+ and L1+S1+ dNK also expressed significant higher levels (MFI) of granzyme B, 
perforin and granulysin compared to the L1-S1- dNK subset (Figure 2D and H).  The 
increase of cytolytic molecules in S1+ cells was specific for dNK and was not observed in 
S1+ pNK (Figure 2 D, E and G).   
 
dNK have a higher potential for activation of signaling pathways downstream of 
KIR2DS1 
The binding of KIR2DS1 to its ligand HLA-C2 triggers DAP12 phosphorylation and 
subsequent recruitment and phosphorylation of adaptor proteins SYK and ZAP-70 (148). To 
determine the potential for activation of these signaling pathways, dNK and pNK from 
KIR2DS1+ and KIR2DS1- donors were stimulated with pervanadate and the levels of 
phosphorylated SYK and ZAP70 (p-SYK/p-ZAP70) were determined by Phosflow assay as 
described in Methods. A significantly higher percentage of dNK had p-SYK/p-ZAP70 
expression than pNK after pervanadate stimulation (Figure 3A-B). The expression levels 
(MFI) of p-SYK/p-ZAP70 were also significantly increased in dNK compared to pNK (Figure 
3B). No difference was found between total expression of SYK or ZAP70 between pNK and 
dNK (data not shown). This data may suggest a previous activation of dNK in vivo or a  
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Figure 2. KIR2DS1 expression increases granule expression in dNK  
A) Representative FACS plots of granule expression in pNK and dNK. B) Percentages of pNK and dNK 
expressing cytotoxic granules. C) Mean Fluorescence Intensity (MFI) for each cytolytic molecule in pNK and 
dNK. D) Representative FACS plots of granzyme B, perforin and granulysin expression in each of the four L1/S1 
subsets in dNK and pNK.  E) Percentage of positive pNK and F) dNK and G) the expression level (MFI) for each 
of the three cytolytic molecules in the four L1/S1 pNK  and H) dNK subsets. The expression level is depicted as 
the relative MFI compared to the double negative subset (dNK n=10, pNK n=7). 
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higher capacity for dNK to signal through these proteins. Furthermore, phosphorylation 
levels of p-SYK/p-ZAP70 were analyzed within KIR2DS1+ and KIR2DS1- individuals. No 
differences in p-SYK/p-ZAP70 were found in dNK from KIR2DS1+ and KIR2DS1- donors, 
whereas pNK from KIR2DS1+ donors have a small but not significant increase in p-SYK/p-
ZAP70 when compared with pNK from KIR2DS1- donors (Figure 3C). 
 
dNK from KIR2DS1+ individuals are not efficiently inhibited by HLA-C2 
Next, cytotoxicity of dNK and pNK from KIR2DS1- and KIR2DS1+ individuals in response to 
MHC class I negative targets 721.221 (221) and 221 that express either HLA-C1 (221.C1) or 
HLA-C2 (221.C2) molecules were compared.  As reported previously, degranulation levels of 
pNK in response to 221 were significantly higher than dNK (Figure 4B) (118). HLA-C1 binds 
the inhibitory KIR2DL2/3 receptors and its expression on 221.C1 significantly inhibited 
cytotoxicity of NK cells from all donors compared to 221. 
In contrast, HLA-C2 can inhibit NK cytotoxicity by engaging with KIR2DL1 or activate NK 
cells through KIR2DS1. Expression of HLA-C2 on 221.C2 significantly inhibited cytotoxicity 
of all pNK and dNK obtained from KIR2DS1- donors and pNK from KIR2DS1+ donors (Figure 
4C, E, F). However, dNK from KIR2DS1+ women were not as effectively inhibited by 221.C2 
(Figure 4D). In addition, the percentage of S1+ single positive dNK, but not pNK, positively 
correlated with the degranulation level of total dNK in response to 221.C2 (R2 0.418 ;  p= 
0.047 – Figure 4G). These results suggest the activation of dNK through KIR2DS1/HLA-C2 
interaction outweighs the inhibition of L1+ by HLA-C2 in dNK but not pNK. 
Figure 3. dNK have higher phosphorylation potential of SYK and ZAP-70 than pNK 
A) Representative FACS plots of p-SYK/p-ZAP-70 expression in pNK and dNK after pervanadate stimulation. NK 
from KIR2DS1- and KIR2DS1+ individuals are depicted. B) Percentage of pNK and dNK with p-SYKp-ZAP-70 
expression from all donors (left) and discriminated in KIR2DS1- and KIR2DS1+ individuals (right). C) Expression 
level (MFI) of p-SYK/p-ZAP70 in pNK and dNK from all donors (left) and discriminated in KIR2DS1- and 
KIR2DS1+ individuals (right). Values are depicted as the ratio between MFI of pervanadate-stimulated cells over 
unstimulated cells. 
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Figure 4. dNK cells from KIR2DS1+ women are not efficiently 
inhibited by HLA-C2+ targets. A) Gating strategy for analysis of 
CD107a+ dNK following co-culture with target cells. B) 
Representative FACS plots of degranulation of dNK (top) and pNK 
(bottom) cells in response to 221, 221.C1 and 221.C2. Percentage 
of CD107a+ cells in C) dNK from KIR2DS1-, D) dNK from  
KIR2DS1+, E)  pNK from KIR2DS1- and F) pNK from KIR2DS1+ 
donors in response to 221, 221.C1 and 221.C2. Correlation between 
the percentage of S1+ single positive cells and percentage of 
CD107a+ cells in G) dNK and H) pNK in response to 221.C2. I) 
Ratios of the degranulation in response of dNK to 221.C2 versus 
221, from KIR2DS1- or KIR2DS1+ mothers pregnant with a HLA-C2- 
or HLA-C2+ fetus. 
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Hiby et al’s studies demonstrated the importance of the presence of the KIR2DS1 gene in 
the maternal genome for a successful pregnancy, and this effect was enhanced if the fetus 
expressed HLA-C2 (71). To determine the effect of the fetal genotype in the dNK response 
to 221.C2 versus 221, fetal and maternal tissues were genotyped for HLA-C. No difference 
was found between the degranulation response of dNK from KIR2DS1- or KIR2DS1+ women 
with HLA-C2- or HLA-C2+ fetuses (Figure 4I). These results indicate previous contact with 
semi-allogeneic HLA-C has no influence in the cytotoxicity of KIR2DS1- or KIR2DS1+ dNK. 
Moreover, the four L1/S1 dNK subsets were analyzed separately for degranulation in 
response to 221, 221.C1 and 221.C2. The degranulation of S1+ single positive dNK in 
response to 221.C2 was significantly higher than all other dNK subsets (Figure 5A, D). The 
response of S1+ single positive dNK to 221.C1 and 221 was comparable to the double 
negative subset and lower than the L1+ subsets, as expected due to NK licensing (53) 
(Figure 5B, C). These data demonstrate HLA-C2-induced activation of S1+ dNK resulting in 
downstream signaling and degranulation. 
 
Figure 5. KIR2DS1+ single positive dNK have higher levels of degranulation in response to HLA-C2+ targets 
A) Gating strategy and representative FACS plots of CD107a dependent degranulation of four dNK subsets (L1-S1-
, L1+S1- L1-S1+ and L1+S1+) in response to 221.C2 targets. Graphs depict degranulation levels of L1+, S1+  and  
L1+S1+ subsets relative to L1-S1- subset  in response to B) 221 (n=21)  C) 221-C1 (n=16) and D) 221.C2 (n=24). 
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HLA-E expression in 221.C2 has no influence in dNK and pNK degranulation  
The 721.221 cell line has genomic deletions in the HLA-A, B and C locus, but not in HLA-E 
(149). HLA-E presents peptides derived from the leader sequence of other MHC Class I 
molecules. 221 do not express MHC class I and this prevents the surfacing of HLA-E. 
However, the transfection of 221 with HLA-C1 and HLA-C2 provide such leader peptides 
and increases the expression of HLA-E on the cell surface (150). dNK and pNK express 
inhibitory receptors for HLA-E (NKG2A); while clear NKG2A- and NKG2A+ populations can 
be identified among pNK, virtually all dNK express NKG2A (Figure 1D, G). To examine if 
HLA-E had an effect in the degranulation results observed in response to 221.C1 and 
221.C2, NKG2A- and NKG2A+ pNK responses were compared. No difference in the 
percentage of CD107a+ NK cells in response to 221.C1 and 221.C2 was found between 
NKG2A- and NKG2A+ pNK (Figure 6A). A clear NKG2A- population cannot be identified in 
dNK and thus blocking of NKG2A was necessary. No difference in the percentage of 
CD107a+ cells in response to 221.C2 was found between dNK previously incubated with 
anti-NKG2A blocking antibody or isotype control (Figure 6B).These results suggest the effect 
observed is due to HLA-C expression only.  
 
K562 is not a suitable cell line for the study of MHC influence in dNK responses 
To overcome some of the disadvantages of the use of 221 (MHC Class II and HLA-E 
expression – Appendix I), the MHC Class I and II-negative cell line K562 (151) (and K562 
transfected with HLA-C1 (K562.C1) and HLA-C2 (K562.C2)) were also used as targets for 
Figure 6: HLA-E expression does not influence 
dNK responses to 221.C2. A) ) Comparison of the 
degranulation levels of NKG2A- with NKG2A+ pNK in 
response to 221.C1 and 221.C2 B) Percentage of 
CD107a+ dNK after co-culture with 221.C2 in the 
presence or absence of anti-NKG2A antibody (or 
isotype control). C) Representative FACS plots of a 
comparison between use of 221 or K562 as target cells 
for degranulation assay, using the same dNK sample 
as effectors.  D) Degranulation of pNK (left) and dNK 
(right) in response to K562.C1 or K562.C2 relative to 
K562, compared to degranulation in response to 
221.C1 or C2 relative to 221. 
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degranulation assay. K562, K562.C1 and K562.C2 were co-cultured with dNK and pNK in 
parallel with 221, 221.C1 and 221.C2. The degranulation of pNK and dNK in response to 
K652 was similar to 221. However, while MHC Class I transfected 221 were able to inhibit 
degranulation, MHC Class I transfected K562 were not (Figure 6C-D). These results showed 
221 are a more reliable NK target for the study of the effect of MHC Class I molecules in NK 
responses. 
  
KIR2DS1 does not influence cytokine secretion of dNK in response to EVT 
dNK have been shown to secrete both pro- and anti-inflammatory cytokines, as well as 
growth factors and chemokines involved in trophoblast invasion and vascular remodeling 
(48, 107, 118). However, all of these studies used cell lines, antibodies or mitogens to 
stimulate dNK. Recently,  it was demonstrated that co-culture of dNK with primary EVT did 
not lead to secretion of the 
cytokines identified in these 
studies (IFN-γ, VEGF) (95). To 
determine if KIR2DS1 
expression has an influence in 
the cytokine response to HLA-
C2+ EVT, dNK were co-cultured 
alone or with 221, 221.C2 and 
matched primary EVT. dNK 
constitutively secreted high 
levels of IL-8 (neutrophil 
chemotactic factor), and the 
secretion was amplified by co-
culture 221 and 221.C2, but 
only slightly with EVT (Figure 
7F). In fact, EVT alone also 
constitutively secreted IL-8 
(data not shown). Co-culture of 
dNK with 221 induced secretion 
of IFN-γ, TNF-, GM-CSF, 
VEGF and IL-6 confirming 
previous studies (48, 107) 
(Figure 7A-E). Interestingly, 
expression of HLA-C2 in 221 
Figure 7. . KIR2DS1 does not influence cytokine secretion of dNK in 
response to EVT.Cell culture supernatants of dNK incubated alone or 
with 221, 221.C2 and EVT analyzed for A) IFNγ, B) TNFα, C) VEGF, D) 
GM-CSF, E) IL-6 and F) IL-8. 
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partially inhibited the secretion of IFN-γ, TNF-α and IL-6, but not GM-CSF and VEGF (Figure 
7A-E), confirming MHC class I may play a direct role in the suppression of pro-inflammatory 
cytokines. Co-culture of dNK with EVT stimulated dNK secretion of IL-6 (Figure 7E), but not 
to the same levels of 221, and did not elicit secretion of IFN-γ, TNF-α, GM-CSF or VEGF 
(Figure 7A-D).  
No significant differences were found in cytokine secretion of dNK from KIR2DS1- vs 
KIR2DS1+ individuals when co-cultured with 221.C2 and HLA-C2+ EVT (Figure 7A-F), 
contrarily to previous published studies regarding GM-CSF secretion by KIR2DS1+ dNK 
(118).  
Together, these data indicate HLA-C expression by EVT has no influence on cytokine 
secretion by dNK, suggesting other stimuli at the maternal-fetal interface may activate dNK 
to secrete cytokines and growth factors.  
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DISCUSSION 
This chapter demonstrates dNK from KIR2DS1+ individuals acquire higher cytotoxic function 
than dNK from KIR2DS1- individuals when exposed to HLA-C2-expressing targets, an effect 
not observed in pNK. Furthermore, the cytotoxic function was correlated with the frequency 
of KIR2DS1+ dNK. KIR2DS1+ dNK had an increased capacity to degranulate in response to 
221 cells that expressed HLA-C2 than KIR2DS1- dNK. This effect was independent of the 
HLA-C genotype of the fetus with which the dNK had had contact in vivo. In addition, HLA-
C2+ EVT did not elicit GM-CSF, IFN-γ or VEGF secretion by dNK from either KIR2DS1- or 
KIR2DS1+ individuals. 
HLA-C expressed by fetal EVT has a unique role in pregnancy, as the only polymorphic 
molecule that can present peptides to maternal T cells and as the main molecule to which 
immune tolerance needs to be established (127). The importance of HLA-C was further 
demonstrated by the observation that the combination of the HLA-C allotype (HLA-C2, 
expressed by fetal trophoblasts) and the expression of its receptor KIR2DS1 in maternal NK 
cells reduce the risk for pregnancy complications and regulate fetal birth weight (71, 76, 
114).  
The previous observation that dNK express higher levels of KIR2DL1 and KIR2DS1 than 
pNK was confirmed. In addition, it was shown expression of KIR2DS1 (both L1-S1+ and 
L1+S1+ subsets) increased the expression of key cytolytic molecules (perforin, granzyme B 
and granulysin) stored intracellularly in dNK but not pNK. Furthermore, dNK from KIR2DS1+ 
individuals were less efficiently inhibited by HLA-C2 expression on target cells. HLA-
E/NKG2A interaction did not influence the HLA-C2 effect. Overall, these data indicate a 
skewing of dNK receptor expression towards recognition of HLA-C, and particularly, the 
potential of dNK to develop an activating response through KIR2DS1 and its interaction with 
HLA-C2. 
Interestingly, the cell line K652 proved not to be a suitable target to study the effect of MHC 
Class I on NK cell cytotoxicity. K562 is an erythroleukemia cell line that does not express 
MHC Class II or MHC Class I (151, 152). Because of this lack of MHC Class I molecules, 
K562 are widely used as classical targets for T cells and NK cells in a variety of cytotoxicity 
assays (153).  However, expression of MHC Class I molecules on transfected K562 lines, 
even at very high levels, was not enough to inhibit dNK and pNK degranulation against 
K562. K562 is a tumor cell line and is known to express very high levels of molecules that 
serve as activating ligands for NK receptors, (e. g. MICA and MICB ligands for NKG2D) 
(154). The expression of MHC Class I was not sufficient to tip the balance towards inhibition 
of NK cells. 
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Although dNK have a higher potential to be activated through the p-SYK/ZAP70 signaling 
pathway, this does not result increased cytolytic activity. On the contrary, dNK have reduced 
ability to degranulate and kill target cells including classical MHC-negative 221. 
Requirements for activation by pro-inflammatory signals may be different between pNK and 
dNK, possibly due to different maturation conditions. The origin of uterine NK cells is not 
completely clear. Several lines of evidence point to an origin in mature peripheral NK cells 
that migrate to the uterus, where their phenotype is modified due to the low inflammatory 
environment of the placenta. Some studies have developed protocols involving the addition 
of cytokines abundant in the maternal fetal interface (such as TGF-β) and low oxygen 
pressure that are able to convert pNK into dNK-like cells (155–157). However, a recent study 
in mice demonstrated mature NK cells do not migrate to the uterus. Instead, immature NK 
precursors migrate from the bone marrow to the endometrium where maturation is 
completed (158). Independently of the origin, NK cells have high plasticity and ability to 
adapt to the surrounding environment to prevent tissue damage due to excess of 
inflammation (53, 159). The threshold for dNK activation is thought to be higher than pNK to 
avoid detrimental effects to pregnancy. However, the expression of high levels of cytolytic 
molecules in dNK shows a cytotoxic potential that may be employed in situations such as 
viral or bacterial infections. 
The increased activation state of S1+ dNK was previously linked to increased ability to 
secrete cytokines and growth factors that facilitate trophoblast invasion and placental growth 
(6). However co-culture of dNK with primary EVT did not enhance cytokine secretion in dNK 
and no differences were found in cytokine responses between dNK or pNK from KIR2DS1+ 
and KIR2DS1− individuals toward any of the target cells, including 221, 221.C2 and EVT (7).  
This suggests other stimuli present in the maternal-fetal interface may be involved in dNK 
function. Interaction of dNK with other immune cells (e.g. macrophages) or decidual stromal 
cells (DSC), in combination with the cytokine environment of the placenta, may lead to dNK 
secretion of growth factors. EVT interaction alone was not sufficient to elicit these functions, 
but may modulate the dNK phenotype. Future focus will be placed on the analysis of the 
cytokine secretion of dNK stimulated with mitogens (e.g. PMA – Ionomycin) after or during 
co-culture with EVT or decidual stromal cells. Furthermore, the analysis of cytokine content 
in the dNK cell culture supernatant only shows the secretion of the total sample of dNK. To 
analyze the contribution of the KIR2DS1+ dNK subset, intracellular staining of cytokines 
following stimulation will be included. 
The protective effect of maternal KIR2DS1 and fetal HLA-C2 was previously thought to be 
related to activation of dNK to secrete growth factors. In this chapter, KIR2DS1+ dNK 
demonstrate a high activation and cytolytic potential that does not translate into cytokine 
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secretion following stimulation with EVT.  In the next chapter, the role of KIR2DS1+ dNK in 
the clearance of placental HCMV infection will be discussed. 
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CHAPTER 3 
 
EXPRESSION OF KIR2DS1 BY DECIDUAL NK CELLS INCREASES 
THEIR ABILITY TO CONTROL PLACENTAL HCMV INFECTION 
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INTRODUCTION 
The establishment of a healthy human pregnancy requires the maternal immune system to 
tolerate fetal alloantigens. HLA-C is the only polymorphic MHC molecule expressed by 
extravillous trophoblast (EVT) that can be directly recognized by maternal NK and T cells 
and elicit an allogeneic response in case of a mismatch between mother and fetus. 
Tolerance is achieved via several mechanisms, such as reduced numbers of effector T cells 
in the maternal decidua, high activity of regulatory T cells, lower cytotoxicity of decidual NK 
and CD8+ T cells and a primarily anti-inflammatory microenvironment with high levels of 
TGF-β and IL-10 (92, 160). However, the immune system must still be able to fight viral and 
bacterial infections that arise during gestation. The balance between fetal tolerance and 
infection clearance is one of the greatest challenges the maternal immune system faces 
during pregnancy. 
Viral infections [e.g. human cytomegalovirus (HCMV), HIV, herpes simplex virus (HSV) and 
influenza virus], can cause severe maternal and fetal disease and morbidity (119–121). 
However, most infections are under-diagnosed due to the high variety of pathogens and the 
difficulty in demonstrating the pathogenic role of the viral pathogens in pregnancy 
complications (122). The most common congenital infection HCMV, occurring in 0.5–2% of 
all live births. HCMV infects the placenta and can inhibit trophoblast differentiation and 
invasion, which can lead to placental insufficiency and fetal growth restriction (123–126). If 
the infection reaches the fetus, it can cause long-term health problems and disabilities such 
as hearing and vision loss, mental disability and seizures (121). CD8+ effector T cells are the 
most important cell type to respond and clear viral infections in the periphery, recognizing 
MHC-viral peptide complexes in infected cells (161). However, in early pregnancy decidual 
tissue, the frequency of CD8+ T cells is very low (2-7% of total CD45+ lymphocytes). In 
addition, decidual effector-memory T cells contain reduced levels of the cytolytic molecules 
perforin and granzyme B, which may limit their cytotoxicity (162). This leaves dNK cells as 
the main potential actors in the clearance of placental viral infections. Decidual NK cells 
represent 60-80% of lymphocytes in decidua. In spite of their low cytotoxicity , dNK express 
very high levels of cytolytic granules (granzymes, perforin, granulysin) and can become 
cytotoxic when activated by pro-inflammatory cytokines (e.g. IL-15, IL-2 IL-12 and IL-18) 
(105, 106).  A recent study demonstrated dNK are capable of killing HCMV-infected 
placental fibroblasts (163). Nevertheless, whether or not dNK or pNK can respond and kill 
HCMV-infected HLA-G+ EVT has not been addressed.  
The presence of activating KIRs, especially KIR2DS1, in the maternal genome has been 
associated with protection from pregnancy complications such as miscarriage, fetal growth 
restriction and preeclampsia (71, 114).  In addition, individuals who carry the KIR-B 
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haplotype (with more activating KIR) have a significantly improved outcome after viral 
infections such as HIV and HCMV (64, 164). The combined presence of KIR3DS1 and its 
putative ligand HLA-Bw4 was associated with significantly slower progression to AIDS, lower 
viral load and slower decline of CD4+ T cells (59–61, 164). In addition, KIR3DS1 and 
KIR2DS1 were shown to be protective against respiratory papillomatosis caused by human 
papillomavirus (62). Activating KIRs have also been shown to play a role in NK mediated 
clearance of HCMV infection following hematopoietic stem cell (HSC) or solid organ 
transplantation (63–66). We therefore postulated the activation of KIR2DS1+ dNK may lead 
to an earlier and more efficient clearing of virus-infected placental cells. This avoids virus 
induced pathology and prevents development of complications in later gestation and would 
provide an explanation to the protective effect of KIR2DS1 in human pregnancy. 
In this chapter, KIR2DS1+ dNK are shown to acquire higher cytotoxicity than KIR2DS1- dNK 
when exposed to HCMV-infected decidual stromal cells (DSC), particularly when DSC 
expresses HLA-C2.  Furthermore, dNK were unable to degranulate or secrete cytokines in 
response to HCMV-infected JEG3 and primary EVT. This emphasizes the immunological 
challenge to clear placental viral infections within the immune privileged compartment of the 
placenta. Additional activation of dNK through KIR2DS1/HLA-C2 interaction may contribute 
to a more efficient control of pregnancy-associated HCMV infection and prevent the spread 
of the infection through the placenta and fetal tissues. 
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MATERIALS AND METHODS 
Isolation of NK, decidua and trophoblast 
Discarded human placental and decidual material (gestational age 6-12 weeks) were 
obtained from women undergoing elective pregnancy termination at a local reproductive 
health clinic. Peripheral blood leukocytes were isolated from discarded Leukopacks® from 
healthy volunteer blood donors at the Massachusetts General Hospital in Boston, MA. All of 
the human tissue used for this research was de-identified, discarded clinical material.  The 
Committee on the Use of Human Subjects (the Harvard IRB) determined this use of 
placental and decidual material is Not Human Subjects Research. The procedure to isolate 
dNK, pNK and trophoblast was described in Chapter 2. Decidual stromal cell lines were 
obtained as described previously (143). HLA typing was performed by the American Red 
Cross tissue typing facility, Dedham, Massachusetts.  
 
Cell culture 
pNK and dNK were cultured in X-VIVO 10TM media (Lonza) supplemented with gentamycin, 
5% human AB serum (Corning) and 2.5 ng/ml rIL-15 (Biolegend). Decidual stromal cells 
were cultured in OPTI-MEM media (GIBCO) supplemented with 3% FCS and 25μg/ml 
gentamycin and passaged once to twice a week. 50.000 CD45- sorted EVT were plated in 
48 well cell culture plates or 8-chamber slides (Costar) pre-coated with fibronectin (100μl of 
20ng/ml for 45 min, BD), in supplemented DMEM/F12 medium (Gibco) as described 
previously (95). The choriocarcinoma cell line JEG-3 was cultured in RPMI 10% FCS. 
 
Flow Cytometry 
Antibodies used for flow cytometric analysis and FACS sort are listed in Supplemental Table 
S1. For surface staining, cells were stained for 30 minutes on ice in the dark in PBS 1%FCS. 
For KIR2DS1 staining,  NK were stained with KIR2DL1 first (Clone 143211, 1.5μg/ml, 20 
min)  and thereafter with KIR2DL1/S1 (Clone EB6, 0.5μl, 15 min) as described previously  
(145). Cells were analyzed immediately or fixed in 1% PFA for 10 minutes for next day 
analysis. Analysis was performed on a FACSCalibur (BD) or LSR II (BD) and FACS sort was 
done using a BD Aria III, MoFlo XDP or MoFlo Astrios (Beckman Coulter). 
 
Degranulation assays 
For degranulation assays, freshly isolated dNK and pNK were co-cultured with uninfected 
and HCMV-infected DSC and JEG-3. For co-culture with EVT, dNK and pNK were cultured 
in X-vivo media (Lonza) supplemented with 5% human serum (Corning) and 2.5ng/ml IL-15 
(Biolegend) for 24h to allow optimal HCMV infection of dNK-matched primary EVT. 150.000 
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dNK or pNK were added to confluent DSC, JEG3 or 50.000 EVT plated in 48 well plates in 
X-VIVO 10TM supplemented with 2.5 ng/ml IL-15 for 10h. 250ng/ml CD107a PerCP-Cy5.5 
antibody was added to all co-cultures. NK were collected and fixed for 10min in 1% PFA and 
subsequently stained for all relevant surface markers for FACS analysis.  
 
Cytokine secretion analysis 
Supernatants from the same co-cultures used for degranulation assays were snap frozen at 
-80 °C and all cytokines were analyzed using a multiplex cytokine assay (Magpix, Bio-Rad) 
according to manufacturer’s protocols.  
 
Infection of DSC, JEG3 cells and EVT 
High titer virus stocks of HCMV AD169 (IE-1-GFP) (a gift from Prof. Donald Coen at Harvard 
Medical School) were obtained by infecting Human Foreskin Fibroblasts (HFF) (ATCC) and 
collecting supernatants. Supernatants were aliquoted and snap frozen in liquid nitrogen until 
use (46). DSC at 80% confluence in 48 well plates were infected at a MOI 0.5 for 1 hour at 
37ºC with frequent shaking, followed by normal culture for 48h before use in assays. JEG-3 
and primary EVT were infected at a MOI 3-4 for 2 or 3 periods of 12 hours (including 1h of 
centrifugation at 2800rpm) before assays. 
 
Fluorescence microscopy 
HCMV-AD169-GFP - infected DSC, JEG3, and EVT were fixed with 4% PFA for 10 minutes 
followed by a 10 min permeabilization with PBS/0.01% Triton-X. Purified primary anti-pp65 
antibody (Abcam) or mouse IgG2a (Biolegend) were added in a 1:200 concentration for 1h, 
followed by washing and staining with goat anti-mouse – AlexaFluor 546 secondary antibody 
(1:500) for 1h. Cells were imaged in a Nikon Eclipse Ti fluorescence microscope. 
 
Statistical analyses 
All data was analyzed using GraphPad Prism (version 6.0) software. To determine 
differences between 2 unpaired groups, a non-parametric Mann-Whitney test was 
performed, whereas between 2 paired groups a non-parametric Wilcoxon Signed Rank test 
was performed. To determine differences among more than 2 unpaired groups, a non-
parametric Kruskal-Wallis test with Dunn’s multiple comparison post-test was performed. To 
determine differences among more than 2 paired groups, a non-parametric Friedman’s test 
with Dunn’s multiple comparison post-test was performed. For correlation analyses, 
Spearman correlation analysis was used. All data are depicted with median and interquartile 
range, except when otherwise indicated. p-values <0.05 were considered to reflect 
significant differences.*-p<0.05;**-p<0.01; *** p<0.005 
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TABLE I. 
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RESULTS 
dNK degranulate in response to HCMV-infected DSC but not to infected JEG3 or EVT 
dNK have recently been shown to be able to eliminate HCMV-infected placental fibroblasts 
(163). The target cells used in the referenced study were a mix of maternal and fetal 
fibroblasts. To discriminate the NK activity in response to HCMV-infected maternal or fetal 
tissue, maternal decidual stromal cells (DSC), the HLA-G+ choriocarcinoma cell line JEG3 
and primary fetal HLA-G+ EVT were infected with HCMV-AD169-GFP. Both dNK and pNK 
showed significantly higher levels of degranulation in response to HCMV-infected DSC 
compared to healthy DSC (Figure 1B and C).  
Interestingly, infection of JEG3 and primary fetal EVT with HCMV significantly increased 
degranulation by pNK compared to uninfected cells. However, dNK did not have an 
increased response to HCMV-infected JEG3 or EVT compared to uninfected cells. (Figure 
1D-E). In addition, both dNK and pNK secreted significantly more IFN-γ, TNF-α and GM-
CSF in response to HCMV-infected DSC compared to healthy DSC, whereas pNK but not 
dNK secreted more of these cytokines in response to HCMV-infected JEG3 and EVT (Figure 
2A-C). In addition, HCMV infection of EVT induced higher IL-6 secretion by pNK but not dNK 
(Figure 2D). These data emphasize the difficulties of dNK in clearing placental viral 
infections, possibly due to the immune privileged status of the placenta. 
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Figure 1. dNK degranulate in response 
to HCMV infected DSC but not to 
HCMV infected JEG3 and EVT   
A( Gating strategy for analysis of 
CD107a+ dNK and pNK following co-
culture with uninfected or HCMV-infected 
target cells. One representative dNK 
sample co-cultured with HCMV-infected 
DSC is shown. B) Representative FACS 
plots of degranulation of dNK (top) and 
pNK (bottom) in response to uninfected 
or infected DSC, JEG3 and EVT. Gates 
for CD107a+ are based on dNK and pNK 
cultured alone. Percentage of CD107a+ 
pNK (left) and dNK (middle) after co-
culture with healthy and HCMV-infected 
D) DSC, E) JEG3 and F) EVT for 10 
hours in the presence of 2.5 ng/ml IL-15. 
Relative degranulation of pNK and dNK 
in response to HCMV-infected relative to 
healthy cells are depicted (right panels). 
Co-culture with DSC and JEG3 was 
established immediately after pNK/dNK 
isolation. To allow for an optimal HCMV 
infection of EVT, dNK/pNK were cultured 
with 2.5ng/ml IL-15 for 24h prior to co-
incubation with dNK matched EVT. 
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HLA-C type of DSC has no influence in total dNK response to HCMV infection 
To evaluate the importance of HLA-C allotype in the response of dNK and pNK from 
KIR2DS1- and KIR2DS1+ donors, two DSC lines were used: one homozygous for HLA-C1 
(DSC.C1) and one expressing both HLA-C1 and C2 (DSC.C2).  No difference was found in 
the ratio of degranulation in response to HCMV-infected cells versus uninfected cells 
between dNK from KIR2DS1- or KIR2DS1+ donors, or in dNK response to HLA-C2+ vs HLA-
C2- DSC (Figure 3A). In contrast, the ratio of degranulation in response to HCMV-infected 
cells vs uninfected cells of pNK was higher in response to HLA-C2+ DSC, particularly in 
KIR2DS1- donors (Figure 3B). These results indicate the presence of activating KIR 
(KIR2DS1) does not enhance the responses of total dNK population to HCMV infection. 
 
Increased degranulation of KIR2DS1+ dNK in response to HCMV-infected HLA-C2+ 
DSC 
To determine the degranulation capacity of each of the four L1/S1 NK subtypes, 
degranulation assays for the response to DSC.C1 and DSC.C2 were performed as 
described previously (Chapter 2). dNK that express KIR2DS1 (L1-S1+ and L1+S1+) 
Figure 2. dNK produce cytokines in response to HCMV- infected DSC but not to HCMV-infected JEG3 and 
EVT. Cell culture supernatants of dNK and pNK incubated with healthy and HCMV infected DSC, JEG3 and EVT 
were analyzed for A) IFNγ B) TNFα, C) GM-CSF and D) IL-6. Cytokine production is depicted as the ratio of 
concentrations in HCMV infected cultures relative to uninfected cultures. (e. g. all ratios >1 indicate a significant 
increased response to HCMV infected versus uninfected cells). 
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demonstrated a significantly increased response to HCMV-infected DSC.C2 compared to L1-
S1- dNK. A similar increase was also showed in response to infected DSC.C1 but it was not 
significant (Figure 4A-B). Moreover, the percentage of total S1+ dNK (both L1-S1+ and 
L1+S1+) positively correlated with the relative degranulation in response to infected DSC.C2 
(Figure 4C). In pNK, the L1+S1+ double positive subset also showed an increased response 
to HCMV-infected DSC but this was independent of HLA-C2 expression on DSC (Figure 4 
D-E).  Furthermore S1+ pNK did not correlate with the degranulation level in response to 
infected DSC.C2 (Figure 4F). These data demonstrate the combination of KIR2DS1 
expression on dNK and the presence of HLA-C2 on DSC increased the ability of dNK to 
clear decidual HCMV infection. 
 
Early HCMV infection reduced HLA-C on DSC, JEG3 and EVT while late infection 
restored HLA-C expression 
HCMV has many molecular strategies to circumvent immune recognition and avoid lysis of 
infected cells (128). Immune evasion strategies by HCMV include the blockade of peptide 
presentation and downregulation of cell surface expression of MHC class I molecules (165). 
Figure 3. dNK KIR2DS1 genotype and DSC HLA-C genotype have no influence in the degranulation 
response to HCMV infected targets (Left) Percentage of CD107a+ dNK (A) and pNK (B) after co-culture with 
uninfected or HCMV-infected DSC. The response to HLA-C2- and HLA-C2+ DSC is compared. Relative 
degranulation of pNK and dNK in response to HCMV-infected relative to healthy HLA-C2- or HLA-C2+ DSC are 
depicted (right panels), comparing KIR2DS1- with KIR2DS1+ donors. 
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This prevents cytolysis by CD8+ effector T cells that require MHC/peptide-TCR binding. 
However downregulation of MHC class I molecules increases the susceptibility of HCMV-
infected cells to lysis by NK cells through missing self-recognition (165). Downregulation of 
MHC, including HLA-C, may also prevent activation of NK cells through KIR2DS1.   
DSC, JEG3 and EVT were infected with HCMV-AD169-GFP. This HCMV strain has GFP 
tagged to an HCMV-Immediate Early (IE) gene. Infected cells were analyzed 48h post 
infection for expression of IE-GFP and stained for pp65 (a late expression gene) for 
fluorescence microscopy (Figure 5). HCMV infection of DSC reached nearly 100% with 
~70% IE-GFP+ and ~30 % pp65+GFP- cells. HCMV infection levels for JEG3 reached closer 
to 40%, with 10% IE-GFP+ cells and ~30% pp65+GFP- cells (Figure 5 and 6A). At 48h, 100% 
of EVT expressed IE-GFP and also pp65, although different levels of expression could be 
observed for the 2 proteins. HCMV-infected and uninfected DSC, JEG3 and EVT were 
analyzed for expression MHC class I molecules. HLA-A2, HLA-E and especially HLA-C 
expression in HCMV-infected DSC was significantly reduced on all infected DSC that 
expressed the IE-GFP protein (Figure 6A, C, D, F). However, when HCMV-infected DSC lost 
Figure 4. S1+ and L1+S1+ dNK respond strongly to HCMV infected HLA-C2+ DSC. Specific degranulation of 
the four L1/S1 NK subsets in response to HCMV infected DSC depicted as the ratio of %CD107a+ NK to HCMV- 
infected versus uninfected DSC. A) dNK HLA-C2+ DSC (n=24) B) dNK to DSC.C1 (n=13) C) pNK to DSC.C2 
(n=13) and D) pNK to DSC.C1.C2 (n=10) E) Correlation plot between percentage of S1 positive dNK and relative 
degranulation of total dNK population in response to HCMV-infected or healthy DSC.C2. F) Correlation plot 
between percentage of S1 positive pNK and relative degranulation of total pNK population in response to HCMV-
infected or healthy DSC.C2. 
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expression of IE-GFP protein and only expressed pp65, HLA-E, HLA-A2 and HLA-C 
expression were restored and HLA-C expression increased in comparison to uninfected 
DSC (Figure 6A, C, D, G). In JEG3 and EVT, HLA-C expression was significantly reduced 
on about ~50% of IE-GFP+ cells compared to uninfected cells (Figure 6A, F). Similarly to 
DSC, when HCMV-infected JEG3 and EVT lost expression of IE-GFP protein, HLA-C 
expression was increased in comparison to uninfected cells (Figure 6F). HCMV infection did 
not change HLA-E and HLA-G expression on JEG3 and EVT. Furthermore, HCMV infection 
did not induce MICA or MICB, two potent activating ligands that bind the activating NK 
receptor NKG2D, on any of the HCMV-infected cells (data not shown). This data 
demonstrate HCMV infection has distinct effects on DSC, JEG3 and EVT 
 
CD57 expression increases pNK responses to HCMV, but not dNK 
pNK expressing high levels of NKG2C and CD57 have been found to be expanded in HCMV 
seropositive individuals (166, 167). NKG2C is an activating receptor for HLA-E, while CD57 
is a marker of maturation in NK cells.  To analyze if expression of NKG2C and CD57 
influence pNK and dNK responses to HCMV-infected cells, degranulation by NKG2C+/- and 
CD57+/- NK subsets were analyzed. Only 2 out of 15 blood donors analyzed had an 
expanded subset of more than 20% NKG2C-expressing pNK, which may indicate HCMV 
seropositivity. The majority of the remaining donors have very low (<5%) percentages of 
NKG2C+ pNK. In contrast, decidua contained high frequencies of NKG2C+ dNK (Figure 7A,  
Figure 5.  HCMV infection of DSC, JEG3 and EVT. Fluorescence microscopy of DSC, JEG3 and EVT 
infected with GFP-tagged AD169 HCMV strain. HCMV infection is represented by expression of viral IE-1-
GFP (immediate early) or pp65 (late infection) after 48 hours of incubation. Scale bars: DSC and JEG3 - 
100μm; EVT - 25μm. 
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Figure 6. HCMV early infection reduces expression of HLA-C in DSC, JEG3 and EVT. 
A) Representative FACS plots of percentage of infection and expression of total MHC Class I (W6/32), HLA-C, HLA-
E, HLA-A2 and HLA-G in healthy or GFP-/GFP+ HCMV-infected DSC, JEG3 and EVT. Graphs depict the ratio 
between the expression levels (MFI) of the MHC Class I molecules (B), HLA-E (C), HLA-A2 (D) and HLA-G (E) in 
GFP-/GFP+ HCMV-infected and healthy DSC (n=10), JEG3 (n=3) and EVT (n=5).. F) Percentage of HLA-C+ DSC 
(n=10), JEG3 (n=3) and EVT (n=3) after infection with HCMV. G) Ratio between expression levels (MFI) of HLA-C in 
GFP- HCMV-infected and healthy DSC and JEG3. For HCMV-infected EVT, no GFP- cells were detected. The grey 
bar refers to the ratio of the MFI of HLA-C+ population in GFP+ HCMV-infected EVT and MFI of HLA-C expression in 
healthy EVT.  Bars indicate mean SE. 
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Figure 7. CD57 expression increases pNK degranulation response to HCMV infected DSC. A) 
Representative FACS plots of NKG2C and CD57 expression in pNK and dNK. Graphs depict the percentages of 
NKG2C (B) and CD57 (C) in pNK and dNK. Ratios of degranulation of NKG2C- and NKG2C+ pNK (D) or dNK (F) 
to HCMV infected vs uninfected DSC. Correlation plot between percentage of NKG2C+ pNK (E) or dNK (G) and 
relative degranulation of total pNK/dNK population in response to HCMV-infected or healthy DSC. H)  Ratios of 
degranulation of CD57- and CD57+ pNK to HCMV infected vs uninfected DSC. I) Correlation plot between 
percentage of CD57+ pNK and relative degranulation of total pNK population in response to HCMV-infected or 
healthy DSC. 
B). CD57 expression followed the opposite pattern of NKG2C: while ~70% of pNK expressed 
CD57 (with some variation), virtually no dNK expressed CD57 (Figure 7A, C). 
To evaluate the possible role of NKG2C in HCMV clearance, the ratio of degranulation in 
response to HCMV-infected versus uninfected DSC of NKG2C- and NKG2C+ dNK and pNK 
were compared. No differences were found between the two subsets in dNK or pNK, and no 
correlation was found between percentage of NK cells expressing NKG2C and the relative 
degranulation in response to HCMV-infected versus uninfected DSC (Figure 7D-G). 
However, in pNK, CD57+ cells had higher ratios of degranulation to HCMV-infected versus 
uninfected DSC than CD57- (Figure 7H), although no correlation between the strength of the 
response and the percentage of CD57-expressing pNK was found (Figure 7I). These results 
indicate mature CD57+ pNK display higher capacity to eliminate HCMV infections. 
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DISCUSSION 
HLA-C expressed by fetal EVT has a unique role in pregnancy, as the only polymorphic 
molecule that can express viral peptides to maternal T cells and as the main molecule to 
which immune tolerance needs to be established (161). The importance of HLA-C was 
further demonstrated by the observation that the combination of the HLA-C allotype HLA-C2 
expressed by fetal trophoblasts and the presence of its receptor KIR2DS1 expressed by 
maternal NK cells reduces the risk for pregnancy complications and are related to fetal birth 
weight (71, 76, 118). Here we present an exciting and novel mechanism to explain how 
expression of KIR2DS1 by dNK increases their ability to control placental HCMV infection 
and thus may limit subsequent virus-induced placental inflammation and pathology.  
dNK and in particular KIR2DS1+ dNK degranulated in response to HCMV-infected decidual 
stromal cells, but failed to respond (degranulate and produce cytokines) to HCMV-infected 
JEG3 and EVT. Thus EVT are tolerant for dNK lysis even when infected. Many molecules, in 
particular HLA-G, but also others (e. g. surface expression of PDL1, CTRAM and secretion 
of anti-inflammatory cytokines such as TGFβ and EBI3) have been shown to be expressed 
on EVT and may explain how EVT are protected (95).  
Interestingly pNK degranulated and produced pro-inflammatory cytokines (IFN-γ, TNF-α and 
GM-CSF) in response to HCMV-infected JEG3 and EVT. pNK are not in direct contact with 
EVT in vivo and whether influx of pNK to HCMV-infected decidua contributes to clearance of 
HCMV-infected EVT requires further investigation. Furthermore, degranulation and cytokine 
production of pNK in response to HCMV-infected EVT demonstrates EVT are not completely 
resistant to killing by immune cells. Additional activation of dNK during virus-induced 
inflammation may be required for dNK to clear infected EVT. Further investigation is needed 
to determine if there are conditions under which dNK are able to kill infected EVT. In the 
present study, dNK were activated with a low dose of IL-15 (2.5ng/ml). However during a 
placental viral infection other decidual immune cells, most importantly macrophages can 
secrete pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12) that can enhance dNK 
activation. 
dNK and in particular KIR2DS1+ dNK may limit the spread of HCMV infection by lysis of 
DSC. DSC require a MOI of 0.5 to be infected and infection reaches 100% after 48 hours. In 
contrast EVT and especially JEG3 require an MOI of 3-4 for only 30-50% of the cells to 
become infected. Previously, miRNAs produced and secreted by EVT exosomes were 
shown to limit HCMV infection of trophoblast cells (168), but HCMV-infected EVT can be 
found in placental tissue (169). Other pathogens such as Listeria monocytogenes have 
previously shown to preferentially infect EVT (170).  
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HLA-C expression was downregulated in HCMV-infected IE-GFP+ DSC, JEG3 and EVT, and 
upregulated during late infection. Other MHC molecules such as HLA-A2 and HLA-E were 
downregulated during early infection of DSC. Interestingly, HLA-G expression in EVT and 
JEG3 was not affected, contrarily to what was claimed in an earlier study (171). Park et al 
demonstrated HCMV infection of HLA-G-transfected human foreskin fibroblasts (HFF) 
downregulated HLA-G expression and identified the HCMV protein US10 as the main factor 
involved in HLA-G degradation. In addition, transfection of JEG3 with US10 also led to 
decrease of HLA-G expression (171). In our study, JEG3 were directly infected with HCMV 
and the efficiency of infection is much lower than HFF. HCMV infection of HFF and US10 
transfection of JEG3 potentially yield high levels of US10 that are not observed in direct 
JEG3 infection. Thus, HCMV infection of JEG3 does not produce sufficient levels of US10 to 
downregulate HLA-G. This hypothesis is reinforced by the observation that HCMV early 
infection of DSC reduces HLA-C expression in ~100% of IE-1-GFP+ cells, compared to 
~50% of JEG3 and EVT. The modulation of HLA-C expression by HCMV potentially leads to 
different responses by dNK in early and late infection.  While early infected cells may 
become susceptible to missing self-recognition through inhibitory KIR (KIR2DL1/2/3), late 
infection and the increase in HLA-C expression levels may provide more potent activation 
through activating KIR such as KIR2DS1. The presence of KIR2DS1+ cells among the total 
sample of dNK does not provide an advantage on viral clearance over dNK from KIR2DS1- 
individuals (Figure 3). However, expression of KIR2DS1 in individual dNK increases their 
cytotoxicity to HCMV-infected cells and may be important in clearing local foci of infections 
(Figure 4).  
The increased activation state of S1+ dNK was previously linked to increased ability to 
secrete cytokines and growth factors that facilitate trophoblast invasion and placental growth 
(118). However co-culture of dNK with primary EVT did not enhance cytokine secretion in 
dNK and no differences were found in cytokine responses between dNK or pNK from 
KIR2DS1+ and KIR2DS1− individuals toward any of the target cells, including 221, 221.C2, 
DSC, JEG3 and EVT (Chapter 2) (95). Our results suggest KIR2DS1 provides protection 
from pregnancy complications due to early elimination of local infections in decidua by 
KIR2DS1+ dNK. This may avoid the spread of the infection in the placenta, which is known to 
inhibit trophoblast invasion that can lead to fetal growth restriction and miscarriage (123). 
Improvement of the diagnosis of congenital infections is crucial to study associations of 
KIR/HLA with susceptibility to pregnancy related HCMV infection or reactivation. 
HCMV reactivation leads to long-term expansion of NKG2C+ pNK, an effect particularly 
observed in recipients of hematopoietic stem cell transplantation. The expanded NKG2C+ 
population was long lived and also expressed the maturation marker CD57. NKG2C+CD57+ 
pNK population expressed several other markers of activation and displayed potent cytolytic 
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function in response to classical NK targets and NKG2C antibody stimulation (172).  In this 
study, high percentages of NKG2C+ dNK were present in the decidua, whereas only two 
blood donors had an expanded population of NKG2C+ pNK. Furthermore no CD57+ dNK 
were found in decidua, while the majority of pNK were CD57+. NKG2C expression was not 
associated with increased degranulation to HCMV-infected DSC in pNK or dNK, but CD57 
expression in pNK increased the response to HCMV. This indicates the maturation status of 
pNK is an important determinant of their anti-viral activity.  
NKG2C expression was associated with lack of FcRγ in NK cells from HCMV-seropositive 
individuals. NKG2C+FcRγ- cells were found primarily in individuals infected with HCMV and 
showed an increased response to HCMV-infected cells in the presence of anti-HCMV 
antibodies or serum from seropositive individuals. Thus, the potent response of NKG2C+ 
pNK is ADCC-dependent (173, 174). NK cells are not able to rearrange somatic receptor 
genes as T or B cells and their ability to generate an immunological memory to antigens is 
controversial. However, several studies of murine models demonstrated that subsets of NK 
cells can proliferate in response to a pathogen and mount a stronger response upon a 
second infection with the same pathogen. An example is mouse cytomegalovirus (MCMV) 
which upon infection produces a MHC-like protein (m157) that is expressed in the surface of 
infected cells and functions as a ligand for the activating NK receptor Ly49H. Ly49H+ mouse 
NK cells proliferate and mount stronger responses upon second MCMV infection (23). In 
humans, more research is required to identify memory NK cells, but NKG2C may serve as a 
marker for memory NK cells formed during virus infections. The existence of NKG2C+FcRγ- 
dNK has not been studied.  It will be important to identify and characterize this subset and to 
find associations with the previous HCMV history of the individual. 
Many pregnancy complications are associated with insufficient trophoblast invasion, 
inadequate spiral artery remodeling and underdeveloped placentas. The interaction of 
maternal immune cells with fetal extravillous trophoblast at the maternal-fetal interface 
regulates these processes. Here we demonstrate that maternal immune cells, especially 
dNK, are able to fight infections in the maternal fetal interface, reducing the risk of infection-
related pregnancy disorders. Moreover, the expression of KIR2DS1 in dNK, in association 
with HLA-C2 expression in decidual stromal cells, increases the response of dNK to HCMV 
infections and contributes to explain the protective effect of KIR2DS1 in pregnancy. These 
results open new pathways for the development of early diagnosis and preventative 
therapies to fight congenital infections, by identifying high-risk pregnancies and enhancing 
dNK immune responses.  
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CHAPTER 4 
 
CONTROL OF BACTERIAL INFECTIONS BY DECIDUAL NATURAL 
KILLER CELL – SECRETED GRANULYSIN 
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INTRODUCTION 
Decidual NK cells (dNK) are the most abundant leukocyte type in the maternal fetal 
interface, but their cytotoxic response to MHC Class I – negative cells and virus-infected 
cells is lower compared to peripheral NK (pNK) (106). dNK contain cytolytic molecules 
(granzymes and perforin) in similar amounts to pNK, and in particular, express increased 
levels of the active form of the anti-bacterial granulysin (Chapter 2). These observations 
suggest dNK may require distinct signals to display their full cytotoxicity and, particularly, 
granulysin may be important in bacterial infection clearance in the placenta. 
 
Granulysin, an unusual lytic peptide 
Cytotoxic T cells (CTL) and NK cells have multiple ways to eliminate target cells. The most 
extensively studied is the directional release of cytolytic granules into the targets during the 
immune synapse. Cytolytic granules contain several types of molecules involved in target 
cell death. Two families of these molecules have been extensively studied: Granzymes and 
Perforin. The granzyme family of serine proteases is involved in the cell death (apoptosis): 
Granzyme B has a role in caspase-dependent apoptosis, while Granzyme A leads to cell 
death independently of caspases. Cell membranes are not permeable to granzymes and for 
these proteins to reach the cytoplasm they require perforin. Perforin polymerizes in the 
plasma membrane of the target cells and forms a pore through which granzymes can enter 
the cytoplasm (14).  
A third cytolytic molecule, granulysin, was identified by Alan Krensky’s lab. The expression 
pattern of granulysin falls in the category of “late” after T cell activation and is similar to that 
of perforin and granzymes (175). Granulysin was found to be in cytoplasmic granules and to 
be exocytosed following stimulation of cytotoxic T lymphocytes (CTL) through the TCR and 
was also identified in NK cells (176). Granulysin is synthesized as a propeptide of 15kDa 
that can be proteolytically cleaved to generate a 9kDa peptide, which in high concentrations 
has lytic activity to tumor cell lines. The carboxyl-terminal region of granulysin shares 
structural homology with a family of proteins named saposin-like proteins (SAPLIP), which 
are generally small peptides that interact with lipids. The most similar member of the SAPLIP 
family is NK-lysin, a porcine NK and T cell granule protein, known to associate with the 
membrane of target cells and for having cytolytic and antibacterial activity (177). The 
proteins of the SAPLIP family share a common structure based primarily on the conserved 
positioning of cysteines and a series of hydrophobic residues. The predicted structure of 
SAPLIP family members, including granulysin, suggests the presence of four relatively 
amphipathic helices held together as a bundle by disulfide bonds (Figure 1) (178).  
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Granulysin has antimicrobial activity 
Although 9 kDa granulysin shows lytic activity to mammalian cells, the activity is dose 
dependent and only very high concentrations of recombinant granulysin are able to yield 
significant lysis (10-100 μM) (177). 9kDa granulysin was subsequently found to be able to 
lyse mycobacteria and parasites when used in much lower concentrations (1-5 μM) (136), 
showing antimicrobial activity similar to NK-lysin. Bacterial death is due to granulysin-
induced lesions in the membrane, an activity similar to that of perforin in mammalian cell 
membranes  – creation of pores in bacterial membranes that alter permeability (179). The 
higher affinity of granulysin to bacterial membranes versus mammalian cell membranes is 
due to the cholesterol content – granulysin preferentially lyses negatively charged 
cholesterol-poor membranes(180). 
Low micromolar concentrations of 9kDa granulysin are enough to lyse extracellular 
mycobacteria, but not to kill intracellular mycobacteria in macrophages. For lysis of 
intracellular bacteria, the addition of recombinant perforin is necessary. Thus CTL must 
respond to bacteria-infected cells and release both perforin (which creates a pore in the 
mammalian cell through which granulysin can enter) and granulysin. In general, formation of 
an immune synapse and granule exocytosis also involves the transfer of granzymes, which 
will then cause the infected cell to die by apoptosis (136). 
 
Concerted action of low-dose granulysin and granzymes lyses bacteria 
Granulysin has lytic activity to mammalian cells, but only at irrelevantly high doses.  The 
Lieberman lab recently described that at nanomolar concentrations (~25 fold less than is 
needed by granulysin on its own to kill bacteria), granulysin delivers granzymes into bacteria. 
The granzymes then rapidly kill the bacteria by cleaving components of bacterial electron 
Figure 1. Sequence of the granulysin protein.  After cleavage of the predicted hydrophobic leader sequence, a 
protein of 15 kDa is produced. The carboxyl-terminal region of the molecule contains a SAPLIP domain that is 
retained in the 9 kDa granulysin protein. Five cysteines important for protein folding in SAPLIP are shown in bold, 
underlined and numbered . The first tyrosine in granulysin-9 kDa (Tyr 1), which normally corresponds to Cys 1 in 
SAPLIP, is also numbered.  Disulfide bonding patterns in NK-lysin and PSP-B are: Cys 1-Cys 6, Cys 2-Cys 5, 
and Cys 3-Cys 4. Adapted from reference (178). 
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transport chain (ETC) complex-I to disrupt electron transport and generate superoxide 
anions. At the same time, granzymes cleave and disrupt key oxidative stress defense 
enzymes that detoxify superoxide anion, rendering the bacteria defenseless to superoxide 
anion-induced death. Killer cell lysis of intracellular bacteria relies on the concerted action of 
all three cytotoxic effector molecules – granzymes, perforin and granulysin, in which perforin 
delivers granzymes and granulysin into the infected mammalian cells and then granulysin 
binds to bacterial membranes to deliver granzymes into bacteria to kill them (135). 
Furthermore these cytolytic molecules activate a similar death pathway in intracellular 
protozoan pathogens (T. cruzi, L. major, T. gondii) (F. Dotiwala et al, Nature Med, 
provisionally accepted).  
 
Decidual NK cells express higher levels of 9kDa granulysin than peripheral NK cells 
dNK at the maternal fetal interface have been shown by various labs, including ours, to 
express cytolytic molecules, even though their cytotoxicity is lower than that of pNK (104, 
105). In 2008, granulysin expression was shown to be increased in spontaneous abortion 
tissue compared to healthy placental tissue, and transfection with granulysin gene was able 
to induce apoptosis in the  trophoblast cell lines HTR8/SV40neo and JEG3 (181).  In 2011, 
the Rukavina lab reported that dNK contained more granulysin than pNK. dNK also 
constitutively secreted granulysin independently of in vitro activation, while pNK did not 
(138). The secretion of granulysin may be due to previous activation in situ (at the maternal 
fetal interface) to which pNKs are not subjected.  
Although the only functional observation of granulysin in the maternal-fetal interface was 
related to tissue apoptosis during spontaneous abortion, its striking abundance raises the 
question of its function in healthy pregnancies. Given its antimicrobial properties, the 
analysis of granulysin role in the clearance of placental bacterial infections is imperative. 
In utero infection with viruses (diverse herpesviruses, rubella, B19 parvovirus), bacteria (L. 
monocytogenes, GBS, syphilis), and parasites (T. gondii) can lead to fetal loss, premature 
labor, congenital anomalies and fetal distress. For example, Listeria monocytogenes 
infection among pregnant women is 17-fold higher than among the general population (12 
vs. 0.7 per 100,000) (131). L. monocytogenes is a Gram-positive rod associated with 
ingestion of raw meats, unwashed raw vegetables, and soft unpasteurized cheeses; fetal 
sequelae are severe with spontaneous abortion in 10–20%, intrauterine fetal death in 11%, 
and preterm birth in 50% (132). L. monocytogenes may spread to the uterus via either an 
ascending infection or a hematogenous route. EVT may control the spread of L. 
monocytogenes at the maternal–fetal interface by confining the bacteria within vacuolar 
compartments destined for lysosome degradation (170). Infection by L. monocytogenes 
during pregnancy can result in miscarriage, stillbirth, preterm delivery, and maternal and 
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neonatal sepsis (134). The mechanism of fetal death may result from impaired suppression 
of maternal T cells to fetal antigens by maternal Foxp3+ T regulatory cells (133).   
Understanding the immune response to infection in the pregnant uterus is critical to 
protecting the fetus and the mother from infection to improve pregnancy outcome. In this 
study, the main aim is to characterize the antimicrobial effect of dNK and pNK on a 
trophoblast-like cell line, JEG3, and the role of granulysin in this process. The abundance of 
dNK in the maternal fetal interface and their potential role in bacterial infection clearance are 
key points that can be targeted for prenatal therapy. 
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MATERIALS AND METHODS 
Isolation of dNK and pNK  
Discarded human placental and decidual material (gestational age 6-12 weeks) were 
obtained from women undergoing elective pregnancy termination at a local reproductive 
health clinic. Peripheral blood leukocytes were isolated from discarded Leukopacks® from 
healthy volunteer blood donors at the Massachusetts General Hospital in Boston, MA. All of 
the human tissue used for this research was de-identified, discarded clinical material.  The 
Committee on the Use of Human Subjects (the Harvard IRB) determined this use of 
placental and decidual material is Not Human Subjects Research. The procedure to isolate 
dNK and pNK was described in Chapter 2.  
 
Cell culture  
pNK and dNK were cultured in X-VIVO 10TM media (Lonza) supplemented with 5% human 
AB serum (Corning) and 2.5 ng/ml recombinant IL-15 (Biolegend). The choriocarcinoma cell 
line JEG-3 was cultured in RPMI 10% FCS supplemented with 1% Pen/Strep (Gibco). 
721.221 (221) immortalized cell line was cultured in RPMI 10% FCS supplemented with 
1%Pen/Strep (Gibco). Whenever target cells (721.221 or JEG3) were plated for bacterial 
infection, cells were washed three times in antibiotic-free media and seeded for overnight 
culture in antibiotic-free media. 
 
Flow Cytometry  
Antibodies used for flow cytometric analysis and FACS sort were as follows: CD45 Pacific 
Orange (HI30), CD14 PE-Texas Red (TüK4), CD3 PE-Texas RedTM (S4.1) (Invitrogen), 
CD14 FITC (ME52), CD56 PE (HCD56), CD56 AlexaFluor 700TM (HCD56), Granulysin 
AlexaFluor 647TM (DH2), Granulysin PE (DH2), CD107a PerCP-Cy5.5 (H4A3) (Biolegend), 
Granulysin AlexaFluor 488TM (RB1) (BD Pharmingen). For surface staining, cells were 
stained for 30 minutes on ice in the dark in PBS 1% FCS. Cells were analyzed immediately 
or fixed in 1% paraformaldehyde (PFA) for 10 minutes for next day analysis. For intracellular 
staining, cells were fixed and permeabilized using the BD CytoFix/CytoPerm kit (BD 
Biosciences). Analysis was performed on a FACSCalibur (BD) or LSR II (BD) and FACS sort 
was done using a BD Aria III, MoFlo XDP or MoFlo Astrios (Beckman Coulter). 
 
Cytolytic granule secretion  
dNK and pNK were cultured overnight in antibiotic-free X-vivo 10TM (Lonza) at a 
concentration of 2x106 cells/ml with 2.5ng/ml IL-15 (Biolegend). Supernatants from these 
cultures were collected and snap frozen at -80ºC till analysis. Granulysin concentration was 
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measured by ELISA (LEGENDMAX, Biolegend). Granzyme A, Granzyme B and Perforin 
concentration were measured by Milliplex MAX (EMD Millipore) in a Luminex instrument. 
 
Colony forming unit assays  
dNK and pNK were cultured overnight in antibiotic-free X-vivo 10TM (Lonza) at a 
concentration of 2x106 cells/ml with 2.5ng/ml IL-15 (Biolegend). Supernatants were collected 
and cells were harvested. JEG3 were seeded overnight in 96 well plates (Corning) at a 
concentration of 10.000 cells/well, and then infected with L. monocytogenes at MOI=5 for 15 
minutes. JEG3 were washed 3 times with RPMI 10% FCS (Gibco) and cultured with 100.000 
dNK/pNK cells or 100 μl of dNK/pNK supernatant in duplicate for 3 hours. 10.000 free L. 
monocytogenes were also cultured in 100 μl of supernatant for 3 hours in duplicate. At 
endpoint, media was removed from cells and replaced with 200μl of deionized water for 
hypotonic lysis. Released bacteria were plated in LB plates at 10-1, 10-2 and 10-3 
concentrations. For free bacteria cultured with dNK/pNK supernatant, aliquots of the cultures 
were plated in LB plates in the same 3 concentrations. LB plates were incubated overnight 
and colonies were counted. 
 
51Cr release assays 
10.000 JEG3 plated on 96 well plates were incubated with 100 μCi of 51Cr for 1h. Half of the 
wells were infected with L. monocytogenes at MOI=5 for the last 15 minutes. Uninfected and 
infected target cells were incubated with 100.000 dNK/pNK or 100 μl of dNK/pNK 
supernatant from the overnight cultures for 4h. Controls for spontaneous release and total 
release (lysed with 0.1%SDS) were also prepared. 50ul of supernatant was transferred to a 
Luma Plate, dried overnight and read in a scintillation counter. Percentage of specific lysis 
was calculated as follows: 
(𝑆𝑎𝑚𝑝𝑙𝑒 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑢𝑛𝑡𝑠)−(𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑢𝑛𝑡𝑠)
(𝑇𝑜𝑡𝑎𝑙 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑢𝑛𝑡𝑠)−(𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 𝑐𝑜𝑢𝑛𝑡𝑠)
 × 100 
 
Degranulation assays  
For degranulation assays, dNK and pNK were cultured overnight in antibiotic-free X-VIVO 
10TM (Lonza) supplemented with 2.5ng/ml IL-15 (Biolegend). The dNK and pNK (effectors) 
were harvested, counted and co-cultured with 721.221 (221) in a 1:3 E:T ratio and with 
uninfected or L. monocytogenes-infected confluent JEG3 in antibiotic free RPMI 10% FCS 
(Gibco) for 4 hours. 250ng/ml CD107a PerCP-Cy5.5 antibody (Biolegend) was added to all 
co-cultures. NK cells were collected and fixed for 10min in 1% PFA and subsequently 
stained for all relevant surface markers for FACS analysis. 
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Confocal microscopy  
Fresh dNK and pNK were plated in 10mm 1.5 coverslips coated with 0.01% poly-L-lysine 
(Sigma) and allowed to adhere for 1 hour. Cells were fixed with 4% paraformaldehyde for 10 
minutes and then permeabilized with PBS/0.01% Triton-X for 10 minutes. Primary 
conjugated antibodies (Perforin AlexaFluorTM 488 (dG9), Perforin AlexaFluor 647TM (dG9), 
Granulysin AlexaFluor 647TM (DH2) (Biolegend) Granulysin AlexaFluor 488 (RB1) (BD) were 
added for 1h. Cells were washed and stained with Hoechst (Immunochemistry 
Technologies) for 10 minutes, and coverslips were mounted in slides for confocal 
microscopy using ProLong Gold Antifade mounting media (Life Technologies). Cells were 
imaged in a Zeiss LSM510 microscope. 
 
Statistical analysis 
All data was analyzed using GraphPad Prism (version 6.0) software. To determine 
differences between 2 unpaired groups, a non-parametric Mann-Whitney test was 
performed. To determine differences among more than 2 unpaired groups, a non-parametric 
Kruskal-Wallis test with Dunn’s multiple comparison post-test was performed. To determine 
differences among more than 2 paired groups, a non-parametric Friedman’s test with Dunn’s 
multiple comparison post-test was performed. P-values <0.05 were considered to reflect 
significant differences.*-p<0.05;**-p<0.01; *** p<0.005 
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RESULTS 
dNK express higher levels of 9kDa and 15kDa granulysin than pNK 
To characterize granulysin expression, dNK and pNK were intracellularly stained for total 
granulysin (15kDa and 9kDa) and the 9kDa isoform separately and analyzed by flow 
cytometry. dNK express significantly higher levels of total granulysin and the 9kDa isoform 
than pNK. pNK do not express the 9kDa isoform and thus the low expression levels as found 
with the total granulysin stain must identify the 15kDa isoform (Figure 2 A and B). 
9kDa granulysin has been described to be confined to the same granular vesicles and 
perforin and granzymes in pNK, while 15kDa was localized in different vesicles (182). To 
determine the localization of granulysin in dNK, freshly isolated dNK and pNK were stained 
intracellularly for total granulysin, 9kDa granulysin and perforin and analyzed by confocal 
microscopy. Granulysin was expressed in granules both with and without perforin, while 
some of the granulysin was diffusely distributed in the cytoplasm of dNK (Figure 2C, upper 
panels). Staining with the antibody specific for 9kDa granulysin combined with the total 
granulysin antibody revealed 9kDa granulysin is confined in granules, which identifies the 
diffuse cytoplasmic granulysin as the 15kDa form (Figure 2C, middle panels). Furthermore, 
pNK did not stain for 9 kDa granulysin (confirming the flow cytometry data), while 15 kDa 
granulysin was found confined to granules that were either perforin-positive or perforin-
negative (Figure 2C, lower panels). 
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dNK spontaneously release high levels of granulysin 
dNK have been shown to spontaneously secrete granulysin, while pNK do not have that 
capacity (138). dNK secreted granulysin in the absence of stimulation (e. g. cytokine 
stimulation IL-15 or IL-2, or stimulation with target cells).  To confirm this observation, freshly 
isolated dNK and pNK were cultured for 12 hours in the presence or absence of IL-15 and 
the culture supernatants were analyzed for the presence of cytolytic molecules by ELISA 
(granulysin) and Bioplex assay (granzyme A, B and perforin). The levels of granzyme A, 
granzyme B and perforin found in the supernatant were negligible (<0.5 nM). In contrast, 
granulysin levels in dNK supernatants were variable, (mean 1.42 ± SD 2.27 nM), while pNK 
supernatants contained virtually no granulysin (0.067 ± 0.064 nM, p<0.001) (Figure 3A). The 
concentrations of all cytolytic molecules found in the supernatants of dNK and pNK cultured 
Figure 2.  dNK express higher levels of granulysin than pNK and granulysin has distinct localization in 
intracellular granules.  A) Representative FACS plots of 9kDa and total granulysin in pNK and dNK. B) Graph 
depicts expression level (MFI) of 9kDa isoform and total granulysin in pNK and dNK. C) Confocal microscopy of 
dNK  and pNK showing the localization of perforin, total granulysin and 9kDa granulysin. Granules containing 1. 
perforin and granulysin; 2. perforin only; 3. granulysin only. 
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in the absence of IL-15 were lower, but only granulysin secretion was significantly decreased 
by lack of IL-15 (Figure 3B). Thus, granulysin release by dNK was independent from perforin 
and granzymes and may point to the existence of special granulysin-exclusive vesicles.  
 
dNK and pNK cells and dNK supernatants eliminate intracellular bacteria without 
lysing the host cell 
Given the high levels of granulysin in dNK and the antimicrobial functions of granulysin, the 
next step was to determine if dNK have a role in eliminating bacterial infections in placenta. 
JEG3 cells (a choriocarcinoma cell line with the same MHC pattern of EVT) were infected 
with Listeria monocytogenes and co-cultured with dNK or pNK at a ratio of 10:1 
(effector:target) for 3 hours. Bacterial and target cell death were analyzed by colony forming 
unit (CFU) assay and 51Cr release assay, respectively. Both dNK and pNK were able to kill a 
significant fraction of the intracellular bacteria compared to control. However, none were able 
to kill infected or uninfected JEG3 (Fig 4 A and C). 
pNK and dNK cell culture supernatants obtained were added to free L. monocytogenes or to 
Figure 3. dNK secrete granulysin and granzyme A in higher levels than pNK. A) pNK and dNK were 
cultured for 12h in the presence of 2.5 ng/ml IL-15. Granulysin levels analyzed by ELISA. Granzyme A, 
Granzyme B and Perforin levels in the culture supernatant were analyzed by Luminex B) Cytolytic granule 
concentrations in the supernatant of dNK cultured in the presence or absence of IL-15. Bars represent meanSE. 
Figure 4. dNK and their supernatants kill intracellular L. monocytogenes but spare infected cells. A) 
Relative colony forming units (CFU) of intracellular L. monocytogenes (MOI 5) in JEG3 co-cultured with dNK or 
pNK (E:T 10:1) for 3h. B) Relative CFU of intracellular L. monocytogenes (MOI 5) in JEG3 cultured with dNK or 
pNK supernatant for 3h C) Killing of L. monocytogenes -infected JEG3 by dNK or pNK (E:T 10:1, 4h) D) Killing of 
L. monocytogenes-infected JEG3 4h by supernatants from dNK or pNK. Bars represent meanSE. 
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JEG3 infected with L. monocytogenes. dNK supernatants were able to kill both extra and 
intracellular L. monocytogenes, while pNK supernatant did not (Figure  4B). In addition, 
neither of the supernatants were able to kill JEG3 (Figure 4D).  
At sites of immune privilege (e. g. eye, testes, and placenta), cell types such as EVT are 
resistant to killer cells by expression of serine protease inhibitors called serpins (183): 
SERPINB9 inhibits granzyme B (and also 
caspase-1 and caspase-8) (184–186); SERPINB4 
and possibly SERPINB9B inhibit granzyme M 
(187); SERPINB1 inhibits granzyme H (188). 
Inhibitors of apoptosis (IAP), namely c-
IAP1(BIRC2), c-IAP2 (BIRC3), livin (BIRC7), 
and/or survivin (BIRC5) (189–191), Bcl-xL 
(BCL2L1) (192) and Bim (BCL2L11) (193) may 
also be involved. As a preliminary study of anti-
apoptotic protein expression by JEG3, the 
available microarray developed in our lab and 
published in (95) was analyzed.  Indeed, EVT and 
JEG3 shows high level expression of several of 
the serpins, IAP and BCL family genes, which 
may explain the failure of dNK and pNK to kill 
JEG3 (Figure 5).  
 
Bacterial killing is not associated with CD107a+ granule exocytosis 
NK mediated target cell death or intracellular bacterial death depends on granule exocytosis 
and the release of granzymes and perforin to the immune synapse. To verify if contact with 
bacteria-infected cells would lead to CD107a mobilization to the cell surface (an indication of 
granzyme and perforin release), dNK and pNK were cultured with L. monocytogenes-
infected or uninfected JEG (and 721.221 for control). While co-culture with 721.221 led to 
CD107a-dependent degranulation by dNK and pNK, co-culture with JEG3 did not, even 
when infected with L. monocytogenes (Figure 6A and B).  Thus, bacterial clearance by NK in 
placental cells is independent of degranulation, suggesting perforin and granzymes may not 
be involved in the process. 
  
Figure 5. – Trophoblasts express high levels 
of apoptosis inhibitors.  Heatmap depicts  the 
expression of  apopotosis inhibitors’ genes 
[Serpin B1, B4 and B9, Bcl-xl (BCL2L1) , Bim 
(BCL2L11), survivin (BIRC5) and livin (BIRC7)] in 
EVT, JEG3 and maternal decidual stromal cells 
(DSC). 
i i it r .  Heatmap depicts
of apopotosis inhibitors’ genes [S rpin
B1, B4 and B9, Bcl-xl (BCL2L1) , im (BCL2L11),
survivin (BIRC5) a d livin (BIRC7)] i EVT, JEG3
and maternal decidual stromal cells (DSC). 
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Figure 6. L. monocytogenes infection of JEG3 does not elicit degranulation of dNK and pNK. A) 
Representative FACS plots of degranulation of dNK (top) and pNK (bottom) in response to 221 and 
uninfected or L. monocytogenes -infected JEG3. B) Percentage of CD107a+ pNK and dNK after co-culture 
with 221, healthy and L. monocytogenes -infected  JEG3. 
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DISCUSSION 
The present work describes a new and exciting phenomenon – NK cells are able to eliminate 
microbes within infected cells without killing the host cell. The killing of intracellular microbes 
does not rely on CD107a-dependent degranulation and is possibly due to granulysin that is 
constitutively secreted by dNK. In dNK, granulysin was found to be diffusely distributed in the 
cytoplasm as well as contained in vesicles. Although some of the granulysin-positive 
vesicles also contained perforin, granulysin-exclusive vesicles were identified. In addition, 
the granulysin secretion was independent of the release of granzymes and perforin. Thus 
granulysin exclusive vesicles may be responsible for the constitutive secretion of granulysin. 
The ability to secrete granulysin constitutively may be due to a high activation state of dNK 
(e.g. constitutive expression of CD69, high levels of cytotoxic granules) (105).    
The concentration of granulysin in the dNK supernatants do not fall within the range 
considered to be microbicidal by itself (1-3μM) (136). In addition, which isoform of granulysin 
is found in dNK supernatants is not known. Previous studies of pNK demonstrated the 
15kDa isoform of granulysin is preferentially secreted. The 15kDa form has not been studied 
extensively, and until recently it was not clear whether it serves only as a precursor of the 
9kDa isoform or if it has a separate function by itself (177). In  activated CTLs and pNK, 
9kDa granulysin co-localizes with granzymes and perforin in cytolytic granules, while 15kDa 
is localized in its own granules that can exocytose upon activation without target cell contact 
and synapse formation(182). Also, the 15kDa form has no cytolytic activity against 
mammalian cells or extracellular microbes. However, it can stimulate monocytes to 
differentiate into dendritic cells, and work as a chemoattractant for leukocytes (182). An 
interesting hypothesis concerns the possibility of the 15kDa form being taken up by bacteria-
infected JEG3 and then proteolytically cleaved within the cells to release 9kDa form, leading 
to intracellular bacteria death. These questions are currently being addressed by performing 
detailed analysis of the contents of the dNK cell culture supernatant.  
The levels of granulysin in dNK supernatants may contribute to the extracellular bacterial 
killing, in combination with other putative antimicrobial substances present in the 
supernatant. In fact, dNK constitutively secrete other molecules, such as galectin-1, which 
may have a role in bacteria elimination (105). Galectins are β-galactoside-binding lectins that 
accumulate in the cytosol before being secreted via a leader-peptide-independent pathway. 
Extracellular galectins bind glycans on cell membranes and modulate cellular behavior. 
However, they can also occur in the cytosol and can act as danger and pattern-recognition 
receptors (194). Galectin 3, for example, binds bacterial lipopolysaccharide (LPS) and acts 
as a negative regulator of LPS functions (195), and Galectin 8 targets damaged vesicles for 
autophagy to defend cells against bacterial invasion (194). pNK supernatants have negligible 
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levels of granulysin and were not able to kill extracellular bacteria, and have also been 
shown to not secrete Galectin-1 (105).  
The ability of dNK supernatants to kill intracellular bacteria may lie in the capacity of 
granulysin to enter JEG3 by binding lipid rafts and subsequently being transported to the 
intracellular space. This mechanism is independent of perforin.  Recombinant granulysin 
was shown to bind lipid rafts of Listeria innocua-infected DCs. Subsequently the 
granulysin/lipid rafts were endocytosed and transported to bacteria-containing vesicles, 
leading to microbe killing (196).  
Although pNK supernatants do not kill bacteria, pNK and dNK cells can kill intracellular L. 
monocytogenes. In this case, an immune synapse may be formed where all three granules 
are transferred to the infected cells and act together to eliminate bacteria. dNK have been 
shown to form immature synapses with EVT,  where perforin was not polarized to the 
synapse (Tilburgs et al, provisionally accepted). In our study, no degranulation was observed 
during dNK and pNK co-culture with infected JEG3, which indicates perforin and granzymes 
were not released. Thus, bacterial death may be due to granulysin in combination with other 
antibacterial peptides.  dNK contact with infected cells may increase secretion or dNK may 
form a new kind of synapse with JEG3 where only granulysin-containing vesicles are 
polarized, resulting in exclusive transfer of granulysin between cells. This mechanism may 
apply to pNK, which are able to kill intracellular bacteria when in contact with infected cells, 
but do not secrete granulysin without activating stimuli.  
Uninfected or infected JEG3 were not killed during interaction with NK, at least during the 
time of assay (4h), which was sufficient to inhibit bacterial growth.  A longer exposure of 
infected JEG3 to NK may result in cell death; indeed, a previous study on HCMV-infected 
primary decidual stromal cells (DSC) demonstrated efficient lysis of infected DSC only 
occurs after 18h of contact (163). In addition, dNK do not degranulate against HCMV-
infected JEG3 or EVT even after 10-12 hours of contact, while pNK are able to degranulate 
in response to infected JEG3 and EVT (chapter 3). pNK do not contact EVT in vivo, but 
whether there is influx of pNK to the decidua during infection has not been explored. dNK 
may form synapses with infected JEG3 that lead to bacterial death. JEG3 may be resistant 
to NK killing due to expression of anti-apoptotic proteins such as serpins ((95) and figure 5). 
The findings reported in this chapter point to an important role of dNK in clearance of 
bacterial infection through the action of granulysin. These observations reveal a novel 
function of dNK as true immune effector cells besides their role in secretion of cytokines and 
growth factors that facilitates trophoblast invasion. Further experiments are necessary to 
study the mechanism of action of dNK-secreted granulysin in the elimination of placental 
infections. Current studies in include the detailed analysis of dNK supernatants and potential 
binding of granulysin to lipid rafts for internalization in infected JEG3. Furthermore, the 
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cytolytic potential of NK in response to bacteria infected-JEG3 and JEG3 resistance to death 
will be studied, in addition to immune synapse formation between dNK and JEG3. The 
influence of cytokines in the expression and secretion of granulysin by dNK and pNK will 
also be analyzed. 
In summary, these data unveil a new target for pre-natal therapies. Bacterial infections in 
early gestations can be treated by increasing the dNK potential to secrete granulysin, or by 
administration of granulysin in microbicidal doses that do not affect the placental cells. The 
treatment of placental infections in an early stage may avoid complications later in 
pregnancy such as miscarriage, congenital malformations or fetal growth restriction. 
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CHAPTER 5 
 
GENERAL DISCUSSION 
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The discovery of the presence of high numbers of large granular lymphocytes (LGL) in 
human decidua, later identified as decidual Natural Killer (dNK) cells (197), led to the 
hypothesis that fetal placental cells actively inhibit maternal dNK to avoid immunologic 
rejection (198). The subsequent characterization of dNK as poor cytotoxic lymphocytes and 
major cytokine and growth factor producers distanced dNK from true immune effector cells. 
The main role for dNK was established as agents that facilitate implantation, trophoblast 
invasion and vascular remodeling. These processes are of key importance for placental 
development and enhance the exchange of gases and nutrients from mother to fetus (94, 
107, 199). Until recently the role of dNK in clearance of infections, a key function of pNK, 
was largely ignored. In 2013, Siewiera et al demonstrated the ability of dNK to clear HCMV-
infected cells (163). The results presented in this thesis build upon this observation and 
highlight the dual role of dNK, capable to mount immune effector responses during viral and 
bacterial infections as well as provide immune tolerance to the fetus and facilitate placental 
growth. The expression of the activating MHC Class I receptor KIR2DS1 by dNK was 
associated with improved clearance of HCMV-infected decidual stromal cells (DSC). In 
addition, dNK eliminated placental bacterial infections without affecting the host cells, 
possibly though secretion of the anti-microbial peptide granulysin. These results emphasize 
the importance of dNK to provide both immunity to infections and tolerance to fetal cells.  
 
KIR2DS1, HLA-C2 and HCMV 
The MHC Class I molecule HLA-C expressed by fetal EVT is the main factor that can cause 
allogeneic recognition and possible immune rejection by maternal immune cells. This 
immune response can be driven by T cells through direct allo-recognition (e.g. fetal EVT 
express a foreign HLA-C molecule that directly activates maternal T cells)  or by NK cells 
due to missing-self (e.g. EVT lack a MHC molecule and fail to inhibit NK cytotoxicity through 
inhibitory receptors) (91, 94). dNK express high levels of receptors for MHC class I [of which 
the killer cell immunoglobulin-like receptors (KIR) are most important for HLA-C]. Particular 
combinations of KIR and MHC haplotypes influence reproductive success, clearance of viral 
infections and development of auto-immune diseases. In particular, women with KIR-AA 
haplotypes (lacking most activating KIR) are in high risk of developing complications such as 
pre-eclampsia, recurrent miscarriage or fetal growth restriction. The effect is enhanced when 
the fetus expresses group 2 HLA-C alleles (71, 112, 114). This observation led to the 
hypothesis that the lack of activating KIR (KIR2DS1) allows for a strong inhibition of dNK 
through KIR2DL1 (inhibitory receptor), reducing dNK secretion of cytokines that enhance 
trophoblast invasion and placental development (117, 118). In this thesis, KIR2DS1+ dNK did 
not respond directly to EVT by degranulation or secretion of growth factors such as GM-CSF 
or VEGF. In addition, degranulation of KIR2DS1+ dNK in response to HLA-C2+ target cells 
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did not correlate with the HLA-C epitope of the fetus, indicating de novo education fetal HLA-
C does not occur (Chapter 2). Instead, KIR2DS1+ dNK were shown to have increased 
cytolytic granule content (granzymes, perforin and granulysin) and to have higher levels of 
degranulation in response to 221.C2 (Chapter 2). Most importantly, KIR2DS1+ dNK 
displayed higher capacity to clear human cytomegalovirus (HCMV)-infected decidual stromal 
cells (DSC), in particular when HLA-C2 molecules were present (Chapter 3). These 
observations were specific for dNK and not observed in pNK. 
HCMV employs many strategies for immune evasion and prevent the lysis of infected cells. 
These strategies include interference with MHC Class I processing and surface expression 
(128). As presented in chapter 3, HCMV infection downregulated HLA-C in DSC in early 
stages, but upregulated HLA-C expression in late infection. Consequently, cells in early 
infection stages are not able to inhibit dNK through KIR2DL1, while cells in late infection 
stages can increase activation of single-positive KIR2DS1+ dNK. Thus the presence of 
KIR2DS1+ dNK can enhance elimination of decidual HCMV-infection and limit virus-induced 
placental pathology. These observations may lead to novel pathways for development of 
immune therapies that prevent congenital infections and virus-induced pregnancy 
complications. 
Interaction of EVT did not induce secretion of growth factors by dNK. Whether or not 
interaction with other cell types in decidua (e.g. decidual macrophages, T cells and stromal 
cells) and modulation by the decidual environment induce cytokine secretion by dNK 
remains to be investigated. Several lines of evidence indicate DSC as conditioners of dNK 
phenotype and function, via direct interaction or production of cytokines such as IL-33 and 
TGF-β (156, 200). DSC decrease pNK cytotoxicity and upregulate the expression of 
inhibitory receptors in dNK (200, 201). Other sources of anti-inflammatory cytokines that can 
influence dNK behavior are decidual macrophages (103). dMϕs have been shown to secrete 
TGF-β and to inhibit dNK cytotoxicity in vitro (202). Crosstalk between dNK and dMϕs or 
dendritic cells in the maternal fetal interface is also involved in decidualization in mice (203).  
The detrimental association of the maternal KIR-AA haplotype with fetal HLA-C2 may have 
been a strong evolutionary force for the distribution of KIR and MHC haplotypes in human 
populations. Frequency of AA haplotype and HLA-C2 epitope is inversely correlated and this 
reduces the frequency of potentially complicated pregnancies: women who are homozygous 
for the group A KIR haplotype paired with men who carry the HLA-C2 epitope (204). 
Infections are also known to be strong forces of evolution and natural selection. 
Combinations of KIR and HLA are associated with increased clearance of viral infections 
(59, 64, 164). For example, KIR2DL2/3 and HLA-C1 are associated with control of HCV 
infection, due to the low affinity interaction of KIR2DL2/3 with HLA-C1 (compared with the 
high affinity interaction of KIR2DL1 and HLA-C2). This leads to a less effective inhibition of 
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NK and consequently higher activation (70). Although the evidence is correlative, it raises 
the hypothesis that KIR-A haplotypes are mainly selected for their role in immune defense, 
whereas KIR-B haplotypes are selected for their role in placental reproduction. An episode of 
viral infection would select for KIR-A haplotypes, which will be enriched in the survivors, but 
in subsequent expansion of the surviving population there will be selection for KIR-B 
haplotypes and against KIR-A. Thus, long-term survival of human populations have been 
selected for retain both KIR-A and KIR-B haplotypes (205, 206). In this thesis, the KIR-B 
haplotype correlates with improved clearance of viral infection in pregnancy, and not KIR-A. 
However, elimination of viral infection leads to reproductive success and contributes to the 
maintenance of KIR B haplotypes in the population. These results suggest a more complex 
model for KIR haplotype influence in evolution and demand further investigation. 
 
dNK, infections and pregnancy complications 
Viral infections in pregnancy, in particular HCMV, are frequent and lead to pregnancy 
complications that include miscarriage and pre-term birth (122, 132). HCMV persists as a 
latent infection and, in the absence of high levels of protective antibodies, HCMV can 
reactivate in the placenta. Placental HCMV infection interferes with trophoblast invasion and 
placental development and can give rise to placental pathology and congenital syndromes 
(123, 126) Due to the high variety of pathogens involved and subclinical nature of some 
infections, occurrence of infections during pregnancy is underdiagnosed. CD8+ T cells 
represent only 2-7% of CD45+ lymphocytes in decidua and thus dNK are the prime 
candidates to respond to viral infections in decidua (162). Siewiera et al provided the first 
evidence that dNK are able to clear HCMV infected DSC (163). In this thesis, we expanded 
these studies and showed while dNK can clear HCMV-infection of maternal DSC, HCMV-
infected trophoblast cannot be cleared (Chapter 3). While dNK degranulated and secreted 
pro-inflammatory cytokines in response to HCMV-infected DSC, no response was observed 
to HCMV-infected JEG3 or primary trophoblast (Chapter 3). The clearance of infected DSC 
limits the viral spread to trophoblast, which are naturally more resistant (168). The failure of 
dNK to kill EVT, even when infected with HCMV, may be due to the immunomodulatory 
properties of EVT, to avoid detrimental consequences to the fetus caused by excessive 
inflammation. Virus, bacteria and parasites may take advantage of the immune privileged 
status of the placenta and EVT to avoid immune attack. However, pNK are able to kill 
infected trophoblasts in vitro, although pNK and EVT do not interact in vivo. These 
observations underline the importance of early diagnosis of infections during pregnancy to 
avoid the spread of pathogens to the placenta and fetus. Understanding the mechanisms 
that regulate the switch in dNK immune tolerance and immunity contribute to discover key 
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factors involved in the immunopathology of placental HCMV infection and lead to novel  
strategies to limit congenital infection. 
 
dNK, granulysin and the control of bacterial infections 
Similarly to viral infections, bacterial (e.g. Listeria monocytogenes, Group B streptococcus) 
and parasite infections (e.g. Toxoplasma gondii, Plasmodium spp) can also cause major 
complications during pregnancy and this includes miscarriage, preterm delivery and 
maternal and fetal sepsis (139, 140). In this thesis, the importance of the high level of 
antimicrobial peptide granulysin in dNK was demonstrated in the clearance of Listeria 
monocytogenes. dNK were shown for the first time to clear intracellular Listeria 
monocytogenes in the trophoblast cell line JEG3 without killing the JEG3 cells (Chapter 4). 
The failure of dNK to lyse infected JEG3 may be due to the expression of anti-apoptotic 
proteins that neutralize the effect of granzymes by JEG3 (95). This reveals a novel function 
of dNK as immune effectors able to clear bacterial infections while maintaining tolerance to 
the trophoblast.  
Killing of intracellular bacteria by NK in most cell types is dependent on the concerted action 
of granzyme, perforin and granulysin (135). However, the elimination of L. monocytogenes 
by dNK in trophoblast lines was independent of degranulation (Chapter 4). This suggests the 
existence of other pathways such as specialized immune synapses that may transfer 
granulysin and other antimicrobial substances to target cells. Furthermore dNK may target 
bacteria through constitutive secretion of granulysin or other antimicrobial peptides that enter 
the infected host cells without killing them (138).  
The stimuli that induce the high granulysin expression and constitutive secretion of 
granulysin by dNK are unknown and may be related to the contact of dNK with the placenta 
bacterial flora. Until recently, the placenta was thought to be sterile, but a multi-center study 
reported the existence of a unique microbiome (207). pNK may require  activating signals 
(e.g. of placental cells or the placental microbiome) to increase the expression and secretion 
of granulysin. 
The data presented in Chapter 4 is preliminary and raises several questions related to the 
regulation of granulysin expression and secretion by dNK, the mechanisms involved in the 
bacterial elimination and trophoblast protection, as well as other microbial compounds that 
may be involved in bacterial elimination. Nevertheless, these novel findings provide 
promising new possibilities for congenital therapies and for the elimination of bacterial and 
parasite infections. This includes a focus on the enhancement of dNK function and 
granulysin activity.  
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Mice are not humans 
Although mouse placentation is not as invasive as human placentation, both mouse and 
human placentation are haemochorial. These arguments have been used to support the 
claim that mouse are both a good and not a good model to study human reproduction. Other 
differences between mouse and humans are gestational length (3 versus 40 weeks), 
exposure to pathogens (mouse are kept in pathogen free environments) and MHC 
differences (mouse are mainly inbred strains with limited polymorphisms) (208). Most 
importantly, the NK receptor repertoire for MHC Class I of mice and humans have evolved 
separately (mouse have Ly49 genes instead of KIR genes) (204). Despite these differences, 
mice are useful to study placental immunology and development of pregnancy complications 
as long as these differences are taken in consideration.  
In particular, Anne Croy and others have shown VEGF and IFN-γ produced by uterine NK 
(uNK) is crucial for an effective vascularization of mouse decidua (108, 209, 210). Mice that 
lack both T and NK cells (Rag2-/-Il2rg-/-) or only NK cells (IL-15 KO), although still bearing 
successful semi-allogeneic pregnancies, have delayed vascularization compared to WT and 
the litter sizes are smaller (211). Although both KO mice were capable to successful semi-
allogeneic pregnancies, the fact that these mice were kept in a pathogen-free environment 
should be considered. This does not address the crucial role of uNK cells in the resolution of 
infection. Interestingly, no interactions occurred between uNK cells and trophoblasts in the 
live tissues studied at early gestation. This is in stark contrast with the claims that interaction 
of dNK with EVT in humans is the main event that triggers cytokine and growth factor 
secretion by dNK (107, 117, 118). In fact, our lab demonstrated, both in early publications 
and in this thesis, that direct co-culture of dNK with EVT does not elicit cytokine or growth 
factor secretion such as IFN-γ, VEGF or GM-CSF (Chapter 2) (95).  
The maternal KIR AA/fetal HLA-C2 detrimental association has been hypothesized to be due 
to strong inhibition of KIR2DS1- dNK cytokine secretion by HLA-C2+ EVT. This theory was 
explored with the use of a mouse pregnancy model in which the fetus expressed an extra 
MHC Class I molecule to increase the inhibition of maternal NK cells. The litter sizes in this 
model were smaller and the secretion of IFN-γ by uNK cells was significantly lower than in 
pregnancies without the extra MHC. However, the effects were independent of the paternal 
or maternal origin of the extra MHC and the results did not account for the presence of NK 
activating receptors (117). These results leave open the possibility that maternal HLA-C2+ 
DSC, and not only fetal EVT, can be involved in the inhibitory interactions in KIR2DS1- 
women and dNK activation in KIR2DS1+ women. Chapter 3 demonstrated maternal HCMV-
infected HLA-C2+ DSC did increase the cytotoxicity of S1+ dNK – showing the influence of 
maternal HLA-C. 
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Other notes and final conclusion 
All the work presented in this thesis was performed using primary NK cells and trophoblasts, 
isolated from human tissue. The use of primary cells yields results relevant for human 
clinical applications However, primary cells have several limitations, such as short culture 
life, lack of proliferation, limited cell numbers, and a great variability in phenotype and activity 
that is inherent to human populations. In addition, it was not possible to obtain peripheral 
blood cells from the same women that donated decidual tissue. All the pNK were obtained 
from unrelated blood donors, and the results may be different from pNK from pregnant 
women.  
The data presented in this thesis on dNK and EVT in healthy and infected pregnancies 
opens exciting new possibilities for therapies that can improve maternal and fetal health, with 
special focus in enhancing dNK function in viral and bacterial infections. Identifying high risk 
pregnancies (e.g. women with KIR-AA genotypes) at early stages for monitoring viral and 
bacterial infections will be crucial to avoid disorders that affect both mother and fetus. The 
preliminary data on the possible role of dNK-derived granulysin will need further 
development, but it presents a promising strategy to eliminate bacteria without disturbing the 
delicate placental tissue. Finally, this work represents a step further on the understanding of 
Peter Medawar’s proposed problem – the balance between immunity and tolerance in the 
maternal-fetal interface. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
88 
 
REFERENCES 
1. Goldsby, R. A., T. J. Kindt, B. A. Osborne, and J. Kuby. 2003. Immunology, 5th ed. (J. 
Noe, M. Ryan, J. Ciprioni, K. Mergen, G. Hadler, A. Kudlacik, and N. Villamora, eds). W.H. 
Freeman and Company, New York. 
2. Medzhitov, R., and C. a Janeway. 2002. Decoding the patterns of self and nonself by the 
innate immune system. Science 296: 298–300. 
3. York, I. a, and K. L. Rock. 1996. Antigen processing and presentation by the class I major 
histocompatibility complex. Annu. Rev. Immunol. 14: 369–396. 
4. Chervin, A. S., J. D. Stone, P. D. Holler, A. Bai, J. Chen, H. N. Eisen, and D. M. Kranz. 
2009. The impact of TCR-binding properties and antigen presentation format on T cell 
responsiveness. J. Immunol. 183: 1166–78. 
5. Bogunia-Kubik, K., and M. Iwaszko. 2011. Clinical Significance of the HLA-E and CD94 / 
NKG2 Interaction. Arch. Immunol. Ther. Exp. 59: 353–367. 
6. Amiot, L., N. Vu, and M. Samson. 2014. Immunomodulatory Properties of HLA-G in 
Infectious Diseases. J. Immunol. Res. 2014: 298569. 
7. Petroff, M. G. 2005. Immune interactions at the maternal – fetal interface. J. Reprod. 
Immunol. 68: 1–13. 
8. Roche, P. a., and K. Furuta. 2015. The ins and outs of MHC class II-mediated antigen 
processing and presentation. Nat. Rev. Immunol. 15: 203–216. 
9. Abbey, J. L., and H. C. O’Neill. 2008. Expression of T-cell receptor genes during early T-
cell development. Immunol. Cell Biol. 86: 166–174. 
10. Starr, T. K., S. C. Jameson, and K. a Hogquist. 2003. Positive and negative selection of 
T cells. Annu. Rev. Immunol. 21: 139–176. 
11. Shah, D. K., and J. C. Zúñiga-Pflücker. 2014. An overview of the intrathymic intricacies 
of T cell development. J. Immunol. 192: 4017–23. 
12. O’Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T 
helper cell subsets. Immunity 8: 275–283. 
13. Toda, A., and C. a Piccirillo. 2006. Development and function of naturally occurring 
CD4+CD25+ regulatory T cells. J. Leukoc. Biol. 80: 458–70. 
14. Chowdhury, D., and J. Lieberman. 2008. Death by a thousand cuts: granzyme pathways 
of programmed cell death. Annu. Rev. Immunol. 26: 389–420. 
15. Thiery, J., D. Keefe, S. Boulant, E. Boucrot, M. Walch, D. Martinvalet, I. S. Goping, R. C. 
Bleackley, T. Kirchhausen, and J. Lieberman. 2011. Perforin pores in the endosomal 
membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. 
Nat. Immunol. 12: 770–7. 
16. Van Lier, R. A. W., I. J. M. ten Berge, and L. E. Gamadia. 2003. HUMAN CD8+ T-CELL 
DIFFERENTIATION IN RESPONSE TO VIRUSES. Nat. Rev. Immunol. 3: 913–918. 
89 
 
17. Ehlich, A., and R. Küppers. 1995. Analysis of immunoglobulin gene rearrangements in 
single B cells. Curr. Opin. Immunol. 7: 281–284. 
18. Hodgkin, P. D., and A. Basten. 1995. B cell activation, tolerance and antigen-presenting 
function. Curr. Opin. Immunol. 7: 121–129. 
19. Armitage, R. J., and M. R. Alderson. 1995. B-cell stimulation. Curr. Opin. Immunol. 7: 
243–247. 
20. Fridman, W. H. 1991. Fc receptors and immunoglobulin binding factors. FASEB J. 5: 
2684–2690. 
21. Leavy, O. 2012. Maturation and function of NK cells. Nat. Rev. Immunol. 12: 150. 
22. Bellora, F., R. Castriconi, A. Dondero, P. Carrega, A. Mantovani, G. Ferlazzo, A. 
Moretta, and C. Bottino. 2014. Human NK cells and NK receptors. Immunol. Lett. 161: 168–
173. 
23. Sun, J. C., J. N. Beilke, and L. L. Lanier. 2009. Adaptive immune features of natural killer 
cells. Nature 457: 557–561. 
24. Biassoni, R., E. Ugolotti, and A. De Maria. 2009. NK cell receptors and their interactions 
with MHC. Curr. Pharm. Des. 15: 3301–10. 
25. Afzali, B., R. I. Lechler, and M. P. Hernandez-Fuentes. 2007. Allorecognition and the 
alloresponse: Clinical implications. Tissue Antigens 69: 545–556. 
26. Afzali, B., G. Lombard, and R. I. Lechler. 2008. Pathways of major histocompatibility 
complex allorecognition. Curr. Opin. Organ Transplant. 13: 438–444. 
27. Charpentier, B., P. Lang, C. Hiesse, and D. Fries. 1986. Effector mechanisms of graft 
rejection. Nephrologie 7: 15–18. 
28. Pegram, H. J., D. M. Andrews, M. J. Smyth, P. K. Darcy, and M. H. Kershaw. 2010. 
Activating and inhibitory receptors of natural killer cells. Immunol. Cell Biol. 89: 216–224. 
29. Moretta, L., E. Montaldo, P. Vacca, G. Del Zotto, F. Moretta, P. Merli, F. Locatelli, and M. 
C. Mingari. 2014. Human Natural Killer Cells: Origin, Receptors, Function, and Clinical 
Applications. Int. Arch. Allergy Immunol. 164: 253–264. 
30. Vivier, E. 2006. What is natural in natural killer cells? Immunol. Lett. 107: 1–7. 
31. Horowitz, A., D. M. Strauss-albee, M. Leipold, J. Kubo, O. C. Dogan, C. L. Dekker, S. 
Mackey, H. Maecker, G. E. Swan, M. M. Davis, P. J. Norman, L. a Guethlein, M. Desai, P. 
Parham, and C. a Blish. 2013. Genetic and Environmental determinants of human NK cell 
Diversity Revealed By Mass Cytometry. Sci. Transl. Med. 5: 208ra145. 
32. Biassoni, R. 2009. Human natural killer receptors, co-receptors, and their ligands. Curr. 
Protoc. Immunol. Chapter 14: 14.10.1–40. 
33. Krzewski, K., and J. L. Strominger. 2008. The killer’s kiss: the many functions of NK cell 
immunological synapses. Curr. Opin. Cell Biol. 20: 597–605. 
90 
 
34. Rak, G. D., E. M. Mace, P. P. Banerjee, T. Svitkina, and J. S. Orange. 2011. Natural 
killer cell lytic granule secretion occurs through a pervasive actin network at the immune 
synapse. PLoS Biol. 9: e1001151. 
35. Shifrin, N., D. H. Raulet, and M. Ardolino. 2014. NK cell self tolerance, responsiveness 
and missing self recognition. Semin. Immunol. 26: 138–144. 
36. Brady, J., S. Carotta, R. P. L. Thong, C. J. Chan, Y. Hayakawa, M. J. Smyth, and S. L. 
Nutt. 2010. The interactions of multiple cytokines control NK cell maturation. J. Immunol. 
185: 6679–88. 
37. Upshaw, J. L., and P. J. Leibson. 2006. NKG2D-mediated activation of cytotoxic 
lymphocytes: unique signaling pathways and distinct functional outcomes. Semin. Immunol. 
18: 167–75. 
38. Arlettaz, L., J. Villard, C. De Rham, S. Degermann, B. Chapuis, B. Huard, and E. 
Roosnek. 2004. Activating CD94 : NKG2C and inhibitory CD94 : NKG2A receptors are 
expressed by distinct subsets of committed CD8 + TCR ab lymphocytes. Eur. J. Cell Biol. 34: 
3456–3464. 
39. Borrego, F., M. Masilamani, A. I. Marusina, X. Tang, and J. E. Coligan. 2006. The CD94 
/ NKG2 Family of Receptors. Immunol. Res. 35: 263–277. 
40. Mori, Y., S. Tsuji, M. Inui, Y. Sakamoto, S. Endo, Y. Ito, S. Fujimura, T. Koga, A. 
Nakamura, H. Takayanagi, E. Itoi, and T. Takai. 2008. Inhibitory immunoglobulin-like 
receptors LILRB and PIR-B negatively regulate osteoclast development. J. Immunol. 181: 
4742–51. 
41. Davidson, C. L., N. L. Li, and D. N. Burshtyn. 2010. LILRB1 polymorphism and surface 
phenotypes of natural killer cells. Hum. Immunol. 71: 942–9. 
42. Middleton, D., and F. Gonzelez. 2010. The extensive polymorphism of KIR genes. 
Immunology 129: 8–19. 
43. Parham, P. 2008. The genetic and evolutionary balances in human NK cell receptor 
diversity. Semin. Immunol. 20: 311–6. 
44. Alari-pahissa, E., C. Grandclément, B. Jeevan-raj, and W. Held. 2014. Inhibitory 
Receptor-Mediated Regulation of Natural Killer Cells. Crit. Rev. Immunol. 34: 455–465. 
45. Culley, F. J., M. Johnson, J. H. Evans, S. Kumar, R. Crilly, J. Casasbuenas, T. 
Schnyder, M. Mehrabi, M. P. Deonarain, D. S. Ushakov, V. Braud, G. Roth, R. Brock, K. 
Köhler, and D. M. Davis. 2009. Natural killer cell signal integration balances synapse 
symmetry and migration. PLoS Biol. 7: e1000159. 
46. Lanier, L. L. 2010. DAP10- and DAP12-associated receptors in innate immunity. 
Immunol. Rev. 227: 150–160. 
47. Moretta, a, D. Pende, F. Locatelli, and L. Moretta. 2009. Activating and inhibitory killer 
immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation 
to cure high-risk leukaemias. Clin. Exp. Immunol. 157: 325–31. 
91 
 
48. Li, C., B. L. Houser, M. L. Nicotra, and J. L. Strominger. 2009. HLA-G homodimer-
induced cytokine secretion through HLA-G receptors on human decidual macrophages and 
natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 106: 5767–72. 
49. Rajagopalan, S., Y. T. Bryceson, S. P. Kuppusamy, D. E. Geraghty, A. Van Der Meer, I. 
Joosten, and E. O. Long. 2006. Activation of NK Cells by an Endocytosed Receptor for 
Soluble HLA-G. PLoS Biol. 4: e9. 
50. Parham, P., P. J. Norman, L. Abi-Rached, and L. a Guethlein. 2011. Variable NK cell 
receptors exemplified by human KIR3DL1/S1. J. Immunol. 187: 11–9. 
51. Colantonio, A. D., B. N. Bimber, W. J. Neidermyer, R. K. Reeves, G. Alter, M. Altfeld, R. 
P. Johnson, M. Carrington, D. H. O’Connor, and D. T. Evans. 2011. KIR polymorphisms 
modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS 
Pathog. 7: e1001316. 
52. Elliott, J. M., and W. M. Yokoyama. 2011. Unifying concepts of MHC-dependent natural 
killer cell education. Trends Immunol. 32: 364–72. 
53. Anfossi, N., P. André, S. Guia, C. S. Falk, S. Roetynck, C. A. Stewart, V. Breso, C. 
Frassati, D. Reviron, D. Middleton, F. Romagné, S. Ugolini, and E. Vivier. 2006. Human NK 
cell education by inhibitory receptors for MHC class I. Immunity 25: 331–42. 
54. Brodin, P., T. Lakshmikanth, S. Johansson, K. Kärre, and P. Höglund. 2009. The 
strength of inhibitory input during education quantitatively tunes the functional 
responsiveness of individual natural killer cells. Blood 113: 2434–41. 
55. Höglund, P., and P. Brodin. 2010. Current perspectives of natural killer cell education by 
MHC class I molecules. Nat. Rev. Immunol. 10: 724–34. 
56. Brodin, P., and P. Höglund. 2008. Beyond licensing and disarming: a quantitative view 
on NK-cell education. Eur. J. Immunol. 38: 2934–7. 
57. Jost, S., and M. Altfeld. 2013. Control of human viral infections by natural killer cells. 
Annu. Rev. Immunol. 31: 163–94. 
58. Nash, W. T., J. Teoh, H. Wei, A. Gamache, and M. G. Brown. 2014. Know thyself: NK-
cell inhibitory receptors prompt self-tolerance, education, and viral control. Front. Immunol. 
5: 1–12. 
59. Martin, M. P., Y. Qi, X. Gao, E. Yamada, J. N. Martin, F. Pereyra, S. Colombo, E. E. 
Brown, W. L. Shupert, J. Phair, J. J. Goedert, S. Buchbinder, G. D. Kirk, A. Telenti, M. 
Connors, S. J. O’Brien, B. D. Walker, P. Parham, S. G. Deeks, D. W. McVicar, and M. 
Carrington. 2007. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. 
Genet. 39: 733–740. 
60. Zipeto, D., and A. Beretta. 2012. HLA-C and HIV-1: friends or foes? Retrovirology 9: 39. 
61. Körner, C., and M. Altfeld. 2012. Role of KIR3DS1 in human diseases. Front. Immunol. 
3: 1–11. 
92 
 
62. Bonagura, V. R., L. J. Hatam, D. W. Rosenthal, J. a. De Voti, F. Lam, B. M. Steinberg, 
and A. L. Abramson. 2010. Recurrent respiratory papillomatosis: A complex defect in 
immune responsiveness to human papillomavirus-6 and -11. Apmis 118: 455–470. 
63. Stern, M., K. Hadaya, G. Hönger, P.-Y. Martin, J. Steiger, C. Hess, and J. Villard. 2011. 
Telomeric rather than centromeric activating KIR genes protect from cytomegalovirus 
infection after kidney transplantation. Am. J. Transplant 11: 1302–7. 
64. Stern, M., H. Elsässer, G. Hönger, J. Steiger, S. Schaub, and C. Hess. 2008. The 
number of activating KIR genes inversely correlates with the rate of CMV 
infection/reactivation in kidney transplant recipients. Am. J. Transplant. 8: 1312–1317. 
65. Cook, M., D. Briggs, C. Craddock, P. Mahendra, D. Milligan, C. Fegan, P. Darbyshire, S. 
Lawson, E. Boxall, and P. Moss. 2006. Donor KIR genotype has a major influence on the 
rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood 
107: 1230–2. 
66. Béziat, V., L. L. Liu, J.-A. Malmberg, M. a Ivarsson, E. Sohlberg, A. T. Björklund, C. 
Retière, E. Sverremark-Ekström, J. Traherne, P. Ljungman, M. Schaffer, D. a Price, J. 
Trowsdale, J. Michaëlsson, H.-G. Ljunggren, and K.-J. Malmberg. 2013. NK cell responses 
to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve 
activating KIRs. Blood 121: 2678–88. 
67. Gazit, R., B.-Z. Garty, Y. Monselise, V. Hoffer, Y. Finkelstein, G. Markel, G. Katz, J. 
Hanna, H. Achdout, R. Gruda, T. Gonen-Gross, and O. Mandelboim. 2004. To the editor: 
Expression of KIR2DL1 on the entire NK cell population: a possible novel immunodeficiency 
syndrome. Blood 103: 1965–1967. 
68. Aranda-Romo, S., C. a. Garcia-Sepulveda, A. Comas-García, F. Lovato-Salas, M. 
Salgado-Bustamante, A. Gómez-Gómez, and D. E. Noyola. 2012. Killer-cell immunoglobulin-
like receptors (KIR) in severe A (H1N1) 2009 influenza infections. Immunogenetics 64: 653–
662. 
69. La, D., C. Czarnecki, H. El-Gabalawy, A. Kumar, A. F. a Meyers, N. Bastien, J. N. 
Simonsen, F. a. Plummer, and M. Luo. 2011. Enrichment of variations in KIR3DL1/s1 and 
KIR2DL2/L3 among H1N1/09 ICU patients: An exploratory study. PLoS One 6: e29200. 
70. Khakoo, S. I., C. L. Thio, M. P. Martin, C. R. Brooks, X. Gao, J. Astemborski, J. Cheng, 
J. J. Goedert, D. Vlahov, M. Hilgartner, S. Cox, A.-M. Little, G. J. Alexander, M. E. Cramp, S. 
J. O’Brien, W. M. C. Rosenberg, D. L. Thomas, and M. Carrington. 2004. HLA and NK cell 
inhibitory receptor genes in resolving hepatitis C virus infection. Science (80-. ). 305: 872–
874. 
71. Hiby, S. E., R. Apps, A. M. Sharkey, L. E. Farrell, L. Gardner, A. Mulder, F. H. Claas, J. 
J. Walker, C. C. Redman, L. Morgan, C. Tower, L. Regan, G. E. Moore, M. Carrington, and 
A. Moffett. 2010. Maternal activating KIRs protect against human reproductive failure 
mediated by fetal HLA-C2. J. Clin. Invest. 120: 4102–4110. 
72. Łuszczek, W., M. Mańczak, M. Cisło, P. Nockowski, A. Wiśniewski, M. Jasek, and P. 
Kuśnierczyk. 2004. Gene for the activating natural killer cell receptor, KIR2DS1, is 
associated with susceptibility to psoriasis vulgaris. Hum. Immunol. 65: 758–766. 
93 
 
73. Kuśnierczyk, P. 2013. Killer cell immunoglobulin-like receptor gene associations with 
autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front. 
Immunol. 4: 8. 
74. Momot, T., S. Koch, N. Hunzelmann, T. Krieg, K. Ulbricht, R. E. Schmidt, and T. Witte. 
2004. Association of Killer Cell Immunoglobulin-Like Receptors with Scleroderma. Arthritis 
Rheum. 50: 1561–1565. 
75. Yen, J. H., B. E. Moore, T. Nakajima, D. Scholl, D. J. Schaid, C. M. Weyand, and J. J. 
Goronzy. 2001. Major histocompatibility complex class I-recognizing receptors are disease 
risk genes in rheumatoid arthritis. J. Exp. Med. 193: 1159–1167. 
76. Hiby, S. E., R. Apps, O. Chazara, L. E. Farrell, P. Magnus, L. Trogstad, H. K. Gjessing, 
M. Carrington, and A. Moffett. 2014. Maternal KIR in combination with paternal HLA-C2 
regulate human birth weight. J. Immunol. 192: 5069–73. 
77. Nakimuli, A., O. Chazara, S. E. Hiby, L. Farrell, S. Tukwasibwe, J. Jayaraman, J. a 
Traherne, J. Trowsdale, F. Colucci, E. Lougee, R. W. Vaughan, A. M. Elliott, J. Byamugisha, 
P. Kaleebu, F. Mirembe, N. Nemat-Gorgani, P. Parham, P. J. Norman, and A. Moffett. 2015. 
A KIR B centromeric region present in Africans but not Europeans protects pregnant women 
from pre-eclampsia. Proc. Natl. Acad. Sci. U. S. A. 112: 845–50. 
78. Martin, M. P., X. Gao, J.-H. Lee, G. W. Nelson, R. Detels, J. J. Goedert, S. Buchbinder, 
K. Hoots, D. Vlahov, J. Trowsdale, M. Wilson, S. J. O’Brien, and M. Carrington. 2002. 
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. 
Genet. 31: 429–34. 
79. Costa-Garcia, M., A. Vera, M. Moraru, C. Vilches, M. Lopez-Botet, and A. Muntasell. 
2015. Antibody-Mediated Response of NKG2Cbright NK Cells against Human 
Cytomegalovirus. J. Immunol. 194: 2715–2724. 
80. Wu, L., and L. Van Kaer. 2011. Natural killer cells: in health and disease. Front. Biosci. 
(Schol. Ed). 3: 236–251. 
81. Sungur, C. M., and W. J. Murphy. 2014. Positive and Negative Regulation by NK Cells in 
Cancer. Crit. Rev. Oncog. 19: 57–66. 
82. Palmer, J. M., K. Rajasekaran, M. S. Thakar, and S. Malarkannan. 2013. Clinical 
relevance of natural killer cells following hematopoietic stem cell transplantation. J. Cancer 
4: 25–35. 
83. Venstrom, J. M., G. Pittari, T. a Gooley, J. H. Chewning, S. Spellman, M. Haagenson, M. 
M. Gallagher, M. Malkki, E. Petersdorf, B. Dupont, and K. C. Hsu. 2012. HLA-C-dependent 
prevention of leukemia relapse by donor activating KIR2DS1. N. Engl. J. Med. 367: 805–16. 
84. Pende, D., S. Marcenaro, M. Falco, S. Martini, M. E. Bernardo, D. Montagna, E. Romeo, 
C. Cognet, M. Martinetti, R. Maccario, M. C. Mingari, E. Vivier, L. Moretta, F. Locatelli, and 
A. Moretta. 2009. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched 
haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR 
and redefinition of inhibitory KIR specificity. Blood 113: 3119–29. 
94 
 
85. Marcenaro, E., S. Carlomagno, S. Pesce, M. Della Chiesa, A. Moretta, and S. Sivori. 
2011. Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell 
transplantation. J. Leukoc. Biol. 90: 661–7. 
86. Moffett, A., and C. Loke. 2006. Immunology of placentation in eutherian mammals. Nat. 
Rev. Immunol. 6: 584–94. 
87. Zhou, Y., K. Bianco, L. Huang, J. K. Nien, M. McMaster, R. Romero, and S. J. Fisher. 
2007. Comparative analysis of maternal-fetal interface in preeclampsia and preterm labor. 
Cell Tissue Res. 329: 559–69. 
88. Yeh, C.-C., K.-C. Chao, and S. J. Huang. 2013. Innate immunity, decidual cells, and 
preeclampsia. Reprod. Sci. 20: 339–53. 
89. Straszewski-Chavez, S. L., V. M. Abrahams, and G. Mor. 2005. The role of apoptosis in 
the regulation of trophoblast survival and differentiation during pregnancy. Endocr. Rev. 26: 
877–97. 
90. Billington, W. D. 2003. The immunological problem of pregnancy : 50 years with the hope 
of progress . A tribute to Peter Medawar. J. Reprod. Immunol. 60: 1–11. 
91. Trowsdale, J., and A. Betz. 2006. Mother’s Little Helpers: Mechanisms of maternal-fetal 
tolerance. Nat. Immunol. 7: 241–246. 
92. Guleria, I., and M. H. Sayegh. 2007. Maternal acceptance of the fetus: true human 
tolerance. J. Immunol. 178: 3345–51. 
93. Apps, R., L. Gardner, and A. Moffett. 2008. A critical look at HLA-G. Trends Immunol. 29: 
313–321. 
94. Moffett-King, A. 2002. Natural killer cells and pregnancy. Nat. Rev. Immunol. 2: 656–63. 
95. Tilburgs, T., Â. C. Crespo, A. van der Zwan, B. Rybalov, T. Raj, B. Stranger, L. Gardner, 
A. Moffett, and J. L. Strominger. 2015. Human HLA-G+ extravillous trophoblasts: Immune-
activating cells that interact with decidual leukocytes. Proc. Natl. Acad. Sci. U. S. A. 112: 
7219–7224. 
96. Guerin, L. R., J. R. Prins, and S. a Robertson. 2009. Regulatory T-cells and immune 
tolerance in pregnancy: a new target for infertility treatment? Hum. Reprod. Update 15: 517–
35. 
97. Zenclussen, A. C., K. Gerlof, M. L. Zenclussen, S. Ritschel, A. Zambon Bertoja, S. Fest, 
S. Hontsu, S. Ueha, K. Matsushima, J. Leber, and H.-D. Volk. 2006. Regulatory T cells 
induce a privileged tolerant microenvironment at the fetal-maternal interface. Eur. J. 
Immunol. 36: 82–94. 
98. Tilburgs, T., S. a Scherjon, B. J. van der Mast, G. W. Haasnoot, M. Versteeg-V D Voort-
Maarschalk, D. L. Roelen, J. J. van Rood, and F. H. J. Claas. 2009. Fetal-maternal HLA-C 
mismatch is associated with decidual T cell activation and induction of functional T 
regulatory cells. J. Reprod. Immunol. 82: 148–57. 
95 
 
99. Munn, D. H., M. Zhou, J. T. Attwood, I. Bondarev, S. J. Conway, B. Marshall, C. Brown, 
and a L. Mellor. 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. 
Science 281: 1191–3. 
100. Mor, G., and V. M. Abrahams. 2003. Potential role of macrophages as 
immunoregulators of pregnancy. Reprod. Biol. Endocrinol. 1: 119. 
101. Repnik, U., T. Tilburgs, D. L. Roelen, B. J. van der Mast, H. H. H. Kanhai, S. Scherjon, 
and F. H. J. Claas. 2008. Comparison of Macrophage Phenotype Between Decidua Basalis 
and Decidua Parietalis by Flow Cytometry. Placenta 29: 405–412. 
102. Abrahams, V. M., Y. M. Kim, S. L. Straszewski, R. Romero, and G. Mor. 2004. 
Macrophages and apoptotic cell clearance during pregnancy. Am. J. Reprod. Immunol. 51: 
275–282. 
103. Houser, B. L., T. Tilburgs, J. Hill, M. L. Nicotra, and J. L. Strominger. 2011. Two unique 
human decidual macrophage populations. J. Immunol. 186: 2633–42. 
104. King, A., P. Wooding, and L. Gardner. 1993. Expression of perforin , granzyme A and 
TIA-1 by human uterine CD56 + NK cells implies they are activated and capable of effector 
functions. Hum. Reprod. 8: 2061–2067. 
105. Koopman, L. a, H. D. Kopcow, B. Rybalov, J. E. Boyson, J. S. Orange, F. Schatz, R. 
Masch, C. J. Lockwood, A. D. Schachter, P. J. Park, and J. L. Strominger. 2003. Human 
decidual natural killer cells are a unique NK cell subset with immunomodulatory potential. J. 
Exp. Med. 198: 1201–12. 
106. Kopcow, H. D., D. S. J. Allan, X. Chen, B. Rybalov, M. M. Andzelm, B. Ge, and J. L. 
Strominger. 2005. Human decidual NK cells form immature activating synapses and are not 
cytotoxic. Proc. Natl. Acad. Sci. U. S. A. 102: 15563–8. 
107. Hanna, J., D. Goldman-Wohl, Y. Hamani, I. Avraham, C. Greenfield, S. Natanson-
Yaron, D. Prus, L. Cohen-Daniel, T. I. Arnon, I. Manaster, R. Gazit, V. Yutkin, D. 
Benharroch, A. Porgador, E. Keshet, S. Yagel, and O. Mandelboim. 2006. Decidual NK cells 
regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12: 
1065–74. 
108. Zhang, J., Z. Chen, G. N. Smith, and A. Croy. 2011. Natural Killer Cell Triggered 
Vascular Transformation: Maternal Care Before Birth? Cell. Mol. Immunol. 8: 1–11. 
109. Hunt, J. S., D. K. Langat, R. H. McIntire, and P. J. Morales. 2006. The role of HLA-G in 
human pregnancy. Reprod. Biol. Endocrinol. 4 (Suppl 1: S10. 
110. Rizzo, R., M. Vercammen, H. van de Velde, P. a Horn, and V. Rebmann. 2011. The 
importance of HLA-G expression in embryos, trophoblast cells, and embryonic stem cells. 
Cell. Mol. Life Sci. 68: 341–52. 
111. King, a, D. S. Allan, M. Bowen, S. J. Powis, S. Joseph, S. Verma, S. E. Hiby, a J. 
McMichael, Y. W. Loke, and V. M. Braud. 2000. HLA-E is expressed on trophoblast and 
interacts with CD94/NKG2 receptors on decidual NK cells. Eur. J. Immunol. 30: 1623–31. 
96 
 
112. Hiby, S. E., L. Regan, W. Lo, L. Farrell, M. Carrington, and a Moffett. 2008. Association 
of maternal killer-cell immunoglobulin-like receptors and parental HLA-C genotypes with 
recurrent miscarriage. Hum. Reprod. 23: 972–6. 
113. Male, V., A. Sharkey, L. Masters, P. R. Kennedy, L. E. Farrell, and A. Moffett. 2011. 
The effect of pregnancy on the uterine NK cell KIR repertoire. Eur. J. Immunol. 41: 3017–27. 
114. Hiby, S. E., J. J. Walker, K. M. O’shaughnessy, C. W. G. Redman, M. Carrington, J. 
Trowsdale, and A. Moffett. 2004. Combinations of maternal KIR and fetal HLA-C genes 
influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200: 957–965. 
115. Parham, P., P. J. Norman, L. Abi-rached, H. G. Hilton, and L. A. Guethlein. 2012. 
Review : Immunogenetics of human placentation. Placenta 33: S71–S80. 
116. Gonzalez-Galarza, F., L. Takeshita, E. Santos, F. Kempson, M. Maia, A. Silva, A. Silva, 
G. Ghattaoraya, A. Alfirevic, A. Jones, and D. Middleton. 2015. Allele frequency net 2015 
update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction 
associations. Nucleic Acid Res. 28: D784–8. 
117. Kieckbusch, J., L. M. Gaynor, A. Moffett, and F. Colucci. 2014. MHC-dependent 
inhibition of uterine NK cells impedes fetal growth and decidual vascular remodelling. Nat. 
Commun. 5: 3359. 
118. Xiong, S., A. M. Sharkey, P. R. Kennedy, L. Gardner, L. E. Farrell, O. Chazara, J. 
Bauer, S. E. Hiby, F. Colucci, and A. Moffett. 2013. Maternal uterine NK cell – activating 
receptor KIR2DS1 enhances placentation. J. Clin. Invest. 123: 4265–4272. 
119. Pass, R. F., C. Zhang, A. Evans, T. Simpson, W. Andrews, M.-L. Huang, L. Corey, J. 
Hill, E. Davis, C. Flanigan, and G. Cloud. 2009. Vaccine prevention of maternal 
cytomegalovirus infection. N. Engl. J. Med. 360: 1191–1199. 
120. Rasmussen, S. a., D. J. Jamieson, and T. M. Uyeki. 2012. Effects of influenza on 
pregnant women and infants. Am. J. Obstet. Gynecol. 207: S3–S8. 
121. Kenneson, A., and M. J. Cannon. 2007. Review and meta-analysis of the epidemiology 
of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol. 17: 253–276. 
122. Nigro, G., M. Mazzocco, E. Mattia, G. C. Di Renzo, G. Carta, and M. M. Anceschi. 
2011. Role of the infections in recurrent spontaneous abortion. J. Matern. Fetal. Neonatal 
Med. 24: 983–989. 
123. Pereira, L., M. Petitt, a Fong, M. Tsuge, T. Tabata, J. Fang-Hoover, E. Maidji, M. 
Zydek, Y. Zhou, N. Inoue, S. Loghavi, S. Pepkowitz, L. M. Kauvar, and D. Ogunyemi. 2014. 
Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J 
Infect Dis 209: 1573–1584. 
124. Revello, M. G., D. Lilleri, M. Zavattoni, M. Furione, E. Genini, G. Comolli, and G. Gerna. 
2006. Lymphoproliferative response in primary human cytomegalovirus (HCMV) infection is 
delayed in HCMV transmitter mothers. J. Infect. Dis. 193: 269–276. 
125. Warner, J. a, K. J. Zwezdaryk, B. Day, D. E. Sullivan, G. Pridjian, and C. a Morris. 
2012. Human cytomegalovirus infection inhibits CXCL12- mediated migration and invasion 
of human extravillous cytotrophoblasts. Virol. J. 9: 255. 
97 
 
126. LaMarca, H. L., a. B. Nelson, a. B. Scandurro, G. S. J. Whitley, and C. a. Morris. 2006. 
Human cytomegalovirus-induced inhibition of cytotrophoblast invasion in a first trimester 
extravillous cytotrophoblast cell line. Placenta 27: 137–147. 
127. Tilburgs, T., and J. L. Strominger. 2013. CD8+ effector T cells at the fetal-maternal 
interface, balancing fetal tolerance and antiviral immunity. Am. J. Reprod. Immunol. 69: 395–
407. 
128. Jackson, S. E., G. M. Mason, and M. R. Wills. 2011. Human cytomegalovirus immunity 
and immune evasion. Virus Res. 157: 151–160. 
129. Cohen, G. B., R. T. Gandhi, D. M. Davis, O. Mandelboim, B. K. Chen, J. L. Strominger, 
and D. Baltimore. 1999. The selective downregulation of class I major histocompatibility 
complex proteins by HIV-1 protects HIV- infected cells from NK cells. Immunity 10: 661–671. 
130. Chen, V. L., F. Y. Avci, and D. L. Kasper. 2013. A maternal vaccine against group B 
Streptococcus: Past, present, and future. Vaccine 31: D13–D19. 
131. Benshushan, A. 2002. Listeria Infection during Pregnancy : A 10 Year Experience. Isr. 
Med. Assoc. J. 4: 776–780. 
132. Adams Waldorf, K. M., and R. M. McAdams. 2013. Influence of infection during 
pregnancy on fetal development. Reproduction 146. 
133. Rowe, J. H., J. M. Ertelt, L. Xin, and S. S. Way. 2012. Listeria monocytogenes 
Cytoplasmic Entry Induces Fetal Wastage by Disrupting Maternal Foxp3+ Regulatory T Cell-
Sustained Fetal Tolerance. PLoS Pathog. 8. 
134. Mateus, T., J. Silva, R. L. Maia, and P. Teixeira. 2013. Listeriosis during Pregnancy : A 
Public Health Concern. ISRN Obstet. Gynecol. 2013. 
135. Walch, M., F. Dotiwala, S. Mulik, J. Thiery, T. Kirchhausen, C. Clayberger, A. M. 
Krensky, D. Martinvalet, and J. Lieberman. 2014. Cytotoxic cells kill intracellular bacteria 
through granulysin-mediated delivery of granzymes. Cell 157: 1309–23. 
136. Stenger, S., D. a Hanson, R. Teitelbaum, P. Dewan, K. R. Niazi, C. J. Froelich, T. 
Ganz, S. Thoma-Uszynski, a Melián, C. Bogdan, S. a Porcelli, B. R. Bloom, a M. Krensky, 
and R. L. Modlin. 1998. An antimicrobial activity of cytolytic T cells mediated by granulysin. 
Science 282: 121–125. 
137. Dieli, F., M. Troye-blomberg, J. Ivanyi, A. M. Krensky, M. Bonneville, M. A. Peyrat, N. 
Caccamo, G. Sireci, and A. Salerno. 2001. Granulysin-Dependent Killing of Intracellular and 
Extracellular Mycobacterium tuberculosis by V g 9 / V d 2 T Lymphocytes. J. Infect. Dis. 184: 
1082–1085. 
138. Vujaklija, D. V., T. Gulic, S. Sucic, K. Nagata, K. Ogawa, G. Laskarin, S. Saito, H. 
Haller, and D. Rukavina. 2011. First trimester pregnancy decidual natural killer cells contain 
and spontaneously release high quantities of granulysin. Am. J. Reprod. Immunol. 66: 363–
72. 
139. Kourtis, A. P., J. S. Read, and D. J. Jamieson. 2014. Pregnancy and infection. N. Engl. 
J. Med. 370: 2211–8. 
98 
 
140. Sappenfield, E., D. J. Jamieson, and A. P. Kourtis. 2013. Pregnancy and susceptibility 
to infectious diseases. Infect. Dis. Obstet. Gynecol. 2013. 
141. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. 
Corliss, D. Tyan, L. L. Lanier, and P. Parham. 1997. Human diversity in killer cell inhibitory 
receptor genes. Immunity 7: 753–63. 
142. Trundley, A., L. Gardner, J. Northfield, C. Chang, and A. Moffett. 2006. Methods for 
Isolation of Cells from the Human Fetal – Maternal Interface. In Placenta and Trophoblast: 
Methods and Protocols, Volume 2, 1st ed. vol. 122. M. J. Soares, and J. S. Hunt, eds. 
Humana Press, New Jersey. 109–122. 
143. Blanco, O., I. Tirado, R. Muñoz-Fernández, A. C. Abadía-Molina, J. M. García-
Pacheco, J. Peña, and E. G. Olivares. 2008. Human decidual stromal cells express HLA-G: 
Effects of cytokines and decidualization. Hum. Reprod. 23: 144–52. 
144. Pazmany, L., O. Mandelboim, M. Valés-Gómez, D. M. Davis, H. T. Reyburn, and J. L. 
Strominger. 1996. Protection from natural killer cell-mediated lysis by HLA-G expression on 
target cells. Science 274: 792–5. 
145. Fauriat, C., M. a Ivarsson, H.-G. Ljunggren, K.-J. Malmberg, and J. Michaëlsson. 2010. 
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. 
Blood 115: 1166–74. 
146. Sharkey, A. M., L. Gardner, S. Hiby, L. Farrell, R. Apps, L. Masters, J. Goodridge, L. 
Lathbury, C. A. Stewart, S. Verma, and A. Moffett. 2008. Killer Ig-like receptor expression in 
uterine NK cells is biased toward recognition of HLA-C and alters with gestational age. J. 
Immunol. 181: 39–46. 
147. Hanson, D. A., A. A. Kaspar, F. R. Poulain, and A. M. Krensky. 1999. Biosynthesis of 
granulysin , a novel cytolytic molecule. Mol. Immunol. 36: 413–422. 
148. Lanier, L. L. 2009. DAP10- and DAP12-associated receptors in innate immunity. 
Immunol. Rev. 227: 150–60. 
149. Kavathas, P., F. H. Bach, and R. DeMars. 1980. Gamma ray-induced loss of 
expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc. Natl. Acad. Sci. U. 
S. A. 77: 4251–4255. 
150. O’Callaghan, C. a. 2000. Molecular basis of human natural killer cell recognition of 
HLA-E (human leucocyte antigen-E) and its relevance to clearance of pathogen-infected and 
tumour cells. Clin. Sci. (Lond). 99: 9–17. 
151. Benz, E. J., M. J. Murnane, B. L. Tonkonow, B. W. Berman, E. M. Mazur, C. 
Cavallesco, T. Jenko, E. L. Snyder, B. G. Forget, and R. Hoffman. 1980. Embryonic-fetal 
erythroid characteristics of a human leukemic cell line. Proc. Natl. Acad. Sci. U. S. A. 77: 
3509–13. 
152. Day, N. E., H. Ugai, K. K. Yokoyama, and A. T. Ichiki. 2003. K-562 cells lack MHC class 
II expression due to an alternatively spliced CIITA transcript with a truncated coding region. 
Leuk. Res. 27: 1027–1038. 
99 
 
153. Duske, H., A. Sputtek, T. Binder, N. Kr, S. Schrepfer, and T. Eiermann. 2011. 
Assessment of physiologic natural killer cell cytotoxicity in vitro. Hum. Immunol. 72: 1007–
1012. 
154. Bae, D. S., Y. K. Hwang, and J. K. Lee. 2012. Importance of NKG2D-NKG2D ligands 
interaction for cytolytic activity of natural killer cell. Cell. Immunol. 276: 122–127. 
155. Allan, D. S. J., B. Rybalov, G. Awong, J. C. Zúñiga-Pflücker, H. D. Kopcow, J. R. 
Carlyle, and J. L. Strominger. 2010. TGF-β affects development and differentiation of human 
natural killer cell subsets. Eur. J. Immunol. 40: 2289–95. 
156. Keskin, D. B., D. S. J. Allan, B. Rybalov, M. M. Andzelm, J. N. H. Stern, H. D. Kopcow, 
L. a Koopman, and J. L. Strominger. 2007. TGFbeta promotes conversion of CD16+ 
peripheral blood NK cells into CD16- NK cells with similarities to decidual NK cells. Proc. 
Natl. Acad. Sci. U. S. A. 104: 3378–83. 
157. Cerdeira, A. S., A. Rajakumar, C. M. Royle, A. Lo, Z. Husain, R. I. Thadhani, V. P. 
Sukhatme, S. A. Karumanchi, and H. D. Kopcow. 2013. Conversion of peripheral blood NK 
cells to a decidual NK-like phenotype by a cocktail of defined factors. J. Immunol. 190: 
3939–48. 
158. Chiossone, L., P. Vacca, P. Orecchia, D. Croxatto, P. Damonte, S. Astigiano, O. 
Barbieri, C. Bottino, L. Moretta, and M. C. Mingari. 2014. In vivo generation of decidual 
natural killer cells from resident hematopoietic progenitors. Haematologica 99: 448–57. 
159. Juelke, K., M. Killig, A. Thiel, J. Dong, and C. Romagnani. 2009. Education of 
hyporesponsive NK cells by cytokines. Eur. J. Cell Biol. 39: 2548–2555. 
160. Von Rango, U. 2008. Fetal tolerance in human pregnancy--a crucial balance between 
acceptance and limitation of trophoblast invasion. Immunol. Lett. 115: 21–32. 
161. Tilburgs, T., and J. L. Strominger. 2013. CD8+ Effector T Cells at the Fetal-Maternal 
Interface, Balancing Fetal Tolerance and Antiviral Immunity. Am. J. Reprod. Immunol. 69: 
395–407. 
162. Tilburgs, T., D. Schonkeren, M. Eikmans, N. M. Nagtzaam, G. Datema, M. Godelieve, 
F. Prins, J. M. Van Lith, B. J. Van Der, D. L. Roelen, S. A. Scherjon, and H. Frans. 2010. 
Human Decidual Tissue Contains Differentiated CD8 + Effector-Memory T Cells with Unique 
Properties. J. Immunol. 185: 4470–4477. 
163. Siewiera, J., H. El Costa, J. Tabiasco, A. Berrebi, G. Cartron, P. Le Bouteiller, P. 
Bouteiller, and N. Jabrane-Ferrat. 2013. Human cytomegalovirus infection elicits new 
decidual natural killer cell effector functions. PLoS Pathog. 9: e1003257. 
164. Qi, Y., M. P. Martin, X. Gao, L. Jacobson, J. J. Goedert, S. Buchbinder, G. D. Kirk, S. J. 
O’Brien, J. Trowsdale, and M. Carrington. 2006. KIR/HLA pleiotropism: Protection against 
both HIV and opportunistic infections. PLoS Pathog. 2: 0741–0745. 
165. Halenius, A., S. Hauka, L. Dölken, J. Stindt, H. Reinhard, C. Wiek, H. Hanenberg, U. H. 
Koszinowski, F. Momburg, and H. Hengel. 2011. Human cytomegalovirus disrupts the major 
histocompatibility complex class I peptide-loading complex and inhibits tapasin gene 
transcription. J. Virol. 85: 3473–85. 
100 
 
166. Björkström, N. K., T. Lindgren, M. Stoltz, C. Fauriat, M. Braun, M. Evander, J. 
Michaëlsson, K.-J. Malmberg, J. Klingström, C. Ahlm, and H.-G. Ljunggren. 2011. Rapid 
expansion and long-term persistence of elevated NK cell numbers in humans infected with 
hantavirus. J. Exp. Med. 208: 13–21. 
167. Foley, B., S. Cooley, M. R. Verneris, M. Pitt, J. Curtsinger, X. Luo, S. Lopez-Vergès, L. 
L. Lanier, D. Weisdorf, and J. S. Miller. 2012. Cytomegalovirus reactivation after allogeneic 
transplantation promotes a lasting increase in educated NKG2C + natural killer cells with 
potent function. Blood 119: 2665–2674. 
168. Delorme-Axford, E., R. B. Donker, J.-F. Mouillet, T. Chu, A. Bayer, Y. Ouyang, T. 
Wang, D. B. Stolz, S. N. Sarkar, A. E. Morelli, Y. Sadovsky, and C. B. Coyne. 2013. Human 
placental trophoblasts confer viral resistance to recipient cells. Proc. Natl. Acad. Sci. U. S. A. 
110: 12048–53. 
169. McDonagh, S., E. Maidji, H.-T. Chang, and L. Pereira. 2006. Patterns of human 
cytomegalovirus infection in term placentas: a preliminary analysis. J. Clin. Virol. 35: 210–
215. 
170. Cao, B., and I. U. Mysorekar. 2014. Intracellular bacteria in placental basal plate 
localize to extravillous trophoblasts. Placenta 35: 139–42. 
171. Park, B., E. Spooner, B. L. Houser, J. L. Strominger, and H. L. Ploegh. 2010. The 
HCMV membrane glycoprotein US10 selectively targets HLA-G for degradation. J. Exp. 
Med. 207: 2033–2041. 
172. Lopez-Vergès, S., J. M. Milush, B. S. Schwartz, M. J. Pando, J. Jarjoura, V. a York, J. 
P. Houchins, S. Miller, S.-M. Kang, P. J. Norris, D. F. Nixon, and L. L. Lanier. 2011. 
Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human 
cytomegalovirus infection. Proc. Natl. Acad. Sci. U. S. A. 108: 14725–14732. 
173. Zhang, T., J. M. Scott, I. Hwang, and S. Kim. 2013. Cutting edge: antibody-dependent 
memory-like NK cells distinguished by FcRγ deficiency. J. Immunol. 190: 1402–6. 
174. Hwang, I., T. Zhang, J. M. Scott, a R. Kim, T. Lee, T. Kakarla, a Kim, J. B. Sunwoo, and 
S. Kim. 2012. Identification of human NK cells that are deficient for signaling adaptor 
FcRgamma and specialized for antibody-dependent immune functions. Int Immunol 24: 793–
802. 
175. Jongstra, B. Y. J. A. N., T. J. Schall, B. J. Dyer, C. Clayberger, J. Jorgensen, and M. M. 
Davis. 1987. The isolation and sequence of a novel gene from a human functional T cell line. 
J. Exp. Med. 165: 601–614. 
176. Houchins, J., T. Yabe, C. McSherry, N. Miyokawa, and F. Bach. 1990. Isolation and 
characterization of NK cell or NK/T cell-specific cDNA clones. J. Mol. Cell Biol. 4: 295–304. 
177. Peña, S. V, D. a Hanson, B. a Carr, T. J. Goralski, and a M. Krensky. 1997. Processing, 
subcellular localization, and function of 519 (granulysin), a human late T cell activation 
molecule with homology to small, lytic, granule proteins. J. Immunol. 158: 2680–2688. 
178. Peña, S. V, and a M. Krensky. 1997. Granulysin, a new human cytolytic granule-
associated protein with possible involvement in cell-mediated cytotoxicity. Semin. Immunol. 
9: 117–125. 
101 
 
179. Ernst, W. a, S. Thoma-Uszynski, R. Teitelbaum, C. Ko, D. a Hanson, C. Clayberger, a 
M. Krensky, M. Leippe, B. R. Bloom, T. Ganz, and R. L. Modlin. 2000. Granulysin, a T cell 
product, kills bacteria by altering membrane permeability. J. Immunol. 165: 7102–7108. 
180. Barman, H., M. Walch, S. Latinovic-Golic, C. Dumrese, M. Dolder, P. Groscurth, and U. 
Ziegler. 2006. Cholesterol in negatively charged lipid bilayers modulates the effect of the 
antimicrobial protein granulysin. J. Membr. Biol. 212: 29–39. 
181. Nakashima, A., and A. Shiozaki. 2008. Granulysin Produced by Uterine Natural Killer 
Cells Induces Apoptosis of Extravillous Trophoblasts in Spontaneous Abortion. Am. J. 
Pathol. 173: 653–664. 
182. Clayberger, C., M. W. Finn, T. Wang, R. Saini, C. Wilson, V. a Barr, M. Sabatino, L. 
Castiello, D. Stroncek, and A. M. Krensky. 2012. 15 kDa granulysin causes differentiation of 
monocytes to dendritic cells but lacks cytotoxic activity. J. Immunol. 188: 6119–26. 
183. Kaiserman, D., and P. I. Bird. 2010. Control of granzymes by serpins. Cell Death Differ. 
17: 586–595. 
184. Bird, C. H., V. R. Sutton, J. Sun, C. E. Hirst, a Novak, S. Kumar, J. a Trapani, and P. I. 
Bird. 1998. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase 
inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell 
death pathway. Mol. Cell. Biol. 18: 6387–6398. 
185. Bladergroen, B. a, M. C. Strik, N. Bovenschen, O. van Berkum, G. L. Scheffer, C. J. 
Meijer, C. E. Hack, and J. a Kummer. 2001. The granzyme B inhibitor, protease inhibitor 9, is 
mainly expressed by dendritic cells and at immune-privileged sites. J. Immunol. 166: 3218–
3225. 
186. Buzza, M. S., P. Hosking, and P. I. Bird. 2006. The granzyme B inhibitor, PI-9, is 
differentially expressed during placental development and up-regulated in hydatidiform 
moles. Placenta 27: 62–69. 
187. De Koning, P. J. a, J. A. Kummer, S. a H. de Poot, R. Quadir, R. Broekhuizen, A. F. 
McGettrick, W. J. Higgins, B. Devreese, D. M. Worrall, and N. Bovenschen. 2011. 
Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. 
PLoS One 6: 1–9. 
188. Wang, L., Q. Li, L. Wu, S. Liu, Y. Zhang, X. Yang, P. Zhu, H. Zhang, K. Zhang, J. Lou, 
P. Liu, L. Tong, F. Sun, and Z. Fan. 2013. Identification of SERPINB1 as a physiological 
inhibitor of human granzyme H. J. Immunol. 190: 1319–30. 
189. Heazell, A. E. P., H. R. Buttle, P. N. Baker, and I. P. Crocker. 2008. Altered expression 
of regulators of caspase activity within trophoblast of normal pregnancies and pregnancies 
complicated by preeclampsia. Reprod. Sci. 15: 1034–1043. 
190. Ka, H., and J. S. Hunt. 2003. Temporal and spatial patterns of expression of inhibitors 
of apoptosis in human placentas. Am. J. Pathol. 163: 413–422. 
191. Kasof, G. M., and B. C. Gomes. 2001. Livin, a Novel Inhibitor of Apoptosis Protein 
Family Member. J. Biol. Chem. 276: 3238–3246. 
102 
 
192. Boise, L. H., M. Gonzblez-garcia, C. E. Postema, L. Ding, T. Lindsten, L. A. Turka, X. 
Mao, G. Nuaez, and C. Thompson. 1993. bcl-x , a bcl-2-Related Gene That Functions as a 
Dominant Regulator of Apoptotic Cell Death. Cell 74: 597–606. 
193. Connor, L. O., A. Strasser, L. A. O. Reilly, G. Hausmann, J. M. Adams, S. Cory, and D. 
C. S. Huang. 1998. Bim : a novel member of the Bcl-2 family that promotes apoptosis. EMB 
17: 384–395. 
194. Thurston, T. L. M., M. P. Wandel, N. von Muhlinen, Á. Foeglein, and F. Randow. 2012. 
Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. 
Nature 482: 414–418. 
195. Rabinovich, G. a, and M. a Toscano. 2009. Turning “sweet” on immunity: galectin-
glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9: 338–352. 
196. Walch, M., E. Eppler, C. Dumrese, H. Barman, P. Groscurth, and U. Ziegler. 2005. 
Uptake of Granulysin via Lipid Rafts Leads to Lysis of Intracellular Listeria innocua. J. 
Immunol. 174: 4220–4227. 
197. King, a., V. Wellings, L. Gardner, and Y. W. Loke. 1989. Immunocytochemical 
characterization of the unusual large granular lymphocytes in human endometrium 
throughout the menstrual cycle. Hum. Immunol. 24: 195–205. 
198. King, a, P. Kalra, and Y. W. Loke. 1990. Human trophoblast cell resistance to decidual 
NK lysis is due to lack of NK target structure. Cell. Immunol. 127: 230–237. 
199. Hanna, J., and O. Mandelboim. 2007. When killers become helpers. Trends Immunol. 
28: 201–6. 
200. Hu, W.-T., L.-L. Huang, M.-Q. Li, L.-P. Jin, D.-J. Li, and X.-Y. Zhu. 2015. Decidual 
stromal cell-derived IL-33 contributes to Th2 bias and inhibits decidual NK cell cytotoxicity 
through NF-κB signaling in human early pregnancy. J. Reprod. Immunol. 109: 52–65. 
201. Croxatto, D., P. Vacca, F. Canegallo, R. Conte, P. L. Venturini, L. Moretta, and M. C. 
Mingari. 2014. Stromal cells from human decidua exert a strong inhibitory effect on NK cell 
function and dendritic cell differentiation. PLoS One 9: 1–11. 
202. Co, E. C., M. Gormley, M. Kapidzic, D. B. Rosen, M. a. Scott, H. a. R. Stolp, M. 
McMaster, L. L. Lanier, a. Barcena, and S. J. Fisher. 2013. Maternal Decidual Macrophages 
Inhibit NK Cell Killing of Invasive Cytotrophoblasts During Human Pregnancy. Biol. Reprod. 
88: 155–155. 
203. González, I. T., G. Barrientos, N. Freitag, T. Otto, V. L. J. L. Thijssen, P. Moschansky, 
P. von Kwiatkowski, B. F. Klapp, E. Winterhager, S. Bauersachs, and S. M. Blois. 2012. 
Uterine NK Cells Are Critical in Shaping DC Immunogenic Functions Compatible with 
Pregnancy Progression. PLoS One 7: 1–10. 
204. Parham, P. 2005. MHC class I molecules and KIRs in human history, health and 
survival. Nat. Rev. Immunol. 5: 201–214. 
205. Gendzekhadze, K., P. J. Norman, L. Abi-Rached, T. Graef, A. K. Moesta, Z. Layrisse, 
and P. Parham. 2009. Co-evolution of KIR2DL3 with HLA-C in a human population retaining 
103 
 
minimal essential diversity of KIR and HLA class I ligands. Proc. Natl. Acad. Sci. U. S. A. 
106: 18692–18697. 
206. Gendzekhadze, K., P. J. Norman, L. Abi-Rached, Z. Layrisse, and P. Parham. 2006. 
High KIR diversity in Amerindians is maintained using few gene-content haplotypes. 
Immunogenetics 58: 474–480. 
207. Aagaard, K., J. Ma, K. M. Antony, R. Ganu, J. Petrosino, and J. Versalovic. 2014. The 
placenta harbors a unique microbiome. Sci. Transl. Med. 6: 237ra65. 
208. Ramathal, C. T., I. C. Bagchi, R. N. Taylor, and M. K. Bagchi. 2010. Endometrial 
Decidualization: of mice and men. Semin. Reprod. Med. 28: 17–26. 
209. Ratsep, M. T., a. M. Felker, V. R. Kay, L. Tolusso, a. P. Hofmann, and B. a. Croy. 2014. 
Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. 
Reproduction 149: R91–R102. 
210. Murphy, S. P., C. Tayade, A. a Ashkar, K. Hatta, J. Zhang, and B. A. Croy. 2009. 
Interferon gamma in successful pregnancies. Biol. Reprod. 80: 848–59. 
211. Hofmann, a. P., S. a. Gerber, and B. a. Croy. 2014. Uterine natural killer cells pace 
early development of mouse decidua basalis. Mol. Hum. Reprod. 20: 66–76. 
212. Parham, P., and L. A. Guethlein. 2010. Pregnancy immunogenetics : NK cell education 
in the womb ? J. Clin. Invest. 136: 4–7.  
 
  
104 
 
APPENDIX I. PRIMARY CELLS AND LINES USED IN THE PRESENT WORK 
Primary cells Description 
pNK 
Peripheral  NK cells 
Defined as CD45+CD14-CD3-CD56lowCD16+ 
Isolated from Leukopacks® processed from healthy blood donations 
Proliferation in culture; growth in suspension 
dNK 
Decidual NK cells 
Defined as CD45+CD14-CD3-CD56highCD16- 
Isolated from discarded decidual tissue from elective pregnancy terminations 
No proliferation in culture; cultured in suspension (1-2 days survival) 
VT 
Villous trophoblast 
Defined as CD45-EGFR+HLA-G- 
Isolated from discarded placental tissue from elective pregnancy terminations 
MHC Class I-negative 
No proliferation in culture, growth in suspension 
EVT 
Extravillous trophoblast 
Defined as CD45-EGFRlowHLA-G+ 
Isolated from discarded placental tissue from elective pregnancy terminations. 
Express HLA-C, HLA-E and HLA-G 
No proliferation in culture.  
Cultured in attachment in fibronectin-coated surfaces  (3-4 days of survival)  
DSC 
Decidual Stromal Cells 
Defined as CD45-CD10+CD29+ 
Isolated from discarded decidual tissue from elective pregnancy terminations 
Express HLA-A, HLA-B, HLA-C, HLA-E 
Proliferation in culture; growth in attachment; lines survive up to 15 passages 
  
Cell Line Description 
221 
721.221 cell line 
EBV-transformed B cell line  
HLA-A, B and C negative 
MHC Class II positive 
Immortalized cell line; growth in suspension 
221.C1 
721.221 cell line constitutively expressing HLA-C1 group alleles 
Retrovirally transfected with HLA-Cw3 or HLA-Cw7  
221.C2 
721.221 cell line constitutively expressing HLA-C2 group alleles 
Retrovirally transfected with HLA-Cw6 or HLA-Cw4 
K562 
Erythroleukemia cell line 
Immortalized myelogenous leukemia line 
MHC Class I negative 
Growth in suspension 
K562.C1 
K562 cell line constitutively expressing HLA-C1 group alleles 
Retrovirally transfected with HLA-Cw1 
K562.C2 
K562 cell line constitutively expressing HLA-C2 group alleles 
Retrovirally transfected with HLA-Cw6 
JEG3 
Choriocarcinoma cell line 
Immortalized cell line isolated from placenta affected with choriocarcinoma 
Expresses HLA-C, HLA-E, HLA-G (same pattern as EVT) 
Growth in attachment 
 
